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ABSTRACT 
Gain-of-Function Effects of Mutant p53 Explored Using a Three-Dimensional 
Culture Model of Breast Cancer 
William A. Freed-Pastor 
 
p53 is the most frequent target for mutation in human tumors and mutation at this 
locus is a common and early event in breast carcinogenesis.  Breast tumors with 
mutated p53 often contain abundant levels of this mutant protein, which has been 
postulated to actively contribute to tumorigenesis by acquiring pro-oncogenic (“gain-
of-function”) properties.  To elucidate how mutant p53 might contribute to mammary 
carcinogenesis, we employed a three-dimensional (3D) culture model of breast cancer.  
When placed in a laminin-rich extracellular matrix, non-malignant mammary epithelial 
cells form structures highly reminiscent for many aspects of acinar structures found in 
vivo.  On the other hand, breast cancer cells, when placed in the same environment, 
form highly disorganized and sometimes invasive structures.  Modulation of critical 
oncogenic signaling pathways has been shown to phenotypically revert breast cancer 
cells to a more acinar-like morphology.  
We examined the role of mutant p53 in this context by generating stable, 
regulatable p53 shRNA derivatives of mammary carcinoma cell lines to deplete 
endogenous mutant p53.  We demonstrated that, depending on the cellular context, 
mutant p53 depletion is sufficient to significantly reduce invasion or in some cases 
actually induce a phenotypic reversion to more acinar-like structures in breast cancer 
cells grown in 3D culture.  Additionally, using stable overexpression of a panel of 
tumor-derived p53 mutants in non-malignant mammary epithelial cells, we found that 
mutant p53 is sufficient to disrupt normal acinar morphogenesis.  Genome-wide 
expression analysis identified the mevalonate pathway as significantly upregulated by 
mutant p53.  Statins and sterol biosynthesis intermediates revealed that this pathway is 
both necessary and sufficient for the phenotypic effects of mutant p53 on mammary 
tissue architecture. We then showed that mutant p53 associates with sterol gene 
promoters at least partly via SREBP transcription factors.  Finally, p53 mutation 
correlates with highly expressed mevalonate pathway genes in human breast tumors 
and elevated expression of the mevalonate pathway correlates with a poor prognosis in 
breast cancer.   
We also queried a number of pathways/proteins that had previously been 
implicated in breast cancer and shown to be sufficient to bring about a phenotypic 
reversion in 3D culture to search for additional mechanisms by which mutant p53 might 
contribute to mammary carcinogenesis. Using this approach, we identified integrin β4 
as a novel target of mutant p53 in breast cancer cells and demonstrated that stable 
knockdown of integrin β4 is sufficient to dramatically reduce invasive processes in 
breast cancer cells grown in 3D culture.  We also show that mutant p53 associates with 
the promoter of ITGB4, the gene encoding integrin β4. Finally, we demonstrated that 
inhibition of NF-κB, a downstream mediator of integrin β4signaling, can mimic the 
phenotypic effects of mutant p53 depletion.   
These findings contribute to our understanding of breast carcinogenesis and may 
offer novel prognostic indicators and therapeutic targets for tumors bearing mutations 
in p53. 
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The TP53 gene, which resides on chromosome 17p13.1 and encodes the p53 protein, is 
the most frequent target for mutation in human cancer, with greater than half of all tumors 
exhibiting mutation at this locus (Petitjean et al., 2007b; Vogelstein et al., 2000).   
The discovery of the p53 “proto-oncogene” 
 The p53 protein was first identified in a complex with the simian virus 40 (SV40) large 
T-antigen (Lane and Crawford, 1979; Linzer and Levine, 1979).  It was subsequently 
demonstrated that many tumors produce abundant levels of this 53 kDa protein, a phenomenon 
that was not observed in normal tissue, suggesting that this tumor-associated protein might act as 
a cellular oncogene (DeLeo et al., 1979; Rotter, 1983).  This notion was reinforced when 
overexpression of newly cloned p53 cDNAs were shown to cooperate with oncogenic Ras to 
transform primary cells in culture (Eliyahu et al., 1984; Parada et al., 1984).  Furthermore, 
overexpression of p53 was demonstrated to increase tumorigenicity in otherwise p53-null cells 
(Wolf et al., 1984).  Thus, throughout the first decade after its discovery, p53 was generally 
acknowledged as a proto-oncogene (Levine and Oren, 2009).   
 However, multiple early findings called into question the role of p53 as a cellular 
oncogene.  For example, the murine Trp53 gene was shown to be inactivated by retroviral 
insertions in several tumor models (Ben David et al., 1988; Wolf and Rotter, 1984).  To resolve 
discrepant findings regarding the ability of p53 to transform primary cells, several groups 
compared the sequences of cloned p53 cDNAs only to find out that no two clones were identical 




demonstrating that p53 overexpression could transform cells and promote in vivo tumor growth, 
were actually performed with mutated versions of p53 which had been isolated from tumor cells 
(Hinds et al., 1989; Hinds et al., 1990; Levine and Oren, 2009).  Consequently, while early 
experiments were originally thought to describe the function of wild-type p53, they were in fact 
detailing the role of mutant p53 in tumor biology (the importance of which will become apparent 
below).   
In 1989, two seminal findings overturned the widely accepted notion that p53 acts as a 
proto-oncogene.  Vogelstein and colleagues, investigated genetic alterations in colorectal 
carcinomas and demonstrated that greater than 50% of these tumors exhibit loss-of-
heterozygosity (LOH), a hallmark of tumor suppressor genes, at the TP53 locus (most 
commonly: mutation of one TP53 allele and deletion of the corresponding TP53 allele) (Baker et 
al., 1989).  Levine and colleagues demonstrated that overexpression of wild-type p53 was 
actually sufficient to suppress oncogenic transformation (Finlay et al., 1989).  These and 
subsequent findings firmly established p53 as a tumor suppressor gene.  However, one should 
never discount seemingly contradictory results and it turns out we can still gain deep insight into 
the role of p53 in tumor biology from these early “artifacts” studying mutant p53.     
p53 and tumor suppression 
 Soon after this paradigm shift took place in the p53 field, a number of studies served to 
confirm the role of wild-type p53 as a tumor suppressor and establish this protein as one of the 
most important players in cancer biology.  In the late 1960s, a number of extremely cancer-prone 
families were identified in the United States and Europe (Li and Fraumeni, 1969a, b).  This 




dominant disorder which predisposes to breast cancer, sarcomas and other neoplasms.  LFS was 
later shown to be caused by germline mutations in TP53 (Malkin et al., 1990; Srivastava et al., 
1990).  A mouse model was soon developed in which p53 was disrupted by homologous 
recombination to explore the role of this protein in cancer.   While p53-/- mice were 
developmentally normal, they were extremely cancer-prone (Attardi and Jacks, 1999; 
Donehower et al., 1992).  Mice devoid of p53 exhibited an extreme susceptibility to multiple 
tumor types, primarily lymphomas and sarcomas, with three out of every four p53-/- mice having 
developed at least one obvious neoplasm by six months of age.  In contrast, wild-type littermates 
failed to develop any tumors by nine months of age (Donehower et al., 1992).  In addition to the 
early findings by the Vogelstein group, myriad studies have now confirmed that TP53 mutations 
are not isolated to colorectal cancer, but are present in greater than 50% of all human tumors 
(Petitjean et al., 2007b; Vogelstein et al., 2000).  This has led some to speculate that p53 
mutations are the most common genetic event in all of human cancer (Levine and Oren, 2009).   
 In fact, it has been hypothesized that p53 function is compromised in most, if not all, 
human tumors (Polager and Ginsberg, 2009).  As mentioned above, most tumors exhibit 
mutation of p53; however, in tumors which retain wild-type p53, its activity can be attenuated by 
a number of other mechanisms.  For example, many DNA tumor viruses encode proteins which 
can inactivate p53; SV40 large T-antigen, adenovirus E1B-55 kDa protein and the E6 
oncoprotein of human papilloma virus (HPV) types 16 and 18 all bind to p53 and inactivate its 
function (Levine and Oren, 2009).  The biological relevance of which is highlighted by the fact 
that HPV types 16 and 18 have been implicated in cervical carcinogenesis (Ferenczy and Franco, 
2002).  Another mechanism by which tumors inactivate p53 is through the upregulation or 




regulator of p53 and serves to keep p53 levels in check under unstressed conditions (Poyurovsky 
and Prives, 2006).  Additionally, a homolog of Mdm2, MdmX (also known as Mdm4), also 
serves as a negative regulator of p53.  Not surprisingly, both Mdm2 and MdmX are 
overexpressed in a variety of neoplasms (Marine et al., 2006).   
 Importantly, not only has p53 been demonstrated to be inactivated in most tumors, but a 
number of in vivo studies have demonstrated that reactivation of wild-type p53 in p53 null or p53 
mutant tumors is sufficient to lead to tumor stasis/regression (Christophorou et al., 2005; 
Christophorou et al., 2006; Kenzelmann Broz and Attardi, 2010; Xue et al., 2007).  This 
observation has paved the way for multiple approaches to activate wild-type p53 in tumor cells.   
p53 and therapeutic approaches 
Three of the more exciting approaches include small molecules that inhibit the interaction 
between p53 and its negative regulators (Mdm2 and/or MdmX), gene therapy to deliver wild-
type p53 to tumors and small molecules to re-activate mutant p53 to a wild-type conformation.  
A number of other strategies are currently in development which also seek to target the p53 
pathway or take advantage of p53 mutation in a large proportion of tumors.   
While targeted therapeutics to disrupt the p53:Mdm2 complex are still in development, it is 
interesting to note that many clinically relevant chemotherapeutics lead to stabilization of p53.  
They do this primarily through induction DNA damage, which activates such pathways as the 
ATM/Chk2 pathway, phosphorylating p53 and releasing it from the negative feedback loop.  In 
terms of the targeted therapies to prevent the p53:Mdm2 interaction, this approach is typified by 
the Nutlins (particularly Nutlin-3a) and RITA (Reactivation of p53 and Induction of Tumor cell 




Mdm2 or p53, respectively, breaking the interaction between p53 and Mdm2, thus stabilizing the 
p53 protein.   
While gene therapy may seem like one of the most straightforward approaches given the 
early success of this approach in preclinical models, this has been one of the slowest to reach the 
clinic.  Currently there are two p53 based gene therapies approved for clinical use in China and 
at least two in clinical trials in the United States (Levine and Oren, 2009).  Both approaches 
involve adenoviral-based delivery of wild-type p53.  The first is a replication-deficient 
adenovirus containing human p53 cDNA (Wolf et al., 2004) and the second is a replication-
competent adenovirus carrying human p53 cDNA, however this adenovirus has the E1B-region 
deleted so it can only replicate in and kill p53-deficient cells (Heise et al., 1997).   
The third approach involves “re-activating” mutant p53 to restore wild-type p53 function in 
mutant p53 expressing cells, allowing p53 to carry out its tumor suppressive functions in cancer 
cells (Brown et al., 2011).  One of the first compounds reported to “re-activate” mutant p53 was 
CP31398, a small molecule that allowed mutant p53 expressing cells to induce the expression of 
canonical p53 target genes, drive expression from a p53 reporter construct and even impair 
tumor growth (Foster et al., 1999).  Despite this promising start, it was later discovered that 
instead of binding directly to mutant p53, CP31398 intercalated into DNA (Rippin et al., 2002).  
However, this setback has not dismayed the many groups looking to identify compounds that 
restore p53 activity in mutant p53 tumors. While many groups are pursuing this approach, by far 
the most successful so far has been PRIMA-1 (also known as APR-246) has been shown to re-
activate missense mutants of p53 to regain at least some functions of wild-type p53 and thus halt 




However, PRIMA-1 has also been shown to exert p53-independent activities potentially 
complicating its use in the clinic (Brown et al., 2011). 
While the above mentioned compounds target multiple p53 mutants, one of the more 
interesting approaches from recent years is to develop “mutant-specific” drugs.  PhiKan083 is a 
small molecule that binds to a small cleft in the C-terminus of p53-Y220C stabilizing the 
conformation of the core domain and restoring transactivation of p53 target genes (Boeckler et 
al., 2008).  While it will take time to determine the utility of PhiKan083 as a clinical agent, it is a 
beautiful proof-of-principle of rational drug discovery based on the crystal structure of a mutant 
p53 and, although it must be noted that this cleft is probably unique to Y220C, a similar 
approach to design drugs specific to hotspot mutants of p53 may be a promising avenue in the 
future.   
Wild-type p53 has now secured its place as a critical player in cancer biology, but before we 
move on to the role of mutant p53 in tumors, it is important to review how exactly p53 acts as a 
tumor suppressor.   
Function of wild-type p53 
Wild-type p53 can be activated by a number of cellular stressors including DNA damage, 
hypoxia and oncogene activation (Vousden and Lu, 2002).  Following activation, wild-type p53 
normally functions as a sequence-specific transcription factor to inhibit cell cycle progression, 
promote senescence or induce apoptotic cell death (Prives and Hall, 1999; Vousden and Lu, 
2002; Vousden and Prives, 2009). 
The p53 protein possesses an acidic N-terminal transactivation domain (now recognized to be 




specific DNA binding domain, followed by an oligomerization domain and a basic C-terminal 
regulatory domain (Figure 1.1) (Laptenko and Prives, 2006).  Wild-type p53 functions as a 
homotetramer in cells, binding to p53 response elements composed of two decamers separated 
by a spacer of 0-14 nucleotides (5’-RRRCWWGYYYn0-14RRRCWWGYYY-3’)1 (el-Deiry et 
al., 1992; Funk et al., 1992; Riley et al., 2008).  Wild-type p53 has been shown to transactivate 
myriad genes, the products of which mediate the downstream cellular outcomes of p53 activation 
such as cell cycle arrest (CDKN1A, MIR34A, etc.), senescence (CDKN1A, PAI1, etc.) and 
apoptosis (PUMA, BAX, etc.) (Prives and Hall, 1999; Riley et al., 2008; Vousden and Lu, 2002).  
Each of these cellular outcomes has been shown to be important for the tumor suppressive 
ability of wild-type p53.  There is substantial evidence to support a role for apoptosis, or 
programmed cell death, in the tumor suppressive function of p53.   For example, mice in which 
the proline-rich domain of p53 had been deleted (this mutant protein lacks the ability to induce 
cell-cycle arrest, but retains the ability to induce programmed cell death) were still efficiently 
protected from spontaneous tumor development, suggesting that the ability to induce apoptosis is 
critical to the tumor suppressive ability of p53 (Toledo et al., 2006).  However, a second mouse 
model argues that cell-cycle arrest plays at least a partial role in tumor suppressive function.  A 
rare tumor-derived mutant of p53 (p53-R175P)2 was identified that was able to induce cell-cycle 
arrest, but was unable to induce apoptosis (Rowan et al., 1996).  Mice expressing the murine 
                                                            
1A=adenine, T=thymine, C=cytosine, G=guanine, R=purine, Y=pyrimidine, W=A/T, n=any 
nucleotide. 
 
2 This nomenclature will be used throughout this text.  The first letter represents the amino acid 
present in the wild-type protein, the number represents the amino acid position number counting 
from the N-terminus and the last letter represents the amino acid present in the mutated protein.  





equivalent to this p53 mutant (p53-R172P) demonstrate a delay in spontaneous tumor formation, 
suggesting that cell-cycle arrest and chromosome stability also protect against tumor 
development (Liu et al., 2004a).  These and many other data support the notion that wild-type 
p53 is unequivocally a tumor suppressor. However, biology, it seems, is never satisfied with a 
simple answer.   
Gain-of-Function Hypothesis 
 One of the more interesting aspects within the p53 field emerged to help explain many of 
the seemingly contradictory results from the first decade of p53 research, when p53 was widely 
considered to be an oncogene.  Unlike most tumor suppressor genes, which are predominantly 
inactivated as a result of deletion or truncation (Weinberg, 1991), the vast majority of cancer-
associated mutations in TP53 are missense mutations, single base-pair substitutions that result in 
the translation of a different amino acid in that position in the context of the full-length protein.  
Interestingly, these missense mutations tend to cluster at a number of “hot-spot” residues in the 
DNA binding domain (Figure 1.1) (Cho et al., 1994; Harris and Hollstein, 1993; Petitjean et al., 
2007a).    This is in striking contrast to the majority of tumor suppressors (examples include 
RB1, APC, NF1, NF2 and VHL), the primary mutations in which are deletion or nonsense, 
leading to little/no expression of the respective proteins (Levine et al., 1995).  While wild-type 
p53, under unstressed conditions, is a very short-lived protein, these missense mutations lead to 
the production of full-length altered p53 protein with a prolonged half-life (Strano et al., 2007).  
Many of these stable mutant forms of p53 exert a dominant-negative effect on the remaining 
wild-type allele, serving to abrogate the ability of wild-type p53 to inhibit cellular 
transformation, particularly when the mutant protein is expressed in excess of its wild-type 




in p53 are usually followed by loss of heterozygosity (LOH) at the corresponding locus, 
suggesting that there is a selective advantage conferred by losing the remaining wild-type p53, 
even after one allele has been mutated (Baker et al., 1990; Brosh and Rotter, 2009).  These 
observations, among others, led to the “gain-of-function” hypothesis, which states that mutation 
of TP53 is not equivalent to simply losing wild-type p53 function.  Instead, the strong selection 
for maintained expression of a select group of mutant p53 proteins suggests a positive role for 
certain p53 mutants in tumorigenesis.   
While inactivating missense mutations in p53 may be selected for during tumor 
progression due to their ability to act as dominant-negative inhibitors of wild-type p53, there is 
also clear evidence that mutant p53 can exert oncogenic, or gain-of-function, activity 
independent of its effects on wild-type p53 (Sigal and Rotter, 2000).  For example, when tumor-
derived mutants of p53 are expressed in non-transformed, otherwise p53-null, cells, this confers 
the ability to form tumors in nude mice, whereas the parental cells cannot (Dittmer et al., 1993; 
Wolf et al., 1984).  As was the case in confirming the tumor-suppressive role of wild-type p53, 
mouse models were essential in demonstrating that mutation of p53 is not equivalent to simply 
losing wild-type p53 function.  Almost a decade after the original p53 knockout mice were 
generated, two groups independently engineered “knock-in” mouse models of Li-Fraumeni 
syndrome.  These groups employed mice expressing tumor-derived mutants of p53, in which the 
murine equivalents of two of the most frequent “hot-spot” mutations in p53 were inserted into 
the endogenous Trp53 locus using homologous recombination, in an attempt to better 
recapitulate the human disease.  Remarkably, both knock-in mutations led to an altered tumor 
spectrum, in addition to more metastatic tumors (Lang et al., 2004; Liu et al., 2000; Olive et al., 




in TP53 have been shown to be associated with an earlier age of onset (approximately nine 
years), when compared with germline deletions in TP53, suggesting a gain-of-function effect of 
missense p53 mutants in human tumors (Bougeard et al., 2008).   
More recently, mutations in p53 have been implicated in diverse aspects of tumorigenesis 
including proliferation, survival, chemoresistance, limitless replication, somatic cell 
reprogramming, inflammation, migration, invasion, angiogenesis and metastasis (Adorno et al., 
2009; Bossi et al., 2006; Brosh and Rotter, 2009; Di Agostino et al., 2006; Irwin et al., 2003; 
Mizuno et al., 2010; Muller et al., 2009; Oren and Rotter, 2010; Sampath et al., 2001; Sarig et 
al., 2010; Stambolsky et al., 2010; Weisz et al., 2007a).  In addition, multiple studies have also 
demonstrated that the mutational status of p53 is a strong predictor for poor outcomes in many 
types of human tumors, particularly breast cancer (Elledge et al., 1993; Langerod et al., 2007; 
Olivier et al., 2006; Petitjean et al., 2007a).   
As noted by Oren and Rotter, while the concept of mutant p53 gain-of-function is now 
well established, the exact criteria for what constitutes “gain-of-function” can still be quite 
confusing (Oren and Rotter, 2010).  The current knowledge on mutant p53 gain-of-function 
comes largely from experiments in which researchers overexpressed mutant versions of p53 in 
cell culture or mouse tumor models.  As discussed above, many cancer-associated p53 mutants 
can exert dominant-negative effects on wild-type p53, so any “gain-of-function” experiments 
performed in the presence of wild-type p53 must be interpreted with extreme caution.  To 
thoroughly demonstrate gain-of-function, two main approaches are now utilized: (1) expression 
of mutant forms of p53 in an otherwise p53-null background or (2) RNA interference (RNAi) to 
deplete the levels of an endogenous mutant p53 from cancer cells that have lost the wild-type 




wild-type p53 do not necessarily prove a gain-of-function, but may simply reflect a dominant-
negative effect.   
Pro-Oncogenic Roles of Mutant p53 
Recent years have seen an explosion of proposed roles for p53 mutations in 
tumorigenesis and diverse mechanisms to explain these roles for mutant p53 proteins.  It is 
important to keep in mind that while the term “gain-of-function” has grown in popularity to 
explain observed effects of mutant p53 proteins, this may not necessarily be the best 
terminology, as will be seen below.  There are three primary categories of proposed mechanisms 
to explain the pro-oncogenic effects of mutant p53 in tumor biology, which are not mutually 
exclusive (Brosh and Rotter, 2009).  First, tumors may select for mutation of p53 solely for loss 
of wild-type p53 tumor suppressive activity.  Second, mutants of p53 may lose certain tumor 
suppressive functions of wild-type p53, while retaining and/or exaggerating other aspects of 
normal wild-type p53 function.  Finally, these mutant p53 proteins may acquire truly 
neomorphic, or gain-of-function, activities which actively promote tumor growth.   
Gain-of-function activities of mutant p53 are now well-established and these are 
commonly attributed to one of two primary mechanisms: (1) an interaction between mutant p53 
and cellular proteins or (2) mutant p53-mediated regulation of novel target genes.  Of course, 
these two options are not mutually exclusive; for example, tumor-derived mutants of p53 have 
been shown to interact with a number of cellular partners, including cellular transcription factors 
(such as: NF-Y, Sp1, VDR, NF-κB and Ets-1) and affect their transcriptional activity.  This will 





Mutant p53 interacting partners 
While wild-type p53 acts predominantly as a transcription factor, a number of the 
described gain-of-function activities of mutant p53 are mediated through non-transcriptional 
processes (Brosh and Rotter, 2009).  Mutant p53 can form aberrant protein complexes with a 
number of interacting partners, perturbing their activity.  A few of the more prominent examples 
will be reviewed below.     
MRE11 was recently identified as a novel interacting partner with two hot-spot p53 
mutants (p53-R248W and p53-R273H) which had been “knocked-in” to a humanized p53 allele 
in mice (p53hki) (Song et al., 2007).  The humanized (“Hupki”) p53 mouse model encodes a 
human/mouse chimeric p53 protein (amino acids 33-332 are human, while the N- and C-termini 
are composed of murine p53) (Luo et al., 2001).  The interaction between the nuclease MRE11 
and mutant p53 was demonstrated to confer a gain-of-function by promoting genetic instability 
in tumors and pre-tumorigenic lesions in the knock-in mice.  This interaction impaired the 
recruitment of the Mre11-Rad50-NBS1 (MRN) complex to double-strand breaks and diminished 
the activation of ataxia-telangiectasia mutated (ATM), enabling the persistence of unrepaired 
DNA breaks (Song et al., 2007).   
Two recently described mutant p53 interacting partners enhance the oncogenic activity of 
tumor-derived p53 mutants.  The promyelocytic leukemia (PML) protein is the major component 
of nuclear PML bodies, which have been implicated in proliferation and programmed cell death.  
Mutant p53 physically associates with PML and this interaction facilitates the transcriptional 
activity of mutant p53 (Haupt et al., 2009).  In addition, mutant p53 interacts with the prolyl 




isomerizes the intervening peptide bond, resulting in conformational changes that affect protein 
stability and activity.  Pin1 was demonstrated to cooperate with mutant p53 to promote a “pro-
aggressiveness” transcriptional program that increased the migration and invasion of breast 
cancer cells (Girardini et al., 2011).  Furthermore, this interaction was shown to be required for 
certain mutant p53 gain-of-function activities since Pin1 was necessary for oncogenic 
transformation of primary mouse fibroblasts by mutant p53 in cooperation with oncogenic H-
RasG12V and deletion of Pin1 attenuated the mutant p53 gain-of-function phenotype in mice 
(Girardini et al., 2011).   
While the mutant p53 interactome is rapidly expanding, the most widely studied mutant 
p53 interacting partners remain the p53 family members, p63 and p73.   
The p53 family: p63 and p73 
 The p53 family consists of three proteins: p53, p63 and p73, which are homologous in the 
three primary domains of p53: transactivation domain, DNA-binding domain and C-terminal 
oligomerization domain (Li and Prives, 2007). The highest degree of homology exists in the 
DNA-binding domains; p63 and p73 exhibit 60% and 63% homology with the DNA-binding 
domain of p53, respectively (Irwin and Kaelin, 2001).  The N-terminal transactivation domain is 
only 30% identical between p53 and p73 and 22% identical between p53 and p63, while the 
oligomerization domains of both p63 and p73 exhibit 38% identity with that of p53 (Irwin and 
Kaelin, 2001).  To complicate matters, both p63 and p73 are expressed as multiple isoforms, 
either through alternate promoter usage (N-terminal TA or ΔN forms for both p63 and p73) or 





As mentioned previously, wild-type p53 functions as a tetramer, so it came as no surprise 
that p63 and p73 were shown to form homo- and hetero-tetramers with each other, although 
neither p63 nor p73 could interact with wild-type p53 (Davison et al., 1999).  However, shortly 
thereafter a number of tumor-derived mutants of p53 were demonstrated to interact with both 
p63 and p73 (Di Como et al., 1999; Gaiddon et al., 2001; Irwin et al., 2003; Marin et al., 2000; 
Strano et al., 2002; Strano et al., 2001) and this interaction has been invoked to explain many of 
the gain-of-function effects of mutant p53.  For example, binding to p63 and/or p73 has been 
linked to the ability of certain tumor-derived mutants of p53 to promote chemoresistance, 
migration, invasion and metastasis (Adorno et al., 2009; Muller et al., 2009; Sampath et al., 
2001).  As mentioned above, the altered tumorigenic phenotypes observed in mutant p53 knock-
in mice (p53R172H/- and p53R270H/-, compared to p53-/-) provide some of the most compelling 
evidence for a mutant p53 gain-of-function in tumorigenesis (Olive et al., 2004).  Interestingly, 
both p53+/-/p63+/- and p53+/-/p73+/- double mutant mice display an altered tumor spectrum and 
display a more metastatic phenotype, highly reminiscent of the phenotype observed in the mutant 
p53 knock-in models (Flores et al., 2005).  This is in line with the idea that gain-of-function p53 
mutants act at least in part by inhibiting the function of p63/p73.    
Interestingly, the site of interaction between mutant p53 and p63/p73 is likely not to 
occur through the oligomerization domains, as was initially expected.  Instead, early reports 
demonstrated that this interaction was mediated through the DNA-binding domains, as the core 
domain of mutant p53 was sufficient to interact with p63 or p73 in co-immunoprecipitation 
assays (Gaiddon et al., 2001; Strano et al., 2002; Strano et al., 2001).  These observations 
provide a potential explanation for the specificity of the interaction between p63/p73 and tumor-




occur within the core DNA-binding domain and many of the hot-spot mutants of p53 have been 
shown to produce either local or global conformational changes (Wong et al., 1999).  However, 
it should be noted that p63/p73 also interact with “DNA-contact” mutants of p53 (albeit less 
effectively than with “conformational” mutants), which are reported not to dramatically alter the 
structure of the mutant p53 protein (Li and Prives, 2007). 
There are multiple lines of evidence that agree with this site of interaction, although the 
debate is not yet settled.  In agreement with this explanation is the fact that there was a strong 
correlation between the observed ability of a tumor-derived mutant to bind to p63/p73 and the 
ability of that p53 mutant to be recognized by PAb240, which recognizes a cryptic epitope within 
the core domain of p53 (Li and Prives, 2007).  In addition, wild-type p53, when denatured, was 
demonstrated to acquire the ability to interact with p73 (Bensaad et al., 2003).  Finally, two 
peptides derived from the p73 DNA-binding domain were demonstrated to disrupt the interaction 
between p73 and tumor-derived mutants of p53 (Di Agostino et al., 2008).  However, there have 
been several recent reports that have implicated the C-terminus as the primary determinant for 
the interaction between mutant p53 and p63/p73, at least in the case of certain tumor-derived 
mutants (Muller et al., 2009; Xu et al., 2011).  Interestingly, several groups have demonstrated 
that a single nucleotide polymorphism (SNP) at codon 72 in p53 (this residue can be either 
arginine or proline) alters the ability of mutant p53 to interact with p73, as mutant p53 with an 
arginine at this residue has a much higher affinity for p73 than a mutant p53 with a proline 
(Marin et al., 2000).    
As the interaction between mutant p53 and p63/p73 has been implicated in many pro-
oncogenic effects of mutant p53, one of the more intriguing therapeutic approaches may be to 




reported to do just that.  In a screen hoping to identify small molecules that could activate 
transcription from a wild-type p53 reporter construct, the top compound, RETRA (RE-activation 
of Transcriptional Reporter Activity), was actually found to disrupt the mutant p53:p73 complex, 
allowing p73 to activate transcription from this reporter construct.  This was elegantly 
demonstrated as RETRA-mediated activity was completely impaired when the cells bearing 
mutant p53 were depleted of p73 using RNAi and then treated with RETRA.  This compound 
could also activate transcription of p53-target genes in mutant p53-bearing tumors in vivo and 
prevent xenografted tumor cell growth (Kravchenko et al., 2008).  While this compound may not 
“re-activate” wild-type p53, it is tempting to speculate that perhaps inhibiting some of the gain-
of-function effects of mutant p53 might be sufficient as a therapeutic approach for mutant p53 
tumors.    
Since p63 and p73 are both sequence-specific transcription factors, mutant p53 binding 
may alter the activity of these family members at their target gene promoters.  Mutant p53 has 
traditionally been assumed to play an inhibitory role towards its family members, particularly 
when assayed using reporter constructs with a consensus p53 response element (Gaiddon et al., 
2001).  However, as more and more p63 and/or p73 target genes are uncovered, many of which 
are independent of wild-type p53, it remains to be seen if the relationship between mutant p53 
and p63/p73 is always antagonistic.   
Mutant p53 and transcription  
Wild-type p53 is a potent transcriptional activator and the transactivation domain (TAD) 
of p53 can be subdivided into two subdomains, TAD1 contained within residues 1-40 and TAD2 




been shown that wild-type p53 is dependent upon four critical hydrophobic amino acids in its 
amino terminus for transactivation activity, Leucine-22, Tryptophan-23, Tryptophan-53, 
Phenylalanine-54.  When these four residues are mutated to polar amino acids 
(L22Q/W23S/W53Q/F54S) p53 transactivation capability is completely abolished (Candau et al., 
1997; Lin et al., 1994; Venot et al., 1999; Zhu et al., 1998).  The transactivation subdomains 
have been shown to be essential for binding to co-activators of p53 such as p300 (Teufel et al., 
2007) and TATA-binding protein (Chang et al., 1995), in addition to mediating other regulatory 
interactions such as Mdm2 (Kussie et al., 1996; Lin et al., 1994) and Mdm4 (Shvarts et al., 
1996). 
Just as wild-type p53 primarily functions as a transcription factor, mutant p53 proteins 
have been shown to transactivate myriad genes involved in many different aspects of 
tumorigenesis (Brosh and Rotter, 2009; Strano et al., 2007; Weisz et al., 2007b).  In addition, a 
number of studies have implicated the transactivation domains of p53 as critical for pro-
oncogenic functions of p53 mutants (Frazier et al., 1998; Lin et al., 1995; Matas et al., 2001; Yan 
and Chen, 2010). While the transactivation targets of wild-type p53 tend to either promote cell 
cycle arrest/senescence or programmed cell death, the targets of tumor-derived p53 mutants are 
quite varied in terms of their biological effects.  Mutant p53 activates a number of target genes 
that serve to increase proliferation, inhibit apoptosis, promote chemoresistance and impinge on 
key metabolic or cell-cell/cell-ECM signaling pathways (Table 1.1).   
Tumor-derived p53 mutants have been demonstrated to transactivate MYC (Frazier et al., 
1998), CXCL1 (Yan and Chen, 2009), PCNA (Deb et al., 1992), MAP2K3 (Bossi et al., 2008), 
CCNA, CCNB, CDK1, CDC25C (Di Agostino et al., 2008), ASNS (Scian et al., 2004), E2F5, 




(Ludes-Meyers et al., 1996), all of which can promote proliferation of cancer cells.  Additionally, 
mutant p53 proteins can upregulate genes, the protein products of which serve to inhibit 
apoptosis or promote chemoresistance.  For example, p53 mutants can transactivate EGR1 
(Weisz et al., 2004), ABCB1 (also known as MDR1 or P-glycoprotein) (Chin et al., 1992; Lin et 
al., 1995; Sampath et al., 2001; Strauss and Haas, 1995), IGF2 (Lee et al., 2000), DUT 
(Pugacheva et al., 2002), BCL2L1 (also known as Bcl-xL) (Bossi et al., 2008), TIMM50 (Sankala 
et al., 2011), LGALS3 (Lavra et al., 2009) and NFKB2 (Scian et al., 2005), which can all inhibit 
cell death.  Finally, p53 mutants can upregulate genes with a variety of other cellular effects such 
as limitless replication (TERT) (Scian et al., 2004), matrix degradation (MMP3 and MMP13) 
(Buganim et al., 2010; Sun et al., 2000) and Rho GTPase signaling (ARHGDIA) (Bossi et al., 
2008).   
To date there is no unifying hypothesis to explain the ability of mutant p53 proteins to 
regulate such a wide variety of target genes, due in part to the absence of a defined “mutant p53 
response element.”  However, there have been a number of proposed mechanisms that account 
for individual genes or classes of genes regulated by p53 mutants.  One of the more common 
mechanisms seems to be that mutant forms of p53 can interact with other sequence-specific 
transcription factors, be recruited to the cognate binding site of that cellular transcription factor 
and either strengthen or dampen the target response.   To this end, at least three mutants of p53 
have been demonstrated to interact with the CCAAT-binding factor NF-Y, and this complex 
serves to upregulate NF-Y target genes such as CCNA, CCNB, CDK1 and CDC25C (encoding 
cyclins and cyclin dependent kinases that serve to promote cell cycle progression) following 
adriamycin (also known as doxorubicin) treatment (Di Agostino et al., 2006).  Recently, it was 




2011) and, as discussed above, the transcriptional activity of mutant p53 toward NF-Y target 
genes is enhanced by mutant p53’s interaction with PML (Haupt et al., 2009).  The ability of 
mutant p53 to upregulate ABCB1 (also known as MDR1), a transmembrane protein characterized 
by an ATP-binding cassette which can efflux a variety of structurally and functionally distinct 
substrates and thus promote tumor chemoresistance (Bush and Li, 2002), has been shown to be 
dependent on a functional interaction with Ets-1 (Sampath et al., 2001).  Mutant p53 can also 
interact with Sp1 bound to the consensus Sp1 response elements in the HIV-LTR and augment 
its activity (Chicas et al., 2000).  Additionally, NF-κB target genes have been found to be 
significantly overrepresented in a ChIP-on-chip analysis of potential mutant p53 binding sites 
and a tumor-derived p53 mutant can enhance the transcriptional activity of NF-κB in response to 
TNF-α (Dell'Orso et al., 2011; Weisz et al., 2007a).  Recently mutant p53 has also been shown to 
bind to the vitamin D receptor (VDR) and serve to synergistically upregulate vitamin D 
responsive genes such as IGFBP3 and CYP24A1 (Stambolsky et al., 2010). 
Interestingly, wild-type p53 has been shown to interact with many of the same 
transcription factors: NF-Y, Sp1 and VDR (Bargonetti et al., 1997; Imbriano et al., 2005; 
Stambolsky et al., 2010).  Likewise, wild-type p53 regulates many of the same target genes as 
described for mutant p53.  However, the outcome of wild-type p53 binding is often exactly 
reciprocal to that mediated by mutant p53.  Whereas mutant p53 augments the expression of NF-
Y, Sp1, NF-κB, Ets-1 and VDR target genes, wild-type p53 most commonly represses these 
same target genes (Di Agostino et al., 2006; Lane and Levine, 2010; Peart and Prives, 2006; 
Sampath et al., 2001; Stambolsky et al., 2010; Sun et al., 2000; Werner et al., 1996).  In partial 
explanation of this, Di Agostino et al. have shown that in response to adriamycin wild-type p53 




type p53 and the histone acetyltransferase p300 in the case of mutant p53 (Di Agostino et al., 
2006).  This switch in epigenetic modifiers serves to increase histone acetylation and thus results 
in increased transcription in the presence of mutant p53 proteins.   
While this mechanism, of co-opting cellular transcription factors to promote the 
transactivation of their target genes, provides some explanation for the activity of mutant p53, a 
critical question still remains: in cells where mutant p53 can be shown to interact with a 
particular transcription factor (e.g. NF-Y, Sp1, Ets-1, etc.), why are only a subset of their target 
genes affected by mutant p53?  One can speculate that perhaps this is due to a necessary co-
factor, in addition to mutant p53 and its partner transcription factor, and the complex is only 
present on certain promoters at any given time.  Alternatively, perhaps the chromatin landscapes 
of certain promoters are particularly amenable to mutant p53 binding. 
While a subset of mutant p53 target gene regulation can be explained by association with 
sequence-specific transcription factors, the different promoters activated by p53 mutants share 
little to no sequence homology.  This has led to the hypothesis that mutant p53 recruitment may 
be determined by DNA structural motifs as opposed to recognition of a sequence-specific mutant 
p53 response element (Kim and Deppert, 2004, 2007).  It has been shown that a number of 
tumor-derived mutants of p53 have a high affinity for nuclear matrix attachments regions 
(MARs), DNA sequences that bind with high affinity to the nuclear matrix, a salt and detergent-
insoluble proteinacious structure (Koga and Deppert, 2000; Muller et al., 1996; Will et al., 1998).  
Matrix attachment regions are highly AT rich regions which promote structural alterations within 
chromatin and often adopt non-B DNA conformations (Kim and Deppert, 2004).  In support of 
this hypothesis, mutant p53 proteins have been shown to bind to non-B DNA in vitro and in vivo 




motifs is presumably a remnant of a wild-type p53 function, as it has now been shown that, in 
addition to sequence-specificity, wild-type p53 binds to DNA via multiple sequence non-specific 
interactions (Kim and Deppert, 2003).  For example, wild-type p53 exhibits high affinity binding 
to double-stranded DNA, single-stranded DNA, secondary DNA structures and mismatched 
bases and DNA bulges (Kim and Deppert, 2003).  Interestingly, the structure-selectivity of both 
wild-type and mutant p53 requires its C-terminus, which is rarely mutated in human tumors 
(Petitjean et al., 2007a; Petitjean et al., 2007b).   
The findings that mutant p53 proteins can interact with target gene promoters through 
other transcription factors and in a DNA-structure-specific manner have been used to justify the 
absence of a well-described consensus mutant p53 sequence-specific response element.  
However, these attributes may in fact mask the existence of a mutant p53 response element if 
one exists.  In other words, using genome-wide analyses to identify mutant p53 binding 
sequences, one could not distinguish between sequences that are bound through other 
transcription factors, through DNA-structural motifs or directly through a (hypothetical) mutant 
p53 response element.   
What can we learn from mutational spectra of TP53? 
 Mutagenic events in DNA are generally accepted to arise from either external events 
(environmental mutagens) or internal events (resulting from replication errors, depurination, 
errors in repair, etc.) (Caron de Fromentel and Soussi, 1992).  The nature of mutations arising 
from external (exogenous) events is determined primarily by the mutagenic agent.  For example, 
ultraviolet (UV) light commonly induces pyrimidine-dimers in adjacent nucleotides, a common 




(endogenous) mutations arise from spontaneous events and preferentially occur at CpG 
dinucleotides.  This is likely due to the fact that the cytosine in this dinucleotide is frequently 
methylated and spontaneous deamination can occur changing the cytosine to uracil and the 
resulting U:G mispair can give rise to a C:G to T:A transition (Barnes and Lindahl, 2004). 
As mentioned previously, there are certain “hot-spot” missense mutations in the TP53 
gene, residues which are mutated at a much higher frequency than expected by chance.  Together 
these account for nearly one third of all p53 mutations (Brosh and Rotter, 2009).  This fact is 
often cited to support a gain-of-function hypothesis as it is suggestive of a selective advantage of 
having certain mutations.  The amino acids generally regarded as hot-spots (R175, G245, R248, 
R249, R273, R282) are found mutated in many malignancies.  Endogenous mutations frequently 
arise from spontaneous deamination of methylated CpG dinucleotides and interestingly, the 
codons at four of these hot-spot residues contain CpG dinucleotides.  A transition (C to T or G to 
A) can occur following deamination of the 5-methylcytosine and not surprisingly, this is exactly 
the type of nucleotide change observed at these hot-spots in p53 (Caron de Fromentel and Soussi, 
1992).   However, the p53 gene contains many other CpG dinucleotides that are rarely found 
mutated in cancer, supporting the notion that these hot-spots are functionally important to either 
inactivate wild-type p53 or that these substitutions offer distinct activities to the neomorphic 
protein.   
However, other p53 mutations occur only in specific tumor types, suggesting that 
environmental mutagens leave their mark on p53 in a tumor and tissue-selective manner.  For 
example, lung, liver and skin cancer all bear unique mutation distributions in TP53, which may 
be a result of carcinogens.  Hepatocellular carcinoma in certain developing nations is marked by 




developed nations (Staib et al., 2003).  In addition to the fact that this mutation is deleterious to 
p53 function, it has a strong association with exposure to Aflatoxin B1.  Aflatoxins are produced 
by fungal species (Aspergillus flavus in the case of Aflatoxin B1), and commonly contaminate 
food supplies in developing areas of sub-Saharan Africa and Asia.  In support of this association 
playing a causal role in hepatocellular carcinogenesis, Aflatoxin B1 has been shown to induce 
the same R249S mutation in TP53 when cultured with hepatocytes in vitro (Staib et al., 2003).  
Similarly, a strong association has been demonstrated between benzo(a)pyrene exposure (found 
in cigarette smoke) and G:C to T:A transversions.  These often occur in lung cancer at amino 
acid positions in p53 that are not otherwise frequently mutated (i.e. 157 and 158) (Toyooka et al., 
2003).   In fact, it has been proposed the mutational spectra for different tumor types might 
represent a “fingerprint” for the mutational agent responsible for tumorigenesis (Lasky and 
Silbergeld, 1996). 
Mutant p53: One name, many proteins 
While many groups choose to use the generic term “mutant p53” to designate any tumor-
derived p53 mutant, it is important to recognize that not all p53 mutants are equal.  Some 
mutants of p53 will exert gain-of-function effects, but many other p53 mutants will be selected 
for during tumorigenesis simply because they abolish wild-type p53 activity.  p53 mutations can 
generally be classified as either “conformational” or “DNA-contact” mutants (Brosh and Rotter, 
2009).  DNA-contact (or class I) mutants, exemplified by p53-R273H, are missense mutations in 
the amino acid residues that normally make direct contact with target DNA sequences.  
Conformational (or class II) mutants, typified by p53-R175H, are those missense mutations that 
disrupt the structure of the p53 protein on either a local or global level (Sigal and Rotter, 2000; 




This distinction is potentially important, particularly when one attempts to make 
generalizations about mutant p53 proteins.  Many target genes have been identified in the context 
of particular missense mutations in p53 (Table 1.1), but are now referred to as mutant p53 target 
genes.  Similarly, many mutant p53 binding partners bind with a higher affinity to a subset of 
tumor-derived p53 mutants.  For example, conformation mutants of p53 tend to have a higher 
affinity for p63/p73, as well as hsp70, and can be readily identified by the conformation-specific 
PAb240 (Gaiddon et al., 2001; Hinds et al., 1990).   In fact, even different amino acid 
substitutions at the same position in the p53 protein can have dramatically different phenotypic 
effects.  For example, p53-R248Q, but not p53-R248W (both of which are common tumor-
derived mutants), was able to confer invasive ability when overexpressed in p53-null cells 
(Yoshikawa et al., 2010).  Additionally, as already mentioned, p53-R175H and p53-R175P have 
dramatically different properties, which is highlighted by the different phenotypes they produce 
when “knocked-in” to the endogenous locus in mice (Donehower and Lozano, 2009). 
Particularly in the case of attempting to identify a “mutant p53 response element” (if one can be 
identified), it is likely that each contact mutant of p53 may have slightly different sequence-
specificity since these mutations affect the amino acid residues that directly contact the DNA 
backbone (Brosh and Rotter, 2009).   
Stabilization of Mutant p53 in Tumors 
 Mutant p53 proteins are often found at extremely high levels in tumors.  In fact, positive 
immunohistochemical staining of p53 in tissue sections is commonly used as a surrogate for 
detecting a missense mutation in TP53 (although this is an imperfect marker) (Alsner et al., 
2008; Bartek et al., 1990).  Wild-type p53 is maintained at very low levels in most cells due 




creating a negative feedback loop (Vousden and Prives, 2009).  Mutant forms of p53, on the 
other hand, are quite stable and often accumulate in tumor cells.  Until recently, the prevailing 
hypothesis to explain the observation of high levels of mutant p53 in tumors was that p53 
mutation broke this feedback loop by rendering the p53 mutant protein incapable of 
transactivating MDM2  (Oren and Rotter, 2010).  Arguing against this hypothesis is the fact that 
in the mutant p53 knock-in mouse models, although all tissues contained the mutant allele, these 
mice did not accumulate mutant p53 in most normal tissues (Lang et al., 2004; Olive et al., 
2004).   On the other hand, mutant p53 was observed at high levels in a subset of the tumors in 
these same mouse models (Terzian et al., 2008).  Interestingly, when the mutant p53 knock-in 
mice were crossed into an Mdm2-null background, the mutant p53 protein was stabilized in 
some normal tissues, albeit not all (Terzian et al., 2008).  Together, these findings strongly 
suggest that levels of mutant p53 can be regulated by similar mechanisms as that of the wild-type 
p53 protein, but additional events occur during tumorigenesis that are necessary to abrogate this 
regulation and lead to accumulation of mutant p53.   
In line with this idea, at least one report has demonstrated an enhanced mutant p53 gain-
of-function phenotype following common chemotherapeutic agents (Di Agostino et al., 2006).  
Similarly, it was recently reported that in a large randomized clinical trial to investigate the 
effects of cisplatin-based adjuvant chemotherapy in non-small cell lung carcinoma (NSCLC) 
patients following tumor resection, TP53 mutational status had a significant predictive impact for 
response to therapy.  While TP53 status had no prognostic significance in the absence of 
adjuvant chemotherapy, patients bearing a mutant p53 had a significantly reduced disease-free 
interval and overall survival only after undergoing treatment with cisplatin (Goldstein et al., 




traditional chemotherapeutics, but particularly as Mdm2 antagonists are under investigation as 
therapeutic agents (Prives and White, 2008).   
 As high levels of mutant p53 have been shown to be important for many aspects of 
tumorigenesis, one potential therapeutic approach is to target cellular proteins responsible for 
mutant p53 stabilization.  One recent development has done just that, in targeting HSP90.  It has 
long been observed that mutant forms of p53 interact with heat shock proteins in tumors 
(Sepehrnia et al., 1996) and that this interaction affects Mdm2-mediated turnover of mutant p53 
(Peng et al., 2001).  Recently, RNAi-mediated depletion or pharmacologic inhibition of HSP90 
has been shown to destabilize mutant p53, counteracting many of its gain-of-function effects (Li 
et al., 2011a; Li et al., 2011b).   
p53 and metabolism 
 Of the many differences between normal and tumorigenic cells, some of the earliest 
recognized were metabolic changes that accompanied transformation (Vousden and Ryan, 2009).  
The most famous of which was first described by Otto Warburg; specifically that transformed 
cells rely almost solely on anaerobic glycolysis as opposed to oxidative phosphorylation to 
obtain energy, a phenomenon which has come to be known as the Warburg effect (Warburg, 
1956; Warburg et al., 1927).  However, it should be noted that although the Warburg effect has 
dominated the focus of cancer metabolism over the past decades, deregulation of sterol 
biosynthesis has also been observed in a high proportion of cancer cells and has been put forth as 
hallmark of transformation (Siperstein, 1970).  Recent years have seen a resurgence of interest in 




role in maintaining the malignant state of tumors and the p53 protein is emerging as a key 
regulator of cellular metabolism (Vousden and Ryan, 2009).   
 Wild-type p53 has been shown to impinge upon glucose metabolism, fatty acid oxidation, 
glutaminolysis and antioxidant response, so it is perhaps no surprise that p53 mutant tumors 
exhibit altered metabolism (Maddocks and Vousden, 2011).  p53 can directly inhibit the 
expression of two glucose transporters, GLUT1 and GLUT4, as well as destabilize the 
phosphoglycerate mutase (PGM) protein (Maddocks and Vousden, 2011).  In addition, p53 
upregulates TIGAR (TP53-induced glycolysis and apoptosis regulator), which functions as a 
fructose-2,6-bisphosphatase, thereby fettering glycolytic flux (Vousden and Ryan, 2009).  The 
action of p53 on this pathway not only limits glycolysis, but also promotes flux through the 
pentose phosphate pathway (PPP) (Maddocks and Vousden, 2011).   Although glucose is the 
primary energy source for most cells, glutamate can also feed into bioenergetic pathways through 
the action of glutaminase.  Recently, glutaminase 2 (encoded by GLS2) has been shown to be a 
wild-type p53 target gene (Hu et al., 2010; Suzuki et al., 2010).  In addition, wild-type p53 
promotes multiple players in oxidative phosphorylation, thus it plays a central role in 
determining the mode by which cells obtain energy (Vousden and Ryan, 2009).   
TP53 and breast cancer 
Breast cancer is the most common malignancy diagnosed among women and the second-
most cause of cancer-related death among women in the United States (Jemal et al., 2009).  At 
the current rates, one in eight women born today in the U.S. will develop invasive breast cancer 
at some point during her lifetime (Warner, 2011).  Over the past twenty years, the mortality 




likely due to earlier detection and better adjuvant therapies; however, as of 2009 one in five 
diagnosed with invasive breast cancer will still die of the disease (Jemal et al., 2009; Warner, 
2011). 
TP53 mutation is a common and early event in breast carcinogenesis.  It is found to be 
altered in 25-40% of breast cancer cases and is often accompanied by subsequent loss of the 
wild-type allele (Borresen-Dale, 2003).  Individuals with Li-Fraumeni Syndrome, who inherit 
germline mutations in TP53, are predisposed to many types of cancers; however, the most 
frequently diagnosed is premenopausal breast cancer (Varley et al., 1997).  Consistent with the 
hypothesis that p53 mutation is an early step in mammary tumorigenesis, multiple studies have 
found that p53 is mutated in up to 30-40% of cases of high-grade ductal carcinoma in situ 
(DCIS), a pre-invasive breast lesion (Done et al., 2001; Ho et al., 2000; Zhou et al., 2009).   
Breast cancer is thought to arise from mammary epithelial cells, found in structures 
referred to as acini, which collectively form terminal ductal lobular units (TDLU).  Each acinus 
consists of a single layer of polarized luminal epithelial cells surrounding a hollow lumen (Figure 
1.2) (Allred et al., 2001; Bissell et al., 2002).  Breast carcinogenesis proceeds through a number 
of well described steps, from ductal carcinoma in situ (DCIS) to invasive breast cancer and 
mammary tissue architecture is invariably disrupted during breast tumor progression (Debnath et 
al., 2003a).  As discussed above, recent reports have connected the mutant p53 gain-of-function 
hypothesis to breast cancer, demonstrating that mutant p53 can lead to increased invasion, 
migration and metastasis (Adorno et al., 2009; Muller et al., 2009); yet mutant p53 induced 





Modeling the mammary gland: From 2D to 3D culture 
The human mammary gland is composed of an extensive network of arborized ducts 
lined by epithelial cells, surrounding a hollow lumen.  In vivo, this epithelium is actually 
comprised of an inner layer of luminal epithelial cells, which is immediately surrounded by an 
outer layer of myoepithelial cells.  The bilayered structure of the mammary epithelium exhibits 
apicobasal polarization, with the luminal epithelial cells on the apical side (facing the lumen of 
the acinus) and the myoepithelial cells making up the basal layer, in close proximity to the 
basement membrane (Bissell et al., 2002).  This mammary epithelium is embedded in a vast sea 
of adipose cells, interstitial dense connective tissue, loose connective tissue and endothelial cells, 
which collectively make up the mammary stroma (Hansen and Bissell, 2000). 
While traditional cell culture has provided deep insight into the process of breast 
carcinogenesis, a fundamental limitation of this approach is that in vitro culture conditions create 
an environment for the cell that markedly differs from the microenvironment that they would 
experience in vivo (Vargo-Gogola and Rosen, 2007).  It has long been recognized that when cells 
are maintained on glass or plastic tissue culture substrata, they rapidly lose many of their 
differentiated characteristics.  For example, when primary mammary epithelial cells from a late-
pregnant, lactating mouse are extracted and placed in traditional cell culture conditions, they no 
longer exhibit the prototypical signs of a secretory breast cell (extensive rough endoplasmic 
reticulum, well-developed Golgi apparatus and abundant casein synthesis), nor do they maintain 
their characteristic organization into three-dimensional glandular structures (Emerman et al., 
1977).  In the mid-1970s, it was demonstrated using floating collagen gels that, given the proper 
microenvironmental cues, it was possible to restore a number of differentiated functions to cells 




Lee et al., 1984; Michalopoulos and Pitot, 1975; Yang et al., 1980).  Following these early 
observations, it was postulated that the functional unit in higher organisms should be thought of 
not simply as a single cell, but a cell in combination with its neighboring extracellular matrix 
(Bissell et al., 1982). 
Pioneering work by the Bissell group established a system utilizing mammary epithelial 
cells grown in a laminin-rich extracellular matrix (ECM), in which they form structures highly 
reminiscent for many of the aspects of acinar structures found in vivo (Barcellos-Hoff et al., 
1989; Bissell et al., 2005; Petersen et al., 1992; Shaw et al., 2004).  As opposed to the early 
studies using floating collagen gels, subsequent studies have primarily utilized a three-
dimensional extracellular matrix (3D ECM) system, in which mammary epithelial cells are 
embedded in a reconstituted laminin-rich basement membrane derived from the Engelbreth-
Holm-Swarm (EHS) mouse sarcoma (Barcellos-Hoff et al., 1989; Kleinman et al., 1986), 
although a number of other 3D culture systems are also employed.  Commonly referred to as 
Matrigel, this laminin-rich ECM is composed primarily of laminin 1 (now referred to as laminin-
111), collagen IV, heparan sulfate proteoglycan, nidogen and entactin (Kleinman et al., 1986).  
The laminin-rich ECM more faithfully recapitulates the microenvironment of the human 
mammary gland and allows normal mammary epithelial cells to develop into polarized glandular 
structures with hollow lumens, which can even be induced to synthesize and vectorially secrete 
milk proteins if given the correct lactogenic signals (Barcellos-Hoff et al., 1989). Therefore, 
although cells often loose tissue-specific functions in cell culture, if these cells are placed in a 
more physiologically relevant context, they can regain many features of their in vivo 
counterparts.  Importantly, one of the hallmarks of tumorigenesis is disruption of normal tissue 




al., 2003a). In fact, pathologists have long recognized that certain histological patterns correlate 
strongly with patient prognosis (Hebner et al., 2008).   
When grown as monolayer cultures, non-tumorigenic and tumorigenic cells are 
essentially indistinguishable.  However, a multitude of studies have demonstrated that if these 
cells are cultured using a 3D laminin-rich ECM, one can readily distinguish normal and 
tumorigenic tissue by their morphological appearance (Kenny et al., 2007; Martin et al., 2008; 
Petersen et al., 1992; Wang et al., 1998; Weaver et al., 1997).   
Modeling breast tumorigenesis in 3D culture 
The importance of studying the effect of genetic alterations on tissue architecture in a 
microenvironment that faithfully recapitulates the in vivo microenvironment has become 
increasingly recognized.  The 3D laminin-rich ECM model system has been used extensively to 
model the effects of oncogene expression (or depletion of tumor suppressors) on the three-
dimensional morphogenesis of non-malignant mammary epithelial cells (Muthuswamy et al., 
2001; Wrobel et al., 2004; Zhan et al., 2008).   
In addition to primary mammary epithelial cells (MECs), a number of non-transformed, 
immortalized mammary epithelial cell lines can be induced to undergo acinar morphogenesis 
when plated in 3D culture.  These include human S1 (from the HMT-3522 progression series) 
and MCF10A mammary epithelial cell lines, as well as murine Eph4 and SCp2 mammary 
epithelial cell lines (Muthuswamy et al., 2001; Niemann et al., 1998; Roskelley et al., 1994; 
Weaver et al., 1997).  These non-malignant mammary epithelial cells undergo a well-




Multiple phenotypic alterations associated with mammary tumorigenesis have been 
studied using the 3D culture system and many of the underlying molecular mechanisms 
governing these phenotypic effects have now been elucidated.  We will explore a number of 
these phenotypic alterations in further detail below, including luminal filling, loss of apicobasal 
polarization, circumvention of growth arrest, disorganization and the invasive behavior of tumor 
cells.  In addition, we will also examine the pathways/proteins that have been implicated as being 
necessary to maintain the malignant state of tumorigenic breast cells.  With these in mind, two 
complementary approaches have been used to extensively study breast carcinogenesis in 3D 
culture, each of which will be discussed in the context of individual proteins below.  The first is 
introduction of putative oncogenes or depletion of putative tumor suppressors to examine their 
effect on otherwise non-malignant mammary epithelial cells and the second is modulation of the 
activity and/or levels of pathways/proteins that can restore a more normal three-dimensional 
acinar-like morphology to disorganized breast cancer cells (referred to hereafter as a “phenotypic 
reversion”).   
Luminal clearance 
 A common feature of most glandular epithelial tumors is absence of a hollow lumen 
(Debnath and Brugge, 2005).  In fact, one of the earliest stages of breast cancer is ductal 
carcinoma in situ, which is defined by an accumulation of cells within the luminal space.  One of 
the primary mechanisms by which at least MCF10A cells undergo luminal clearance is through a 
specific form of apoptosis known as anoikis (Debnath et al., 2002).  Anoikis is a unique form of 
programmed cell death which occurs in cells that detach from the basement membrane 
(Boudreau et al., 1995).   Bim, a pro-apoptotic BH3-only Bcl family protein, has been implicated 




clearance in 3D culture (Reginato et al., 2005; Reginato et al., 2003).  However, lumen formation 
occurs in vivo even in the absence of Bim, demonstrating that there are alternative mechanisms 
of lumen formation (Mailleux et al., 2007).  For example, recent work has demonstrated that 
reactive oxygen species (ROS) can lead to formation of a hollow lumen in the setting of 
apoptotic inhibition (Schafer et al., 2009).  In fact, lumen formation has even been shown to 
spontaneously occur within small clusters of epithelial cells, suggesting that there may be 
intrinsic mechanisms to generate a hollow lumen (Hall et al., 1982; Ojakian et al., 1997).   
Mechanistic insights into the process of lumen formation using MCF10A cells grown in 
3D culture suggest that either an inhibition of apoptosis or an increase in cell proliferation alone 
is not sufficient to prevent luminal clearance; however, the combination of the two can prevent 
formation of a hollow lumen (Debnath et al., 2002).  For example, forced expression of anti-
apoptotic proteins in MCF10A cells (i.e. expression of Bcl-2 or Bcl-xL) does not prevent lumen 
formation, instead this only delays lumen formation by several days (Debnath et al., 2002).  
Similarly, expression of pro-proliferative factors such as Cyclin D1 or inactivation of critical cell 
cycle checkpoint proteins such as the retinoblastoma protein Rb (by the E7 viral product of 
human papilloma virus 16), increases proliferation in MCF10A 3D structures, but does not lead 
to luminal filling due to a compensatory increase in luminal apoptosis (Debnath et al., 2002).  
There have now been numerous proteins and/or pathways which have been implicated in 
disruption of acinar morphogenesis, a subset of which have been shown to be necessary to 
maintain the malignant state of breast cancer cells (Table 1.2).  Of particular note to this study, 
luminal clearance in the mammary gland does not appear to be affected by p53 loss, suggesting 





Driving Tumorigenesis: effects on mammary tissue architecture 
 As we examine the myriad putative oncogenes and tumor suppressors that have been 
studied using the 3D culture model, we will travel inward from the extracellular environment to 
cell surface proteins to cytoplasmic signaling molecules to primarily nuclear factors.  While this 
organization is helpful in conceptualizing these factors, it is important to keep in mind one of the 
key principals garnered from the 3D culture system, dynamic reciprocity.  By this, we mean that 
there is a constant flux of information transmitted from extracellular to intracellular 
environments as well as from intracellular to extracellular environments, thus one must always 
keep in mind the interplay between these compartments.    
Extracellular Factors 
 The matrix metalloproteinase (MMP) family comprises a large number of secreted or 
membrane-associated proteins that cleave a wide range of extracellular matrix, cell surface and 
secreted proteins (Kessenbrock et al., 2010).   Matrix metalloproteinases have been shown to 
play critical roles in a number of tumorigenic processes including cell proliferation, apoptosis, 
migration and invasion (Bissell et al., 2005).  Non-malignant mouse mammary epithelial cells 
(SCp2) were engineered to express an inducible autoactivated version of MMP-3 (also known as 
stromelysin-1), which led to a disorganized and invasive phenotype in 3D culture, subsequent to 
cleavage of E-cadherin and release of transcriptionally-active β-catenin to the nucleus (normally 
found in adherens junctions) (Lochter et al., 1997).  Of note, MMP3 has been shown to be a 
transactivation target for mutant p53, in cooperation with oncogenic Ras (Buganim et al., 2010).  
Intriguingly, using this same system MMP-3 expression was later shown to induce genomic 




chromosomal regions) by regulating the alternative splicing of Rac1 to Rac1b, the prominent 
isoform found in breast cancer (Radisky et al., 2005).  MMP-3 is not the only protease that can 
initiate this pathway, as MMP-9 (although not MMP-2) could substitute for MMP-3 (Radisky et 
al., 2005). 
 In fact, MMP-9 has also been shown to profoundly influence acinar morphogenesis in the 
3D culture system.  Activated MMP-9 can disrupt polarity and re-initiate proliferation in non-
tumorigenic MCF10A cells, disrupting acinar morphogenesis (Beliveau et al., 2010).  
Additionally, using two cell lines derived from the same patient, S1 (non-tumorigenic) and T4-2 
(tumorigenic) (Briand et al., 1987; Weaver et al., 1997), it has been elegantly demonstrated that 
not only is activated MMP-9 sufficient to disrupt acinar morphogenesis when expressed in S1 
cells, but MMP-9 is necessary to maintain the malignant state, as inhibition or downregulation of 
MMP-9 was sufficient to revert disorganized T4-2 cells to a more normal acinar-like 
morphology (Beliveau et al., 2010).  T4-2 cells, which are highly tumorigenic in 
immunocompromised mice, exhibited dramatically reduced tumor growth in vivo upon MMP-9 
downregulation by RNAi, supporting the notion that 3D phenotype can accurately predict 
tumorigenicity (Beliveau et al., 2010).  Highlighting the dynamic reciprocity mentioned earlier, it 
was demonstrated that MMP-9 can cleave all three subunits of laminin-111, rearranging tissue 
architecture, altering signal transduction through the Raf/MEK/Erk pathway, which in turn 
regulates the levels of MMP-9 (Beliveau et al., 2010). 
 The ADAM (A Disintegrin And Metalloproteinase) family of proteins is a related group 
of peptidases that is critical for the shedding of a number of growth factors (Kenny and Bissell, 
2007).  Similar to the phenotypic reversion observed upon MMP-9 inhibition, when ADAM-17 




acinar-like structures in a 3D microenvironment.  This reversion was dependent upon the ability 
of ADAM17 to cleave, and thus shed, TGF-α and amphiregulin.  These growth factors could 
then signal through the epidermal growth factor receptor (EGFR) to amplify the mitogen-
activated kinase (MAPK, also known as Raf/MEK/ERK) pathway (Kenny and Bissell, 2007).   
 However, the relationship between MMPs and tissue architecture is not as clear cut is it 
may appear.  Matrix metalloproteinases are endogenously controlled by tissue inhibitors of 
metalloproteinases (TIMPs).  Although two MMPs can disrupt acinar morphogenesis, 
overexpression of TIMP-1, a natural inhibitor of MMPs, is sufficient to disrupt MCF10A acinar 
morphogenesis (Jung et al., 2006; Liu et al., 2005).  While this may appear contradictory, in fact 
it rather points to the importance of the tight regulation for the levels/activity of MMPs in normal 
cells and highlights the dysregulation that occurs during tumorigenesis.      
 Further illustrating the intricate connection between the extracellular microenvironment 
and tissue architecture, it has been observed that antibodies directed against fibronectin, a key 
component of the ECM, can phenotypically revert tumorigenic T4-2 cells in 3D culture.  These 
cells which are normally highly disorganized, formed a hollow lumen with proper basal 
polarization of integrin β4, demonstrating the dominance of the microenvironment (Sandal et al., 
2007).  The question still remains, how do microenvironmental changes modulate gene 
expression to disrupt acinar morphogenesis in 3D culture?  The answer, to which we have 
already alluded, is that the ECM can transmit biochemical as well as biomechanical signals to a 






Cell Adhesion Molecules 
 Cell-matrix and cell-cell adhesion is largely mediated by the integrin family, but it is 
important to remember that these proteins also impinge upon multiple signal transduction 
pathways that affect various cellular processes.  Integrins are heterodimeric transmembrane 
proteins, each is composed of a single α and β subunit from which they derive their names, and a 
number of integrins have been implicated in tumorigenesis (Gilcrease, 2007; Wang et al., 2002; 
Wang et al., 1998; Weaver et al., 1997).   Altered levels/localization of integrins α2, α3, α6, β1 
and β4 have all been reported in breast cancer (Weaver et al., 1997). 
 Using the HMT-3522 breast cancer progression series (described above), it was noted 
that tumorigenic T4-2 cells express much higher levels of integrin β1 compared to their non-
tumorigenic counterparts (S1 cells). When integrin β1 was inhibited by function-blocking 
antibodies, T4-2 cells underwent a phenotypic reversion in 3D culture (Weaver et al., 1997).  It 
was subsequently discovered that an intimate relationship exists between the levels of integrin β1 
and the epidermal growth factor receptor (EGFR) in 3D culture, as each protein can regulate the 
levels of the other, although this cross-modulation is not present in 2D monolayers (Wang et al., 
1998).  A number of other breast tumor cell lines have now been shown to undergo phenotypic 
reversions in response to integrin β1 inhibition when combined with either a phosphatidylinositol 
3-kinase (PI3K) inhibitor, a mitogen-activated protein kinase (MAPK) inhibitor or E-cadherin re-
expression (Wang et al., 2002).   
As mentioned previously, integrins are composed of an α and β subunit, and integrin α2 
most commonly pairs with integrin β1.    Re-expression of integrin α2 into a tumorigenic mouse 




reversion in these cells, restoring their ability to form acinar-like structures in a laminin-rich 
ECM (Zutter et al., 1995).  This seemingly paradoxical result, similar to the observed roles of 
MMPs in 3D culture,  may reflect cell line dependent differences in response to integrin β1 or 
perhaps integrin β1 is pairing with a different alpha subunit (i.e. α1, α3, α4, α5, α6) in these other 
breast cancer cell lines to mediate its oncogenic effects. 
 The story with integrin β4 is no less complex.  Integrin β4 almost exclusively associates 
with integrin α6 and functions as the primary receptor for laminin-5 (laminin-332) (Guo and 
Giancotti, 2004).  Tumors often express high levels of integrin β4, which may have prognostic 
impact (Lu et al., 2008; Weaver et al., 2002).  A large body of literature has linked the α6β4 
integrin to multiple aspects of tumorigenesis including increased survival, angiogenesis and 
invasion (Lipscomb et al., 2005; Nikolopoulos et al., 2004; Shaw et al., 1997).  In fact, β4 
integrin has been shown to augment ErbB2-mediated breast tumorigenesis in vivo (Guo et al., 
2006).  However, the role that α6β4 integrin plays in tumorigenesis remains controversial.  Other 
studies have demonstrated a reduced expression of integrin β4 in tumors and integrin β4 
expression has been shown to mediate multiple tumor suppressive mechanisms in cell culture 
studies (i.e. apoptosis in a wild-type p53 dependent manner, as well as cause growth arrest 
mediated by p21) (Bachelder et al., 1999; Clarke et al., 1995; Davis et al., 2001; He et al., 2008).  
 Fitting with this theme, the role of integrin β4 in acinar morphogenesis is still up for 
debate.  It has been demonstrated that downregulation of integrin β4 from non-tumorigenic S1 
cells can disrupt their morphology in 3D culture (Weaver et al., 2002; Weaver et al., 1997).  
However, it has also been demonstrated that downregulation of integrin β4 from disorganized or 
invasive breast cancer cells can partially revert their morphology (Dutta and Shaw, 2008; 




differ in their p53 mutational status, it is tempting to speculate that this may impact the function 
of integrin β4 in tumorigenesis (this theme will be explored further in Chapter 3). 
In addition to the integrin family of proteins, a number of other adhesion molecules have 
been implicated in acinar morphogenesis.  Dystroglycan, a non-integrin laminin receptor, has 
been shown to be downregulated in a subset of mammary tumors.  Re-expression of 
dystroglycan in T4-2 cells, which normally express very low levels, was sufficient to restore 
proper apicobasal polarization and acinar morphogenesis in response to culture in a laminin-rich 
ECM (Muschler et al., 2002). 
E-cadherin is a critical component of adherens junctions, which are important for cell-cell 
adhesion among epithelial cells, and is commonly lost in invasive mammary lobular carcinomas 
(Meiners et al., 1998).  Acinar morphogenesis was severely disrupted in non-tumorigenic 
mammary epithelial cells when E-cadherin was inhibited by function-blocking antibodies or 
downregulated by means of RNAi (Fournier et al., 2009).  Likewise, tumorigenic breast cell lines 
could be partially phenotypically reverted by re-expression of E-cadherin (Meiners et al., 1998), 
and could completely revert breast cancer cells to an acinar-like morphology when combined 
with inhibition of PI3K, MAPK or integrin β1 (Wang et al., 2002).  Likewise, CEACAM1, a 
critical cell adhesion molecule expressed in a number of epithelial cell types, is frequently lost in 
tumors and has been demonstrated to be necessary for mammary lumen formation.  When 
CEACAM1 was downregulated by siRNA in MCF10F cells (derived from the same patient as 
MCF10A cells), they could no longer form a hollow lumen and when CEACAM1 was 
exogenously expressed in MCF7 breast cancer cells, which normally cannot form a hollow 
lumen and which basally lack CEACAM1 expression, these cells could now form a hollow 




In addition to cell adhesion molecules, one of the primary ways that signals are 
transmitted from the extracellular microenvironment is through receptor tyrosine kinases, a 
number of which have now been implicated in acinar morphogenesis.   
Receptor Tyrosine Kinases 
Modulation of a number of receptor tyrosine kinases (RTKs) can disrupt acinar 
morphogenesis in 3D culture.   The human epidermal growth factor receptor 2, HER2/neu (also 
known as ErbB2), is commonly amplified in breast cancer and associated with a very poor 
prognosis (Muthuswamy et al., 2001; Sorlie et al., 2001).  When MCF10A cells were engineered 
to express an inducible version of ErbB2, activation of this receptor in growth-arrested, polarized 
acinar structures resulted in a re-initiation of proliferation, disruption of apicobasal polarity, with 
consequent luminal filling (Muthuswamy et al., 2001).  Interestingly, overexpression of the 
human epidermal growth factor receptor 1, EGFR (also known as ErbB1) can prevent anoikis, 
however this was not sufficient to disrupt acinar morphogenesis in MCF10A cells (Muthuswamy 
et al., 2001; Reginato et al., 2003).  On the other hand, it has now been elegantly demonstrated 
that by inhibiting the activity of EGFR (with specific inhibitors, function-blocking antibodies or 
inhibiting the shedding of its ligands as described above) in disorganized, tumorigenic T4-2 cells 
this is sufficient to lead to a phenotypic reversion to a more acinar-like morphology in 3D culture 
(Kenny and Bissell, 2007; Wang et al., 2002; Wang et al., 1998).  Intriguingly, EGFR is a well-
recognized transcriptional target of tumor-derived p53 mutants (Ludes-Meyers et al., 1996). 
Elevated activity of the insulin-like growth factor 1 receptor (IGF1R) has also been 
shown to induce a luminal filling phenotype in MCF10A cells grown in 3D culture (Irie et al., 




comprises two ligands (IGF-1 and IGF-2), two cell surface receptors (IGF1R and IGF2R), in 
addition to a number of binding proteins (IGFBP1-6).  Expression of the IGF family members is 
often altered in human cancers, including breast cancer (Litzenburger et al., 2009).  Of particular 
interest to this work, a number of IGF family members are transactivation targets of mutant p53, 
including IGF1R (Table 1.1).  Similarly, elevated activity of the fibroblast growth factor receptor 
1 (FGFR1) is commonly observed in invasive lobular carcinoma of the breast.  MCF10A cells 
that had been engineered to activate FGFR1 in an inducible manner, exhibit an inability to 
undergo luminal clearance upon FGFR1 activation, in addition to displaying altered apicobasal 
polarization.  FGFR1 signals downstream to the mitogen-activated protein kinase (MAPK) 
pathway and the phenotypic alterations in 3D culture were shown to be dependent on the activity 
of this downstream pathway (Xian et al., 2009).   
Colony-stimulating factors (CSF) have been most widely studied for their role in 
promoting the proliferation and survival of hematopoietic cells; however, the CSF-1/CSF-1R 
pair has also been implicated in outgrowth of the human mammary gland and shown to be 
elevated in breast tumors (Dai et al., 2002; Kacinski et al., 1991).  Colony-stimulating factor 1 
receptor (CSF-1R) encodes a tyrosine kinase transmembrane receptor and expression of a 
constitutively active version of CSF-1R, or co-expression of CSF-1/CSF-1R, profoundly 
disrupted acinar morphogenesis in MCF10A cells, by preventing luminal clearance and 
disrupting cell-cell adhesion (Wrobel et al., 2004).  As a consequence of CSF-1R 
hyperactivation, E-cadherin was progressively lost from the cell membrane, which may account 
for the discohesive phenotype observed in 3D culture.  Mechanistically, CSF-1R signals 
downstream to Src, a proto-oncogenic tyrosine kinase, and Src activation was shown to be 




overexpression alone was subsequently demonstrated to be sufficient to disrupt acinar 
morphogenesis of MCF10A cells in 3D culture (Reginato et al., 2005).  Conversely, c-Met, the 
key cellular receptor for hepatocyte growth factor (HGF), is another receptor tyrosine kinase that 
signals downstream to Src.  Expression of c-Met in conjunction with HGF resulted in a similar 
activation of Src to that of CSF-1R, which led to the formation of branched tubules in 3D 
culture.  However, unlike the severely disrupted phenotype with hyperactive CSF-1R, structures 
formed with hyperactive c-Met retain a hollow lumen and proper adherens junctions (Wrobel et 
al., 2004).  This highlights the fact that although many of the same signaling molecules are 
activated in response to different stimuli, disparate receptor activation can result in markedly 
different phenotypic changes.   
 While not receptor tyrosine kinases themselves, protein tyrosine phosphatases normally 
suppress the activity of a variety of RTKs.   Recently, protein tyrosine phosphatase non-receptor 
type 12 (PTPN12), which regulates the activity of EGFR and HER2/neu, among others, has been 
implicated in disruption of mammary tissue architecture.  Depletion of PTPN12 in MCF10A 
cells using RNAi resulted in hyperactivation of a number of RTKs (HER2 and EGFR, primarily), 
which severely compromised acinar morphogenesis in 3D culture, bypassing proliferative 
suppression and inducing a luminal filling phenotype, in addition to structures with altered 
shapes (Sun et al., 2011). 
 Interestingly, extracellular factors, cell adhesion molecules and receptor tyrosine kinases 
impinge on similar, and often overlapping, intracellular signaling cascades. 




 The phosphatidylinositol 3-kinase (PI3K) pathway, which signals to Akt and mTOR, 
promotes cell proliferation and survival.  Not surprisingly, it is one of the most commonly 
altered pathways in human cancer (Cantley, 2002).  The two most commonly mutated genes are 
PIK3CA and PTEN.  PIK3CA encodes the p110α catalytic subunit for phosphatidylinositol 3-
kinase, which similar to other mutated oncogenes, commonly incurs gain-of-function missense 
mutations on hot-spot residues (i.e. E542K, E545K and H1047R) leading to elevated activity 
(Gymnopoulos et al., 2007).  Functional loss of phosphatase and tensin homolog (PTEN), an 
endogenous inhibitor of PI3K that signals to convert phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3) back to phosphatidylinositol (4,5)-bisphosphate (PIP2), commonly occurs in 
tumorigenesis (Simpson and Parsons, 2001).  Multiple studies have implicated this pathway as 
playing a significant role in acinar morphogenesis. 
 When two of the most commonly occurring tumor-derived PIK3CA mutants (E545K and 
H1047R) were introduced into MCF10A cells, this resulted in highly proliferative, multi-acinar 
3D structures (Isakoff et al., 2005).  Importantly, treatment with rapamycin, an inhibitor of 
mTOR, reversed these phenotypic effects, suggesting that the canonical Akt/mTOR pathway was 
mediating the effects of mutant PIK3CA on tissue architecture (Isakoff et al., 2005).  Similarly, 
expression of a conditionally activated version of the serine/threonine kinase Akt1 was sufficient 
to disrupt MCF10A acinar morphogenesis (Debnath et al., 2003b).  Likewise, Akt signaling was 
shown to be necessary for the disrupted phenotype induced by IGF1R; however, a specific role 
for Akt2 was noted in this context (Irie et al., 2005).  Downregulation of PTEN has also been 
examined in the 3D culture system, although with somewhat contradictory results.  RNAi-
mediated depletion of PTEN from non-tumorigenic S1 cells was sufficient to disrupt acinar 




from MCF10A cells prevented anoikis, but did not disrupt acinar morphogenesis (Vitolo et al., 
2009).  A number of reports now exist that demonstrate the importance of the PI3K pathway in 
maintaining the malignant state.  Specific inhibition of PI3K has been shown to phenotypically 
revert a number of tumorigenic breast cell lines, either alone or in combination with other 
inhibitors (Beliveau et al., 2010; Liu et al., 2004b; Wang et al., 2002).   
In addition to the PI3K pathway, the Raf/MEK/ERK pathway has been shown to be 
deeply involved with the process of acinar morphogenesis.  Inducible expression of Raf, a 
mitogen-activated kinase kinase kinase that phosphorylates and activates MEK-1/2, in growth-
arrested acinar structures was sufficient to re-initiate proliferation and lead to a disorganized, 
apolar 3D phenotype (Beliveau et al., 2010).  Similarly, inducible expression of an oncogenic 
variant of B-Raf (V600E) in growth-arrested MCF10A acinar-like structures, profoundly 
disrupted their 3D morphology, with a re-initiation of proliferation, disorganization and invasion 
into the surrounding matrix (Herr et al., 2011).  Interestingly, acinar-like structures could be 
recovered upon shutting off expression of oncogenic B-Raf, illustrating the plasticity of the 
malignant phenotype (Herr et al., 2011).  Furthermore, by using specific MEK inhibitors, it has 
been demonstrated that this pathway is necessary to maintain the malignant state of many 
tumorigenic breast cell lines.  Relating to previously mentioned work, the Raf/MEK/ERK 
pathway is downstream of EGF and integrin β1, and this pathway controls the expression of 
MMP-9 (Beliveau et al., 2010; Wang et al., 2002; Wang et al., 1998).   
  Rap1 is a member of the Ras superfamily of small GTPases and plays a critical role in 
mediating signals from a number of cytokines, growth factors and adhesion molecules.  Like all 
regulatory GTPases, Rap1 can exist in either an inactive guanine nucleotide diphosphate (GDP)- 




elevated by specific guanine nucleotide exchange factors (GEFs), which promote dissociation of 
bound GDP thus allowing the protein to bind a new GTP.  Conversely, GTPase activating 
proteins (GAPs) promote the intrinsic GTPase activity of the protein leading to hydrolysis of the 
bound GTP to GDP, therefore cycling the protein back to its inactive state.  Of particular interest 
to this work, Rap1 is anchored to lipid membranes through the covalent attachment of 
geranylgeranyl lipid moieties to the C-terminus of the protein, which is necessary for proper 
functioning (Stork and Dillon, 2005).  Using the HMT-3522 breast cancer progression series, it 
was observed that while Rap1 levels were not dramatically altered between non-tumorigenic S1 
cells and tumorigenic T4-2 cells, the levels of GTP-bound Rap1 was much higher in 
disorganized T4-2 clusters of cells.  Interestingly, this distinction was only evident when assayed 
from 3D culture (Itoh et al., 2007).  Inhibition of Rap1 activity in T4-2 cells using a dominant-
negative version of Rap1 (S17N), restored proper apicobasal polarization and lumen formation 
(Itoh et al., 2007). Interestingly, the ability of EGFR and MAPK inhibition to phenotypically 
revert malignant T4-2 cells to a more acinar-like morphology with correct polarity and a hollow 
lumen has been shown to be dependent upon regulation of Rap1 activity, as this could be 
prevented by expression of dominant-active Rap1 (Itoh et al., 2007).   
While the primary insult(s) that disrupts acinar morphogenesis in many of the above 
examples appears to be either escape from proliferative suppression, inhibition of cell death or a 
combination of the two, a group of cytoplasmic signaling proteins have now been described the 
principal function of which is to govern apicobasal polarity.  A number of proteins have been 
implicated in determining apicobasal polarity in Drosophila melanogaster and many of these 
proteins are conserved among vertebrates.  These include the partitioning defective 3 




scribble (Scrib)/lethal giant larval (Lgl)/discs large (Dlg) proteins (Zhan et al., 2008).   Since 
formation of apicobasal polarity is an essential step in proper acinar development, many of these 
proteins have now been explored in the context of the 3D laminin-rich ECM system.   
Loss of Scrib, the mammalian ortholog of Scribble, is frequently observed in invasive 
mammary lobular carcinoma (Zhan et al., 2008).  Depletion of Scrib using RNAi from MCF10A 
cells resulted in disrupted polarity in 3D culture with consequent luminal filling.  Loss of Scrib 
not only affected ductal morphogenesis, but also cooperated with Myc to induce murine 
mammary tumors (Zhan et al., 2008).    Likewise, PKCζ, a member of the Par complex, has been 
shown to be critical for proper acinar development.  Using a non-phosphorylatable mutant of 
PKCζ, it was demonstrated that activity of this protein is essential for proper apicobasal 
polarization of MCF10A cells in 3D culture (Whyte et al., 2010).  Additionally, expression of a 
kinase-dead version of PKCζ led to hyperproliferative, multi-acinar structures, suggesting that, 
like Scrib, the Par polarity complex may function as a tumor suppressor in breast cancer (Whyte 
et al., 2010).  However, the Par6/aPKC complex has been shown to interact with ErbB2 and a 
dominant-negative version of Par6 can actually rescue the phenotypic effects of ErbB2 
overexpression on MCF10A in 3D culture (Aranda et al., 2006).   
Nuclear Proteins 
One of the most famous genes associated with familial breast cancer is the breast cancer 
1, early onset (BRCA1) gene, which functions as a tumor suppressor largely by maintaining 
genomic stability.  In fact, mutations in the BRCA1 gene may account for up to half of all 
inherited breast cancers (Furuta et al., 2005).  Depletion of BRCA1 (the protein encoded by 




culture.  Very interestingly, proper acinar development could be rescued if BRCA1-deficient 
cells were supplemented with conditioned medium taken from normally developing MCF10A 
cells in 3D culture, suggesting that there are certain critical factors being secreted by BRCA1-
positive cells that are necessary for proper acinar morphogenesis (Furuta et al., 2005). 
 A screen for copy number changes in breast cancer identified an amplified region on 
11q22, containing the Yes-Associated Protein (YAP), using a p53/BRCA1-deficient model of 
mammary carcinogenesis.  Expression of YAP in MCF10A cells led to highly invasive structures 
when grown in a laminin-rich ECM (Overholtzer et al., 2006).  Interestingly, YAP has 
previously been shown to physically interact with p73, enhance its transcriptional activity and 
promote apoptosis (Strano et al., 2001).  Thus, YAP appears to play both tumor suppressive and 
oncogenic roles depending on cellular context.   
Homeobox (Hox) genes encode proteins that function as “master regulator” transcription 
factors to direct many developmental processes.  In addition to their functions during embryonic 
development, it has now been observed that expression of Hox proteins is often altered in 
tumorigenic tissue.  HoxD10 expression is often reduced in breast cancer and re-expression of 
this critical transcription factor in highly malignant MDA-231 breast cancer cells was sufficient 
to induce a phenotypic reversion to a growth-arrested, polar acinar-like morphology in 3D 
culture (Carrio et al., 2005).   
Of particular interest to this work, it was recently demonstrated that expression of three 
of the most common hot-spot p53 mutants (R175H, R248W, R273H) could disrupt MCF10A 
acinar morphogenesis, while expression of a different hot-spot mutant (G245S) had no effect on 




these p53 mutants, this group engineered MCF10A cells depleted of wild-type p53 using RNAi 
and demonstrated that wild-type p53 is not required for acinar development, although they did 
note a mild effect on luminal clearance upon wild-type p53 depletion.  In fact, expression of 
tumor-derived p53 mutants in the background of wild-type p53 depletion amplified the luminal 
filling phenotype (Zhang et al., 2011).  However, it is important to keep in mind that despite the 
strong suggestion of gain-of-function effects of mutant p53 in this 3D system, it is not possible to 
rule out a dominant-negative effect of the tumor-derived mutants on remaining wild-type p53 
even after RNAi-mediated depletion.   
3D culture and metabolism 
 While a few studies have examined metabolic differences between cells grown under 2D 
or 3D culture conditions, this is an area that is just beginning to be widely recognized.  For 
example, it has long been known that transformed cells grown in 3D culture exhibit lower levels 
of glucose uptake compared to the same cells grown as monolayers (Bissell et al., 1977).  
Additionally, one of the key biological processes regulated during acinar morphogenesis is lipid 
metabolism (Fournier and Martin, 2006; Fournier et al., 2006), which may offer important 
insight into this work.  This is particularly important for tissue-specific functions, such as 
lactation (Rodriguez-Cruz et al., 2006; Rudolph et al., 2007).  As noted above, one mechanism 
by which mammary epithelial cells can clear cells from their lumina is through depletion of ATP 
in cells detached from the ECM, the importance of which becomes apparent when apoptosis is 
inhibited.  In fact, HER2/neu overexpression in MCF10A cells not only inhibits luminal 
apoptosis, but also bypasses this backup mechanism by increasing glucose uptake and therefore 




In addition, the activity of a number of transcription factors has been shown to be highly 
regulated by culture in a 2D versus a 3D environment.  Of particular interest to this work, the 
activity of the SREBP1 transcription factor (as measured by binding affinity to its cognate 
response element) was shown to be approximately 60 times higher in 3D culture compared to 2D 
culture (Dozmorov et al., 2008).  
The History of Cholesterol 
 The isolation of cholesterol dates back nearly two hundred years to Michel Chevreul, a 
French chemist, who first proposed the name “cholesterine” (derived from Greek: chole=bile and 
stereos=solid), as it had first been identified in gallstones (Vance and Van den Bosch, 2000).  
The molecule was later renamed cholesterol and was shown to be a vital component of all animal 
cells.  Heinrich Wieland and Adolf Windaus shared the 1928 Nobel Prize in Chemistry for 
elucidating the complex structure of cholesterol (an interesting historical note is that the structure 
for which they shared the Nobel Prize was not entirely correct, the structure we now know to be 
cholesterol was not solved until 1932) (Vance and Van den Bosch, 2000).  As noted above, all 
animal cells require cholesterol, which they can acquire through two mechanisms: de novo 
biosynthesis and uptake of low density lipoproteins (LDL) that contain esterified cholesterol 
(Vance and Van den Bosch, 2000).    
Rudolph Schoenheimer, first in Berlin and then at Columbia University, pioneered the 
technique of isotope-labeling to study biosynthetic processes which would be used to elucidate 
the complex process of cholesterol biosynthesis.  In fact, Schoenheimer’s groundbreaking work 
paved the way for at least three later Nobel Prizes as he began the work of elucidating the 




Bloch the Nobel Prize in Physiology or Medicine in 1964, and was the first to demonstrate the 
feedback regulation of cholesterol biosynthesis, which led Michael Brown and Joe Goldstein to 
their Nobel Prize in Physiology or Medicine in 1985 (Vance and Van den Bosch, 2000).  It was 
subsequently shown that nearly all mammalian cells have the ability to carry out de novo 
cholesterol biosynthesis (Siperstein, 1970).   
The Mevalonate Pathway (isoprenoid/sterol biosynthetic pathway) 
 The biosynthesis of cholesterol is achieved through a series of enzymatic events 
involving over 30 different enzymes and numerous cofactors (Vance and Van den Bosch, 2000).  
This pathway also produces a number of biomolecules that are important for a variety of cellular 
processes including cell growth, protein glycosylation, protein prenylation and mitochondrial 
electron transport (Waterham, 2006).  The key enzymatic steps in the mevalonate pathway are 
detailed below and depicted in Figure 2.S3 (Brown and Goldstein, 1980; Goldstein and Brown, 
1990; Waterham, 2006).   
 The mevalonate pathway begins with the two carbon acetyl-CoA, which combines with 
another molecule of acetyl-CoA to become acetoacetyl-CoA through the action of cytosolic 
acetyl-CoA acetyltransferase (encoded by ACAT2).  Condensation of acetoacetyl-CoA with 
another molecule of acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) is 
catalyzed by cytosolic HMG-CoA synthase (encoded by HMGCS1).  HMG-CoA is subsequently 
reduced to mevalonate through two molecules of NADPH.  This reaction is catalyzed by an 
endoplasmic reticulum (ER)-bound enzyme, HMG-CoA reductase (encoded by HMGCR), which 
is the rate limiting step in the mevalonate pathway.  Mevalonate is then phosphorylated by two 




PMVK, respectively).  Mevalonate decarboxylase (encoded by MVD) then catalyzes the 
decarboxylation of 5-pyrophosphate mevalonate to isopentenyl pyrophosphate.  This is the basic 
5-carbon isoprene unit used for all subsequent isoprenoid synthesis.  Cytosolic isopentenyl 
pyrophosphate isomerase (encoded by IDI1) interconverts isopentenyl pyrophosphate (IPP) with 
dimethylallyl pyrophosphate (DMAPP).  One molecule of IPP combines with one molecule of 
DMAPP in a “head-to-tail” condensation to form geranyl pyrophosphate, which subsequently 
combines with another molecule of IPP in another “head-to-tail” condensation reaction catalyzed 
by farnesyl pyrophosphate synthase (encoded by FDPS) to form 15-carbon farnesyl 
pyrophosphate (FPP).  Farnesyl pyrophosphate represents the major branchpoint in the 
mevalonate pathway as it can continue on to cholesterol or be diverted into a number of 
biologically active metabolites such as geranylgeranyl pyrophosphate, dolichol and ubiquinone.  
The importance of these offshoots will be detailed below.   
 If cholesterologenesis is to continue, squalene synthase (encoded by FDFT1) combines 
two molecules of FPP in a “head-to-head” condensation reaction to form 30-carbon squalene, the 
first committed intermediate in the sterol biosynthetic pathway.  Squalene epoxidase (encoded by 
SQLE) next converts squalene to 2,3-oxidosqualene, a reaction which requires O2 and NADPH.  
2,3-oxidosqualene is then cyclized to lanosterol, catalyzed by lanosterol synthase (encoded by 
LSS).  Lanosterol is then converted to cholesterol through at least eight additional enzymatic 
steps, the order of which is thought to be tissue-dependent.  The end-product of the canonical 
mevalonate pathway is the 27-carbon cholesterol molecule, which can subsequently be 





Non-sterol products of the mevalonate pathway 
While the mevalonate pathway has been studied most extensively in relation to 
cholesterol production, particularly in the liver, it is important to keep in mind that nearly all 
mammalian cells have this pathway intact and have the ability to generate cholesterol de novo.  
This pathway is not only responsible for cholesterol production, but for many mevalonate-
derived intermediate metabolites that have diverse biological functions.  Some of the key 
biomolecules produced by the mevalonate pathway will reviewed below. 
As mentioned above, farnesyl pyrophosphate (FPP) is a critical branch point in the 
mevalonate pathway, as it can give rise to squalene and thus cholesterol, or be diverted to 
geranylgeranyl pyrophosphate on route to a number of important non-sterol products (Mo and 
Elson, 2004).  Additionally, farnesyl pyrophosphate and geranylgeranyl pyrophosphate can be 
post-translationally attached to proteins on their C-terminus, serving to anchor these proteins to 
lipid membranes (Basso et al., 2006).  Protein prenylation, the term that encompasses 
farnesylation and geranylgeranylation of proteins, can occur through the action of farnesyl 
transferase or geranylgeranyl transferases.   
These lipid moieties are covalently attached to cysteine residues embedded in specific 
sequences in the extreme C-terminal regions of target proteins.  The cysteine residue in CaaX 
motifs3 is the target for farnesylation by farnesyl transferase.  Geranylgeranylation can occur 
through the activity of geranylgeranyl transferase-1 (GGTase-1) or geranylgeranyl transferase-2 
(GGTase-2).  GGTase-1 targets proteins with a C-terminal leucine residue (CaaL motifs)4, 
                                                            
3 C=cysteine, A=aliphatic amino acid (I, L, V, A or P), X=any amino acid 
 




whereas GGTase-2 targets proteins with two C-terminal cysteines (XXCC, XCXC or CCXX)5 
(Basso et al., 2006).  While a number of target proteins can be either farnesylated or 
geranylgeranylated, a subset of target proteins are specific for one modification (Maurer-Stroh et 
al., 2007).  For example, H-Ras is farnesylated and RhoA is geranylgeranylated (Casey et al., 
1989; Fried, 2008; Yoshida et al., 1991).  In addition to these famous targets, other proteins 
targeted by prenylation include nearly all small G-proteins in addition to proteins such as nuclear 
lamins (Basso et al., 2006). 
Another form of post-translational modification is also regulated by the mevalonate 
pathway, as dolichol is a critical determinant in N-linked glycosylation of proteins (Graaf et al., 
2004).  Additionally, the mevalonate pathway produces ubiquinone (also known as coenzyme 
Q10), a vital component of the mitochondrial electron transport chain, and isopentyladenine, a 
key constituent of transfer RNAs (tRNAs) (Brown and Goldstein, 1980; Fears, 1981).   
Regulation of the mevalonate pathway 
 Since the early experiments by Schoenheimer in the 1930’s, later confirmed by a number 
of groups in the 1950’s-1960’s, it has been demonstrated that cholesterol biosynthesis is tightly 
regulated to maintain homeostasis (Edwards et al., 2000; Vance and Van den Bosch, 2000).  The 
two major mechanisms controlling cholesterol homeostasis are the levels/activity of enzymes 
involved in de novo biosynthesis and levels of the low density lipoprotein receptor (LDLR), 
responsible for uptake of cholesterol in the form of plasma LDL (Goldstein and Brown, 1990).  
When adequate levels of sterols are present in cells, the levels of LDLR and the cascade of 
enzymes involved in cholesterologenesis are kept at a relatively constant level; however, upon 
                                                            




conditions of sterol deprivation, the expression of the LDL receptor and nearly all enzymes in the 
mevalonate pathway are rapidly induced (Bengoechea-Alonso and Ericsson, 2007).  
 This finely tuned regulation has been shown to occur at multiple levels, including 
degradation of the rate-limiting enzyme HMG-CoA reductase, but is thought to occur primarily 
at the level of transcription (Sato, 2010).  A family of transcription factors dubbed the sterol 
regulatory element binding proteins (SREBPs) was found to regulate the expression of nearly 
every enzyme in the cholesterol (as well as the fatty acid) biosynthetic pathways (Goldstein et 
al., 2006; Hua et al., 1993; Wang et al., 1994).  SREBPs are basic-helix-loop-helix-leucine-
zipper (bHLH-leucine zipper) transcription factors; however, they are unique members of this 
class of transcription factors in at least two important respects.  First, they are synthesized as 
inactive precursors (approximately 1150 amino acids), which are bound in the endoplasmic 
reticulum (ER) (Eberle et al., 2004).  These precursor SREBPs are bound in a hairpin fashion 
through the ER membranes with both the N-terminal transcription factor domains and C-terminal 
regulatory domains facing the cytosol.  A short loop projecting into the ER lumen connects the 
two membrane-spanning helices (Goldstein et al., 2006).  When levels of cellular sterols drop, 
SREBPs are transported to the Golgi apparatus where they undergo successive cleavage events 
to release N-terminal fragments of approximately 480 amino acids.  These N-terminal (mature) 
SREBPs are subsequently transported into the nucleus where they can dimerize and function as 
sequence-specific transcription factors (Bengoechea-Alonso and Ericsson, 2007).  Secondly, 
while other bHLH-leucine zipper transcription factors recognize E-boxes (5’-CANNTG-3’)6, 
SREBPs can recognize both E-boxes as well as sterol regulatory elements, represented as SRE-1 
                                                            




(5’-TCACNCCAC-3’)7 (Eberle et al., 2004; Hua et al., 1993; Wang et al., 1994).  Both SREBP-
1 and SREBP-2 conserve the critical amino acids in the bHLH-leucine zipper, implicated in 
DNA recognition by Max, another bHLH-leucine zipper transcription factor (Hua et al., 1993).  
This altered sequence-specificity has been shown to be due to a tyrosine substitution for a 
conserved arginine in the basic region, which allows the SREBPs to recognize the direct repeats 
instead of palindromic sequences (Osborne and Espenshade, 2009).   
There are three known members of the SREBP family: SREBP-1a and SREBP-1c 
(encoded by the same gene SREBF1) and SREBP-2 (encoded by SREBF2).  SREBP-1a and 
SREBP-1c use alternative transcriptional start sites, differing only in their first exon (Osborne, 
2000).  As the transactivation domain of SREBP-1 is largely contained in the first exon, SREBP-
1c encodes significantly fewer acidic residues and is thus a much weaker transcriptional activator 
compared to SREBP-1a (Eberle et al., 2004).  SREBP-1 and SREBP-2 share 47% homology 
overall and are 71% identical in the bHLH-leucine zipper region, yet interestingly they have 
been shown to preferentially transactivate distinct subsets of target genes (McPherson and 
Gauthier, 2004).  SREBP-1a has been shown to be capable of transactivating nearly every key 
enzyme in the fatty acid and cholesterol biosynthetic pathways.  Likewise, SREBP-2 can 
transactivate nearly every gene in both biosynthetic pathways, although it shows a strong 
preference for cholesterol biosynthetic enzymes.  SREBP-1c, on the other hand, is very specific 
for fatty acid biosynthetic genes and as mentioned previously, is a much weaker transcriptional 
activator than either of the other family members.  In order to function as transcription factors, 
SREBPs most commonly homo-dimerize.  To complicate matters hetero-dimerization between 
isoforms has also been shown to occur, although the effect on target selectivity has not yet been 
                                                            




examined (Datta and Osborne, 2005).  It has also been observed that the SREBPs are rather weak 
transcriptional activators on their own and most often require co-activators such as NF-Y or Sp1 
for efficient transactivation (Osborne, 2000; Reed et al., 2008).  
In normal cells, SREBP activation is tightly regulated by two proteins, the SREBP 
Cleavage Activating Protein (SCAP) and insulin-induced genes (INSIGs) (Brown and Goldstein, 
2009).  SCAP directly binds the C-terminus of SREBPs and this SCAP-SREBP complex is held 
in the ER by INSIG, which is anchored in the ER membrane.  The interaction between SCAP 
and INSIGs is mediated by regulatory sterols.  Thus when sterol levels in the cell fall, the 
interaction between SCAP and INSIG is alleviated and the SCAP-SREBP complex is transported 
to the Golgi apparatus in a COPII-dependent manner (Osborne and Espenshade, 2009).  In the 
Golgi, the SREBPs are cleaved by two proteases bound within the Golgi-membrane.  Site-1 
protease (S1P) first cleaves the precursor SREBP within the luminal loop.  Only then can the 
site-2 protease (S2P) cleave SREBP within the transmembrane segment, releasing the N-terminal 
mature SREBP, which is then translocated to the nucleus through a pathway that requires 
importin-β.  Completing the feedback loop, mature SREBPs transactivate the gene encoding 
INSIG thus shutting off SREBP signaling once sufficient sterol levels are restored (Goldstein et 
al., 2006; Osborne and Espenshade, 2009).   
Mevalonate pathway inhibitors 
 Cholesterol has long been associated with atherosclerosis and coronary heart disease 
(Tobert, 2003).  Thus effective inhibitors for cholesterol biosynthesis were avidly pursued during 
the 1970s.  In 1976, Endo and colleagues isolated a compound from a fermentation broth of 




reductase, the rate-limiting step in cholesterologenesis, which came to be known as compactin 
(also known as ML236B) (Brown and Goldstein, 1980).  Four years later, a second HMG-CoA 
reductase inhibitor was isolated from a fermentation broth of Aspergillus terreus.  This second 
compound was initially named mevinolin, but was later renamed lovastatin, and went on to 
become the first FDA-approved HMG-CoA reductase inhibitor in 1987 (Tobert, 2003). 
 The statin class of compounds are structurally similar and all function as competitive 
inhibitors to HMG-CoA reductase, competing for HMG-CoA binding (Tobert, 2003; Wong et 
al., 2002).  Statins can be categorized into either a lipophilic or hydrophilic class.  Whereas 
lipophilic statins exhibit no tissue selectivity and thus permeate multiple tissue types, hydrophilic 
statins are specifically designed to have a higher affinity for hepatic tissue (Tobert, 2003).  While 
this is often seen as a benefit for treatment of hypercholesterolemia, as hepatic-selective statins 
exert fewer systemic side effects, lipophilic statins appear to have a much more potent anti-
cancer effect on non-hepatic tissue, as will be discussed in more detail later.   
 In addition, a number of other inhibitors that perturb the mevalonate pathway are being 
explored.  For example, a number of compounds which inhibit farnesyl transferase or 
geranylgeranyl transferase are under investigation as anti-cancer agents, although these have not 
shown much promise in early phase clinical trials (Mo and Elson, 2004).  A recently described 
inhibitor that blocks SREBP activation, termed Fatostatin, may also show promise as an anti-
cancer therapeutic (Kamisuki et al., 2009).  In addition, Metformin, a first-line agent for type II 
diabetes, has also been shown to inhibit the mevalonate pathway (Nilsson et al., 2011).   This is 
presumably due to its activation of AMP-activated protein kinase (AMPK), which inhibits the 
SREBP transcription factors (Li et al., 2011c).  Interestingly, Metformin has previously been 




The Mevalonate Pathway and Cancer 
A number of different tumor types, including breast cancer, exhibit elevated or 
dysregulated activity of the mevalonate pathway (Koyuturk et al., 2007; Wong et al., 2002).  In 
fact, a number of studies have suggested that malignant cells are more highly dependent on the 
continuous availability of metabolites produced by the mevalonate pathway than their non-
malignant counterparts (Buchwald, 1992; Larsson, 1996).  Additionally, many tumor cells have 
lost the feedback inhibition normally present in the mevalonate pathway (Buchwald, 1992; 
Siperstein, 1970).  The mevalonate pathway has been demonstrated to be necessary for DNA 
synthesis (Langan and Volpe, 1986; Quesney-Huneeus et al., 1979) and a high levels of multiple 
enzymes in this pathway have been shown to have prognostic significance in breast cancer 
(Clendening et al., 2010).  Ectopic expression of HMG-CoA reductase or supplementation with 
additional mevalonate has been shown to increase tumorigenicity in mouse models (Clendening 
et al., 2010; Duncan et al., 2004).   In accordance with these findings, HMG-CoA reductase 
inhibitors have been highly effective in pre-clinical models of tumorigenesis, both in cell culture 
and in vivo (Campbell et al., 2006; Cao et al., 2011; Denoyelle et al., 2001; Kidera et al., 2010; 
Lim et al., 2009; Sanchez et al., 2008; Shachaf et al., 2007; Shibata et al., 2004; Shibata et al., 
2003; Sutter et al., 2005; Zhong et al., 2005). 
 There is also a growing body of literature suggesting that inhibition of the mevalonate 
pathway, particularly with HMG-CoA reductase inhibitors, may reduce tumor growth or even 
prevent tumor formation.  Multiple retrospective analyses have observed dramatically decreased 
rates of breast, colon, lung and prostate cancers in patients prescribed statins for 
hypercholesterolemia (Blais et al., 2000; Katz et al., 2005; Khurana et al., 2007a; Khurana et al., 




potential chemopreventive agents in breast cancer (Ahern et al., 2011; Blais et al., 2000; Cauley 
et al., 2003; Garwood et al., 2010; Kumar et al., 2008; Kumar et al., 2006; Kwan et al., 2008; 
Pedersen et al., 2000; Prowell et al., 2006; Stein E A, 1993).  However, it should be noted that 
the anti-cancer activity of HMG-CoA reductase inhibitors is still hotly debated, as a number of 
meta-analyses have failed to show any correlation between statin use and tumor incidence 
(Baigent et al., 2005; Browning and Martin, 2007).  One possibility, which will be raised in 
Chapter 2, is that statins may target a specific molecular subtype (or subtypes) of tumors and this 
anti-cancer effect is diluted by grouping all patients together for epidemiologic purposes.  In 
relation to this work, it will be particularly interesting to examine the rate of TP53 mutations in 
tumors that develop in statin users.   
Concluding Remarks 
 p53 plays a pivotal role in many aspects of tumor biology, thus it is not surprising that it 
is mutated in the majority of human malignancies (Vogelstein et al., 2000).  It is now clear that 
many tumor-derived p53 missense mutants not only reflect a loss of wild-type p53 function, but 
actually promote certain aspects of tumor progression (Lang et al., 2004; Olive et al., 2004; 
Terzian et al., 2008).  Elucidation of the molecular mechanisms by which these p53 mutant 
proteins contribute to tumorigenesis will deepen our understanding of cancer biology as well as 
potentially offer novel therapeutic targets for mutant p53 expressing tumors.   
In this dissertation, we explore the role of mutant p53 proteins and their role in breast 
tumorigenesis using a three-dimensional culture model system.  It is increasingly recognized that 
the microenvironment that a cell experiences in traditional monolayer culture dramatically 




Bissell and Petersen groups, which allows one to easily distinguish non-malignant and 
tumorigenic cells based on their morphology and behavior in 3D culture (Barcellos-Hoff et al., 
1989; Petersen et al., 1992), to recapitulate physiologic conditions.  We identify the mevalonate 
pathway as upregulated by endogenous p53 mutants and provide evidence that inhibition of this 
critical cellular pathway may offer a much needed therapeutic target for mutant p53 tumors.   
 
“Those sterols! Dr. Obisopo frowned…Longbotham had even suggested a 
connexion fatty alcohols and neoplasms.  In other words, cancer might be 
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Figure 1.1 TP53 Mutational Spectrum in Human Breast Cancer 
(A) TP53 missense mutation data for human breast cancer patients (N=2,207) was obtained from 
the p53 IARC database and plotted as a function of amino acid position.  Schematic of the p53 
protein with domain structures illustrated.  TAD: Transactivation Domain (1-42); PRD: Proline-
Rich Domain (40-92), which also contains a second transactivation domain; DBD: DNA-Binding 
Domain (101-306); OD: Oligomerization Domain 307-355), also contains a nuclear export 
signal; CTD: C-Terminal Regulatory Domain (356-393), also contains three nuclear localization 
signals (adapted from p53.free.fr) 
Figure 1.2 Schematic of Normal Acinar Development 
(A) When non-malignant mammary epithelial cells are plated as single cells in a laminin-rich 
extracellular matrix (left), they first proliferate to form a spheroid.  When the cells in the center 
of the spheroid lose contact with the basement membrane, they are induced to undergo apoptosis, 
leaving a single layer of apicobasally polarized cells surrounding a hollow lumen (right). 
Table 1.1 Select list of mutant p53 transcriptionally-activated genes 
A literature search was performed for mutant p53 transcriptionally-activated genes.  Genes were 
grouped into biological categories based on reported functions and Gene Ontology annotations. 
Table 1.2 Select list of proteins implicated in 3D acinar morphogenesis  
A literature search was performed for proteins/pathways reported to disrupt acinar 
















Freed-Pastor et al., Table 1.1 
Category Gene 
Symbol 
Name/Synonym Mutant(s) Reference(s) 
Increased 
Proliferation 
MYC c-Myc V143A, R175H, 
R273H, R248W, 
D281G 
(Frazier et al., 
1998) 
 CXCL1 Chemokine (C-X-C motif) 
ligand 1; GRO1 
R175H, R273H, 
R248W, G245S  
(Yan and Chen, 
2009, 2010) 
 MAP2K3 Mitogen activated protein 
kinase kinase 3 
R175H, R273H, 
R280K 
(Bossi et al., 2008; 
Gurtner et al., 
2010) 
 FOS c-Fos C174Y (Preuss et al., 
2000) 





(Deb et al., 1992) 
 MAD1L1 MAD1 mitotic arrest 
deficient-like 1 
D281G (Iwanaga and 
Jeang, 2002) 
 CCNE2 Cyclin E2 R280K, R273H (Girardini et al., 
2011) 
 CCNA2 Cyclin A2 R175H, L194F, 
R273H 
(Di Agostino et al., 
2006) 
 CCNB1 Cyclin B1 R175H, L194F, 
R273H 
(Di Agostino et al., 
2006) 
 CCNB2 Cyclin B2 R175H, L194F, 
R273H, D281G 
(Di Agostino et al., 
2006) 
 CDK1 Cyclin dependent kinase 1 R175H, L194F, 
R273H 
(Di Agostino et al., 
2006) 




(Di Agostino et al., 
2006) 
 E2F5 E2F5 D281G (Scian et al., 2005) 
 ASNS Asparagine Synthetase R175H, R273H, 
D281G 
(Scian et al., 2004) 




(Bossi et al., 2008; 
Werner et al., 
1996) 
 IGFBP3 Insulin-like growth factor 
binding protein 3 
R175H (Stambolsky et al., 
2010) 







 MCM6 Minichromosome 
maintenance complex 
component 6 
D281G (Scian et al., 2005) 




EGR1 Early growth response 1 R175H, H179E, 
R248W, R273H, 
D281G 
(Weisz et al., 2004) 
 NFKB2 NF-κB (p52) R175H, R273H, 
D281G 
(Scian et al., 2005) 




family B member 1; MDR1 D281G Lin et al., 1995; 
Sampath et al., 
2001; Strauss and 
Haas, 1995)  
 TIMM50 Translocator of the inner 
mitochondrial membrane 50 
R175H, R273H (Sankala et al., 
2011) 
 LGALS3 Lectin, galactoside-binding, 
soluble; Galectin-3 
R273H (Lavra et al., 2009) 
 BCL2L1 Bcl-xL R273H (Bossi et al., 2008) 
 IGF2 Insulin-like growth factor 2 R249S (Lee et al., 2000) 
 DUT Deoxyuridine triphosphatase; 
dUTPase 
R175H, R248W (Pugacheva et al., 
2002) 
Metabolism DHCR24 24-dehydrocholesterol 
reductase; Seladin-1 
R175H, R273H (Bossi et al., 2008) 
 CYP24A1 Cytochrome P450, family 24, 
subfamily A, polypeptide 1 





MMP3 Matrix metalloproteinase 3 R175H (Buganim et al., 
2010) 
 MMP13 Matrix metalloproteinase 13 R175H, D281G (Sun et al., 2000) 
 ITGA6 Integrin alpha 6 D281G (Scian et al., 2005) 
 PXN Paxillin beta R175H, R273H (Bossi et al., 2008) 
GTPase 
activity 
ARHGDIA Rho GDP dissociation 
inhibitor alpha 
R175H, R273H (Bossi et al., 2008) 
 RANGAP1 Ran GTPase activating 
protein 1 
R175H, R273H (Bossi et al., 2008) 
 DEPDC1 DEP domain containing 1 R280K, R273H (Girardini et al., 
2011) 




TERT Telomerase reverse 
transcriptase 
D281G (Scian et al., 2004) 
Cytoskeleton  KIF20A Kinesin family member 20A; 
RAB6KIFL 
R175H, R273H (Bossi et al., 2008) 
Cytoskeleton EPB41L4B Erythrocyte membrane 
protein band 4.1 like 4B 
R280K, R273H (Girardini et al., 
2011) 
M-phase BUB1 Budding uninhibited by 
benzimidadazoles 1 homolog 
R280K, R273H (Girardini et al., 
2011) 
Centromere NCAPH Non-SMC condensing I 
complex, subunit H 
R280K, R273H (Girardini et al., 
2011) 
Centromere MIS18A MIS18 kinetochore protein 
homolog A; C21orf45 
R280K, R273H (Girardini et al., 
2011) 




CPSF6 Cleavage and polyadenylation 
specific factor 6 
R280K, R273H (Girardini et al., 
2011) 
Unknown FAM64A Family with sequence 
similarity 64, member A 
R280K, R273H (Girardini et al., 
2011) 
RNA stability ID4 Inhibitor of DNA binding 4 R175H, R273H (Fontemaggi et al., 
2009) 
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Extracellular MMP-3 Yes (OE: SCp2) N.D. (Lochter et al., 
1997) 












 TIMP-1 Yes (OE: 
MCF10A) 
N.D. (Jung et al., 2006; 
Liu et al., 2005) 
 Fibronectin N.D. Yes (Inh: T4-2) (Sandal et al., 
2007) 
Cell Adhesion Integrin β1 N.D. Yes (Inh: T4-2) (Wang et al., 
2002; Wang et 
al., 1998; Weaver 
et al., 1997) 
 Integrin β4 Yes (Inh: S1) Yes (KD/inh: 
SUM159) 
(Gabarra et al., 
2010; Lipscomb 
et al., 2005; 
Weaver et al., 
1997) 
 Integrin α2 N.D. Yes (OE: 
Mm5MT) 
(Zutter et al., 
1995) 
 Dystroglycan N.D. Yes (OE: T4-2) (Muschler et al., 
2002) 
 E-Cadherin Yes (KD: S1) Yes (OE: 
SKBR3, MDA-
231) 
(Fournier et al., 
2009; Meiners et 
al., 1998; Wang 
et al., 2002) 
 CEACAM1 Yes (KD: 
MCF10F) 









N.D. (Wrobel et al., 
2004) 
 c-Met/HGF Yes (OE: 
MCF10A)  














Yes (Inh: T4-2) (Beliveau et al., 






al., 2001; Wang 
et al., 2002; 
Wang et al., 
1998) 
 IGF1R Yes (OE: 
MCF10A) 
N.D. (Irie et al., 2005; 
Irie et al., 2010; 
Litzenburger et 
al., 2009) 
 FGFR1 Yes (OE: 
MCF10A) 
N.D. (Xian et al., 2009)
 PTPN12 Yes (KD: 
MCF10A) 
N.D. (Sun et al., 2011) 
Intracellular 
signaling 




Yes (Inh: T4-2) (Beliveau et al., 
2010; Isakoff et 
al., 2005; Liu et 
al., 2004b; Wang 
et al., 2002) 
 Akt Yes (OE: 
MCF10A) 
N.D. (Debnath et al., 
2003b) 
 PTEN Yes (KD: S1)* N.D. (Fournier et al., 
2009) 
 Raf Yes (OE: S1, 
MCF10A) 
N.D. (Beliveau et al., 





N.D. Yes (Inh: T4-2) (Wang et al., 
2002; Wang et 
al., 1998) 
 Rap-1 N.D. Yes (DN: T4-2) (Itoh et al., 2007) 
 Src Yes (OE: 
MCF10A) 
N.D. (Reginato et al., 
2005) 
 Scribble Yes (KD: 
MCF10A) 






N.D. (Whyte et al., 
2010) 
Nuclear Factors BRCA1 Yes (KD: 
MCF10A) 
N.D. (Furuta et al., 
2005) 
 p53 (mutant) Yes (OE: 
MCF10A) 








N.D. (Overholtzer et 
al., 2006) 









N.D. Yes (OE: T4-2) (Chen et al., 
2000) 
*However PTEN homozygous deletion from MCF10A cells does not affect 
acinar morphogenesis (Vitolo et al., 2009) 
 
OE=overexpression; KD=knockdown via RNAi; Inh=inhibition by specific inhibitors or inhibitory 














Mutant p53 Disrupts Mammary Acinar Morphogenesis via the Mevalonate Pathway 
 
William A Freed-Pastor1, Hideaki Mizuno2,3, Xi Zhao4,5, Anita Langerød4, Sung-Hwan Moon1, 
Ruth Rodriguez-Barrueco6, Anthony Barsotti1, Agustin Chicas7, Wencheng Li8, Alla Polotskaia9, 
Mina J Bissell10, Timothy F Osborne11, Bin Tian8, Scott W Lowe7, Jose M Silva6, Anne-Lise 
Børresen-Dale4,5, Arnold J Levine2, Jill Bargonetti9, Carol Prives1 
1Department of Biological Sciences, Columbia University, New York, NY 10027, USA, 2The 
Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ 08540, USA, 
3Discovery Science and Technology Department, Chugai Pharmaceutical Co. Ltd., Kamakura, 
Kanagawa 247-8530, Japan, 4Department of Genetics, Institute for Cancer Research, Oslo 
University Hospital Radiumhospitalet, 0310 Oslo, Norway, 5Institute of Clinical Medicine, 
Medical Faculty, University of Oslo, Norway, 6Institute for Cancer Genetics, Columbia 
University, New York, NY 10032, USA, 7Cold Spring Harbor Laboratory, Cold Spring Harbor, 
NY 11724, USA, 8Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey 
Medical School, Newark, NJ 07107, USA, 9Department of Biological Sciences, Hunter College 
and The Graduate Center Biochemistry and Biology Programs, CUNY, New York, NY 10065, 
USA, 10Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, 
USA, 11Metabolic Signaling and Disease Program, Sanford-Burnham Medical Research Institute, 
Orlando, FL 32827, USA 
Correspondence: Carol Prives 




p53 is a frequent target for mutation in human tumors and mutant p53 proteins can actively 
contribute to tumorigenesis. We employed a three-dimensional culture model in which non-
malignant breast epithelial cells form spheroids reminiscent of acinar structures found in vivo, 
whereas breast cancer cells display highly disorganized morphology.  We found that mutant p53 
depletion is sufficient to phenotypically revert breast cancer cells to a more acinar-like 
morphology. Genome-wide expression analysis identified the mevalonate pathway as 
significantly upregulated by mutant p53.  Statins and sterol biosynthesis intermediates reveal that 
this pathway is both necessary and sufficient for the phenotypic effects of mutant p53 on breast 
tissue architecture. Mutant p53 associates with sterol gene promoters at least partly via SREBP 
transcription factors.  Finally, p53 mutation correlates with highly expressed sterol biosynthesis 
genes in human breast tumors. These findings provide insight into breast carcinogenesis and 
implicate the mevalonate pathway as a therapeutic target for tumors bearing mutations in p53. 
 
HIGHLIGHTS 
 Depletion of mutant p53 phenotypically reverts breast cancer cells in 3D culture 
 Mutant p53 upregulates 17 genes encoding enzymes in the mevalonate pathway  
 HMG-CoA reductase inhibitors mimic the phenotypic effects of mutant p53 depletion 
 TP53 mutation correlates with high levels of mevalonate pathway genes in human tumors 
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INTRODUCTION 
 The TP53 gene, which encodes the p53 protein, is the most frequent target for mutation 
in tumors, with over half of all human cancers exhibiting mutation at this locus (Vogelstein et al., 
2000). Wild-type p53 functions primarily as a transcription factor and possesses an N-terminal 
transactivation domain, a centrally located sequence specific DNA binding domain, followed by 
a tetramerization domain and a C-terminal regulatory domain (Laptenko and Prives, 2006).  In 
response to a number of stressors, including DNA damage, hypoxia and oncogenic activation, 
p53 becomes activated to promote cell cycle arrest, apoptosis or senescence thereby suppressing 
tumor growth.   It also plays many additional roles including regulating cellular metabolism 
(Vousden and Prives, 2009).   
Unlike most tumor suppressor genes, which are predominantly inactivated as a result of 
deletion or truncation, the majority of mutations in TP53 are missense mutations, a few of which 
cluster at “hotspot” residues in the DNA binding core domain (Petitjean et al., 2007), while the 
N- and C-terminal domains of this protein are relatively spared from mutation (Hussain and 
Harris, 1998; Soussi and Lozano, 2005; Unger et al., 1993).  In contrast to wild-type p53, which 
under unstressed conditions is a very short-lived protein, these missense mutations lead to the 
production of full-length p53 protein with a prolonged half-life (Brosh and Rotter, 2009; 
Davidoff et al., 1991; Rotter, 1983). While many tumor-derived mutant forms of p53 can exert a 
dominant-negative effect on the remaining wild-type allele, serving to abrogate the ability of 
wild-type p53 to inhibit cellular transformation, the end result in many forms of human cancer is 
frequently loss of heterozygosity (LOH), where the wild-type version of p53 is lost and the 
mutant form is retained, suggesting that there is a selective advantage conferred by losing the 
remaining wild-type p53, even after one allele has been mutated (Brosh and Rotter, 2009).   
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There is substantial evidence that mutant forms of p53 can exert oncogenic, or gain-of-
function, activities independent of their effects on wild-type p53.  In vivo models, in which mice 
harboring two tumor-derived mutants of p53 (equivalent to R175H and R273H in humans) that 
were substituted for the endogenous wild-type p53 locus within the mouse genome, display an 
altered tumor spectrum as well as more metastatic tumors (Lang et al., 2004; Olive et al., 2004).  
The mutational status of p53 has been shown to predict poor outcomes in multiple types of 
human tumors, including breast cancer, and certain p53 mutants associate with an even worse 
prognosis (Olivier et al., 2006; Petitjean et al., 2007).  Mutant p53 has also been demonstrated to 
lead to increased survival, invasion, migration and metastasis in preclinical breast cancer models 
(Adorno et al., 2009; Muller et al., 2009; Stambolsky et al., 2010).  Despite these findings, 
mutant p53-induced phenotypic alterations in mammary tissue architecture have not been fully 
explored.   
Breast cancer is thought to arise from mammary epithelial cells found in structures 
referred to as acini, which collectively form terminal ductal lobular units (TDLU).  Each acinus 
consists of a single layer of polarized luminal epithelial cells surrounding a hollow lumen (Allred 
et al., 2001; Bissell et al., 2002).  While traditional “2D” cell culture has provided insight into the 
process of breast carcinogenesis, such in vitro culture conditions create an environment that 
markedly differs from the microenvironment that a cell would experience in vivo (Vargo-Gogola 
and Rosen, 2007).  By contrast, normal mammary epithelial cells, when grown in a laminin-rich 
extracellular matrix, form three-dimensional structures highly reminiscent of many aspects of 
acinar structures found in vivo (Debnath et al., 2003; Petersen et al., 1992) and the processes and 
pathways that govern and disrupt normal mammary epithelial development in this setting have 
been elegantly defined (Debnath et al., 2002; Muthuswamy et al., 2001; Schafer et al., 2009; 
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Wrobel et al., 2004; Zhan et al., 2008).  Since one of the hallmarks of breast tumorigenesis is the 
disruption of mammary tissue architecture (Friedrich, 2003), three-dimensional (3D) culture 
conditions allow one to readily distinguish normal and tumorigenic tissue by morphological 
phenotype (Kenny et al., 2007; Martin et al., 2008; Muthuswamy et al., 2001).  In addition, 
inhibition of key oncogenic signaling pathways is sufficient to phenotypically revert breast 
cancer cells grown in 3D culture (Beliveau et al., 2010; Bissell et al., 2005; Wang et al., 1998; 
Weaver et al., 1997). In this study we implicate mutant p53 in the disruption of acinar 
morphology and identify a critical cellular pathway by which mutant p53 disrupts mammary 
tissue architecture.  Specifically, we identified seventeen genes encoding enzymes within the 
mevalonate pathway, by which cells produce cholesterol and essential metabolites for a diverse 
set of cellular processes, as novel activation targets of mutant p53 in breast cancer.  The 
mevalonate pathway has been previously implicated in multiple aspects of tumorigenesis (Cao et 
al., 2011; Clendening et al., 2010; Koyuturk et al., 2007; Shachaf et al., 2007; Wong et al., 2002) 
and this pathway is the target of the safe and effective class of statin drugs (Buchwald, 1992; 
Wong et al., 2002). Our data have also revealed a potential mechanism by which mutant p53 
expression increases expression of the genes in the mevalonate pathway. 
RESULTS 
Mutant p53 depletion in breast cancer cells leads to a phenotypic reversion in 3D culture 
To investigate the role of mutant p53 in breast cancer, we employed the 3D culture 
protocol where mammary epithelial cells are grown in a laminin rich extracellular matrix 
(Matrigel). In 3D culture, non-malignant MCF10A mammary cells with wild-type p53 undergo a 
well-characterized progression of three-dimensional morphogenesis, which results in spherical 
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acinus-like structures (Debnath et al., 2003; Petersen et al., 1992) (Figure 2.S2A).  We examined 
the 3D morphologies of two cell lines derived from metastatic breast tumors that each expresses 
exclusively a single mutant p53 allele; MDA-231 (R280K) and MDA-468 (R273H). These cells 
were engineered to stably express a miR30-based doxycycline-inducible shRNA targeting 
endogenous mutant p53 in the 3’ UTR (designated MDA-231.shp53 and MDA-468.shp53).  In 
both cases mutant p53 reduction by shRNA led to dramatic changes in the behavior of the cells 
when cultured in a 3D microenvironment.  MDA-231 cells, when grown in 3D culture, normally 
exhibit an extremely disordered and invasive morphology, which has been characterized as 
“stellate” (Kenny et al., 2007). Depleting these cells of mutant p53 in 3D culture conditions 
almost completely abrogated the stellate morphology of large, invasive structures with bridging 
projections (Figure 2.1A). Instead, MDA-231 cells with reduced p53 developed smaller, less 
invasive appearing cell clusters.  By titrating doxycycline, we observed a progressive loss of 
malignant, invasive characteristics as a function of decreasing levels of mutant p53 (Figure 
2.S1A-D).  This reduction in invasive behavior in 3D culture supports the recent findings that 
mutant p53 promotes the invasion of breast cancer cells (Adorno et al., 2009; Muller et al., 
2009).  Nevertheless, when plated in 3D culture, MDA-231 cells with reduced p53 did not 
assume the ordered acinus-like morphology that is characteristic of non-malignant mammary 
epithelial cells.   
MDA-468 cells have a less invasive, but highly disorganized appearance, and have been 
classified as “grape-like” rather than “stellate” (Kenny et al., 2007). Under 3D culture 
conditions, MDA-468.shp53 cells displayed three types of cellular morphologies (1) 
constellations of cells with a highly disordered “malignant” appearance that comprise about 30-
40% of the population, (2) spherical cell clusters with an “intermediate” morphology that, while 
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disordered, appear less malignant (about 55-65% of the population) and (3) a very small 
proportion (<5%) of structures that closely resemble small acini and contain a hollow lumen 
(examples of these categories are shown in Figure 2.1C). Strikingly, when mutant p53 was 
depleted from these cells, a significant proportion of the population underwent a full phenotypic 
reversion from highly disorganized structures to acinus-like structures with a hollow lumen 
(Figure 2.1D).  These reverted structures also display proper localization of alpha 6 integrin, 
suggesting that they have regained apicobasal polarization (Figure 2.S1E).  Consistent with 
previous studies implicating programmed cell death in the process of luminal clearance (Debnath 
et al., 2002), we occasionally identified dying cells within the luminal space (Figure 2.1D; image 
in right panel reveals dying cell within the central luminal region).  Using either a stable pool of 
MDA-468.shp53 cells (Figure 2.1F) or a stable clone derived from these cells (Figure 2.1G), we 
observed a significant increase in the hollow lumen population upon mutant p53 depletion, with 
nearly 50% of the population falling into this acinus-like morphology in the latter case.  It is 
important to note that while in the experiment shown in Figure 2.1G, we observed a concomitant 
decrease in predominantly the intermediate population upon the reversion to hollow lumen 
structures, in other cases we observed a decrease in both the malignant and intermediate 
populations (e.g. Figure 2.4A below). Since the stable clone of MDA-468.shp53 cells exhibited a 
higher degree of reversion, all further experiments were carried out using these cells.  
Importantly, since both of these breast cancer cell lines express only mutant p53, these 
phenotypic changes may be attributed directly to the reduction in mutant p53 levels. 
To confirm and expand upon these observations, we engineered MDA-468.shp53 cells to 
express an shRNA-resistant version of the p53 mutant that is endogenously found in these cells 
(p53-R273H) or a control vector (Figure 2.2A-B).  Introducing excess mutant p53 into these 
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already malignant cells prevented the phenotypic reversion that normally occurs after depleting 
cells of mutant p53 (Figure 2.2B).  In fact, exogenous mutant p53, combined with the 
endogenous level of mutant p53 led to an even more exaggerated malignant phenotype (highly 
disorganized and invasive) than parental cells (compare left panels of Figure 2.2A and 2B). 
Wild-type p53 primarily functions as a transcription factor and the transactivation 
domains of p53 have previously been implicated in oncogenic functions of mutant p53 such as 
survival and resistance to chemotherapeutics (Lin et al., 1995; Matas et al., 2001; Yan and Chen, 
2010). To interrogate the role of the transactivation domains in the effects of mutant p53 in 3D 
culture, we engineered MDA-468.shp53 cells to express an shRNA-resistant version of the 
endogenous mutant p53 that had been mutated at four key residues (L22Q/W23S/W53Q/F54S), 
shown previously to render its transactivation domains non-functional (Lin et al., 1994; Venot et 
al., 1999). As opposed to mutant p53 with a functional transactivation region (Figure 2.2B), the 
transactivation-dead version of mutant p53 failed to rescue the phenotypic reversion (Figure 
2.2C), suggesting that the oncogenic effects in this system were due to transcriptional changes 
mediated by mutant p53.   
In order to test whether the effects of mutant p53 on 3D morphology of breast cancer 
cells were generalizable between tumor-derived mutants of p53, we replaced the endogenous 
mutant p53 in MDA-231 cells (R280K) with an shRNA-resistant version of p53-R273H, the 
mutant that is endogenously expressed in MDA-468 cells.  While control cells behaved like the 
cells with just the shRNA-targeting p53, expression of p53-R273H partially prevented the 
phenotypic changes of knocking down the endogenous p53-R280K (Figure 2.S1F).  We also 
engineered the non-malignant human mammary epithelial cell line, MCF10A, to express Flag-
tagged versions of the five most frequent p53 mutants found in breast tumors (p53-R175H, -
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R248Q, -R273H, -R248W, -G245S) (http://p53.free.fr). MCF10A cells infected with a control 
vector exhibited normal acinar morphogenesis.  However, in agreement with recently published 
findings (Zhang et al., 2011), expression of the four most frequent mutant p53 proteins led to an 
inhibition of luminal clearance, reminiscent of the filled lumen phenotype observed in ductal 
carcinoma in situ (DCIS) lesions, with p53-R273H and p53-R248W exhibiting the highest 
degree of luminal filling (Figure 2.S2B-F).  To examine whether this phenotype was also 
dependent on the transactivation capacity of p53 mutants, we generated MCF10A cells 
expressing transactivation-deficient versions (mTAD) of these same five p53 mutants, which 
were unable to block luminal clearance, with p53-R273H and p53-R248W displaying the highest 
dependence on their transactivation domains (Figure 2.S2I-J).  Thus, not only can depletion of 
mutant p53 from breast cancer cells lead to a phenotypic reversion in 3D culture, but also mutant 
p53 expression in non-malignant mammary epithelial cells is sufficient to disrupt their 
morphology in 3D culture and the transactivation domain of mutant p53 is required in both cases.   
Tumor-derived mutants of p53 regulate the mevalonate pathway in breast cancer cells 
Since the transactivation activity of mutant p53 is very likely to be critical for its 
phenotypic effects in 3D culture, we performed genome-wide expression profiling on MDA-
468.shp53 cells grown in 3D culture, with or without mutant p53 knockdown.  We identified 989 
genes as significantly altered (p<0.01) following shRNA-mediated downregulation of 
endogenous mutant p53, suggesting that mutant p53 acts promiscuously to affect many cellular 
processes.  To guide our identification of those pathways/processes necessary for mutant p53 
function in 3D culture, we employed two analysis methods, Ingenuity Pathway Analysis (IPA) 
and Gene Ontology (GO) Analysis.  Since each of these analysis tools has a unique approach for 
grouping genes according to the pathway or process in which their protein products are reported 
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to function, we exploited both techniques in hopes that pathways/processes that were identified 
using the two analyses would be more likely to have functional significance.  The mevalonate 
pathway was the most overrepresented cellular pathway using IPA (labeled “Steroid 
Biosynthesis Pathway” by Ingenuity); in fact, it was the only pathway detected with 99% 
confidence (p<0.01) following mutant p53 downregulation (Figure 2.3A).  This pathway, along 
with the related isoprenoid biosynthetic process, was also detected using GO analysis and was 
significantly downregulated upon mutant p53 ablation across three independent experiments 
(Figure 2.3B). 
The mevalonate pathway is responsible for de novo cholesterol synthesis as well as for 
many important non-sterol isoprenoid derivatives (Figure 2.S3) (Goldstein and Brown, 1990).    
Of the many steps that convert Acetyl-CoA to cholesterol, seven genes (HMGCR, MVK, MVD, 
FDPS, SQLE, LSS, DHCR7) encoding enzymes within the mevalonate pathway were found to be 
significantly reduced by mutant p53 depletion according to the IPA. In separate experiments, 
using qRT-PCR we confirmed that expression of all of these genes were markedly reduced 
(p<0.005) when mutant p53 was depleted by shRNA (Figure 2.3C).  We also confirmed that 
p53-mediated regulation of a subset of these genes in MDA-468 cells occurs as a result of RNA 
transcription (as opposed to mRNA stability or some later point of regulation) by using primers 
for nascent transcripts that anneal to intronic regions (data not shown). The genes that were 
affected by mutant p53 knockdown encode key enzymes throughout the mevalonate pathway 
(Figure 2.S3), including the rate-limiting enzyme, 3-Hydroxy-3-methylglutaryl-CoA reductase 
(HMG-CoA reductase).   
The effects of mutant p53 on breast cancer morphology are mediated through the 
mevalonate pathway 
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Elevated or deregulated activity of the mevalonate pathway has been demonstrated in a 
number of different tumors, including breast cancer (Koyuturk et al., 2007; Wong et al., 2002), 
and high levels of many of the enzymes in this pathway have been shown to have prognostic 
significance in breast cancer (Clendening et al., 2010).  This pathway was demonstrated to be 
necessary for DNA synthesis (Langan and Volpe, 1986; Quesney-Huneeus et al., 1979) and a 
number of studies have suggested that malignant cells are more highly dependent on the 
continuous availability of metabolites produced by the mevalonate pathway than their non-
malignant counterparts (Buchwald, 1992; Larsson, 1996).  While the mevalonate pathway has 
been explored most extensively in the context of cholesterol production, which is necessary for 
membrane integrity and thus cell division, many of the intermediate metabolites and side 
products play key roles in other essential cellular processes.  For example, farnesyl 
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) are critical for post-
translational modifications of Ras and RhoA, respectively (Casey et al., 1989; Fried, 2008; 
Yoshida et al., 1991). Cholesterol is necessary for the formation of steroid hormones, such as 
estrogen, progesterone and vitamin D (Goldstein and Brown, 1990).  Coenzyme Q10 
(ubiquinone) plays a vital role in cell respiration, dolichol is essential for N-linked glycosylation 
of proteins and mevalonic acid has been suggested to promote the cell cycle directly (Graaf et al., 
2004; Quesney-Huneeus et al., 1979).  
We took advantage of the fact that many of the biologically active intermediate 
enzymatic products produced by the mevalonate pathway can be readily taken up by cells in 
culture (Denoyelle et al., 2001).  To test whether this pathway is necessary for the phenotypic 
effects of mutant p53, add-back experiments were performed in which breast cancer cells grown 
in 3D culture were depleted of mutant p53 and supplemented with intermediate metabolites 
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produced by the mevalonate pathway.  Addition of the two earliest metabolites, mevalonic acid 
(MVA) and mevalonic acid phosphate (MVAP), was sufficient to dramatically inhibit the 
phenotypic reversion caused by mutant p53 knockdown in MDA-468 cells without affecting the 
amount of p53 depletion (Figure 2.4A and S4A-B). This confirms that activity of the mevalonate 
pathway is sufficient to compensate for the loss of mutant p53 and suggests that up-regulation of 
at least the initial steps of the mevalonate pathway is necessary for the effects of mutant p53 on 
tissue architecture. 
HMG-CoA reductase, which catalyzes the formation of mevalonic acid, is the rate 
limiting step in cholesterol biosynthesis and is famously the target of numerous cholesterol 
reducing statins (Katz et al., 2005).  The use of statins is well established in the clinic to treat 
patients with hypercholesterolemia and there have been multiple reports demonstrating that 
statins can exhibit anti-cancer activity; however, their anti-tumorigenic mechanism has not been 
firmly established (Campbell et al., 2006; Cao et al., 2011; Koyuturk et al., 2007; Shibata et al., 
2003).   
We hypothesized that pharmacologic inhibition of the rate-limiting enzyme in the 
mevalonate pathway might be sufficient to mimic the effects of knocking down mutant p53.  
Strikingly, we found that treatment of breast cancer cells in 3D culture with Simvastatin, a 
lipophilic statin, used at clinically achievable concentrations (Wong et al., 2002), resulted in a 
reduction in growth in both cell lines, in addition to extensive cell death in MDA-468 cells 
(Figure 2.4B) and a significant reduction of the invasive morphology of MDA-231 cells (Figure 
2.4C). In fact, in MDA-231 cells the morphological changes seen with either statin treatment or 
mutant p53 knockdown were virtually the same. The consequence of inhibiting sterol 
biosynthesis in MDA-468 cells was even more dramatic than mutant p53 downregulation alone 
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(cell death as opposed to formation of structures with a hollow lumen).  On the other hand, 
inhibition of HMG-CoA reductase in wild-type p53 expressing MCF10A cells did not result in 
gross morphologic changes when used at clinically achievable concentrations (Figure 2.S4C). 
This suggests that breast cancer cells bearing mutations in p53 upregulate the mevalonate 
pathway and eventually become dependent upon its activity for survival.  Similar results were 
obtained with another lipophilic statin, Mevastatin (Figure 2.S4D and E). Importantly, 
supplementation of mevalonic acid, the enzymatic product of HMG-CoA reductase, to either 
MDA-468 or MDA-231 cells treated with a statin blocked many of the phenotypic effects of 
statins (Compare Figure 2.4D to 4B or 4C).  These results indicate that the effects of statins on 
breast cancer cells in 3D culture occur because of the function of HMG-CoA reductase to 
produce mevalonic acid, and further implicate the upregulated mevalonate pathway in the 
malignant 3D phenotype of these cells.  In addition, we tested whether flux through the 
mevalonate pathway was sufficient to disrupt normal acinar morphogenesis.  We cultured 
MCF10A cells in 3D culture with or without supplementation of mevalonic acid (MVA) and 
demonstrate that, similar to overexpression of tumor-derived mutants of p53, exogenous 
mevalonic acid is sufficient to block luminal clearance in MCF10A cells (Figure 2.4E).   
We extended the effects of statins on breast cancer cells in three other assays. First, we 
tested whether statin treatment had an impact on anchorage-independent growth and observed 
that Simvastatin can significantly impair anchorage-independent growth in both MDA-468 and 
MDA-231 cells (Figure 2.S5A).  Second, inhibition of HMG-CoA reductase has previously been 
reported to induce cell cycle arrest and/or apoptosis in a variety of cell lines grown in traditional 
(2D) cell culture (Jakobisiak et al., 1991; Sanchez et al., 2008).  In line with these findings, we 
noted a G1 cell cycle arrest, with a concomitant drop in S phase, in both breast cancer cell lines 
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treated with 24 hours of Simvastatin at varying concentrations (Figure 2.S5B-C).  It is therefore 
likely that the observed phenotypic effects of statins in 3D culture are due to a combination of 
factors (i.e. decreased growth, increased death and decreased invasion).  Third, in addition to 
these ex vivo experiments, we also examined whether statin-mediated inhibition of HMG-CoA 
reductase would have an effect on breast cancer cells in vivo.  Using a xenograft model of MDA-
231 breast cancer cells, we demonstrate that Simvastatin significantly impairs tumor growth of 
these cells when implanted into immunocompromised mice (Figure 2.S5D).  This supports 
earlier studies that demonstrate that HMG-CoA reductase inhibition can impact tumor formation 
using breast cancer xenograft models (Ghosh-Choudhury et al., 2010; Mori et al., 2009).   
Geranylgeranylation is required for the phenotypic effects of mutant p53 in MDA-231 
breast cancer cells grown in 3D culture 
Next we tested whether inhibition of later enzymes within the mevalonate pathway would 
have similar phenotypic effects as mutant p53 depletion from breast cancer cells grown in 3D 
culture.  An inhibitor of Mevalonate Decarboxylase, 6-Fluoromevalonate (Cuthbert and Lipsky, 
1990), had remarkably similar phenotypic effects on both MDA-468 and MDA-231 cells grown 
in 3D culture to that seen with inhibition of HMG-CoA reductase by statins (Figure 2.S4). Thus, 
not only HMG-CoA reductase, but several downstream enzymatic steps in the mevalonate 
pathway are involved in the ability of mutant p53 to prevent normal morphological behavior of 
breast cancer cells in 3D culture conditions.   
Because the mevalonate pathway is not only vital for producing cellular cholesterol, but 
many other biologically active intermediate metabolites, we examined whether the phenotypic 
effects of mutant p53 knockdown were due to decreased cholesterol synthesis or the production 
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of an earlier metabolite.  To do this, we utilized three inhibitors that inhibit distinct actions of the 
mevalonate pathway (Figure 2.S3).  YM-53601 inhibits squalene synthase (and thus cholesterol 
production) at submicromolar concentrations (Ugawa et al., 2000), but spares all upstream 
intermediate metabolites.  FTI-277 blocks farnesylation of proteins via inhibition of farnesyl 
transferase at nanomolar concentrations in whole cells, but has no effect on geranylgeranyl 
transferase or squalene synthesis at low micromolar concentrations (Lerner et al., 1995).  GGTI-
2133 blocks geranylgeranylation of target proteins via inhibition of geranylgeranyl transferase, 
while sparing farnesylation and squalene synthesis (Vasudevan et al., 1999).   
While inhibition of squalene synthase and farnesyl transferase had only a mild effect on 
the growth of MDA-231 cells in 3D culture, inhibition of geranylgeranylation had a profound 
impact on both the growth and the invasive morphology of these cells in 3D culture (Figure 
2.5A).  To examine whether downregulation of geranylgeranylation is necessary for the 
phenotypic effects observed after mutant p53 depletion or HMG-CoA reductase inhibition, we 
performed add-back experiments using GGPP to cells either depleted of mutant p53 or cells 
treated with Simvastatin (Figure 2.5B and C, respectively).  Since supplementation with 
geranylgeranyl pyrophosphate was sufficient to rescue the invasive phenotype in a portion of the 
population of MDA-231 cells in 3D culture, this suggests that geranylgeranylation is indeed a 
vital component of why breast cancers have selected for mutant p53 upregulation of the 
mevalonate pathway.   
Mutant p53 is recruited to the promoters of genes encoding sterol biosynthesis enzymes 
Much of the physiologic regulation of the sterol biosynthesis enzymes takes place at the 
transcriptional level in a manner that requires the sterol regulatory element binding proteins, 
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SREBP-1 and SREBP-2 (Sato, 2010). SREBPs activate the genes encoding nearly every key 
enzyme in both the fatty acid and sterol biosynthetic pathways (Horton et al., 2002). The 
SREBPs belong to the basic helix-loop-helix–leucine zipper (bHLH-Zip) family of transcription 
factors, but they are unique among this class of transcription factors in that they are synthesized 
as inactive precursors bound to the endoplasmic reticulum (ER), and only upon signals such as 
sterol depletion are they cleaved into mature fragments that translocate to the nucleus to bind to 
and regulate their target genes (Bengoechea-Alonso and Ericsson, 2007; Goldstein et al., 2006). 
Most tumor-derived mutants of p53 are mutated in the DNA binding domain (DBD), and 
have thus lost the ability to recognize wild-type p53 response elements.  Transcriptional 
regulation by mutant p53 may occur in many cases through interactions with other sequence-
specific transcription factors binding to their cognate sites (Chicas et al., 2000; Di Agostino et 
al., 2006; Sampath et al., 2001; Stambolsky et al., 2010).   Since the SREBPs are known to 
transactivate virtually every enzyme within the mevalonate pathway that we identified as being 
regulated by mutant p53 (in addition to many other sterol and fatty acid biosynthesis genes), and 
since mutant p53 requires a functional transactivation domain to disrupt morphogenesis in 3D 
culture (Figure 2.2), we hypothesized that mutant p53 might serve as a co-activator with one or 
more of the SREBPs. The following experiments support this hypothesis.   
First, co-immunoprecipitation experiments using transiently expressed proteins 
demonstrated that mutant p53 (p53-R273H) can interact with the mature forms of all three family 
members, SREBP-1a, SREBP-1c and SREBP-2 (Figure 2.6A). Furthermore, we demonstrated 
that endogenous mutant p53 can interact with endogenous mature SREBP-2 in MDA-468 cells 
(Figure 2.6B) and MDA-231 cells (Figure 2.S6A). Second, mutant p53 regulates myriad SREBP 
target genes in addition to those identified by pathway analysis.  MDA-468.shp53 cells were 
115 
grown in 3D culture with or without full levels of mutant p53 and the levels of a number of other 
SREBP target genes were assayed.  In addition to the seven sterol biosynthesis genes uncovered 
by our initial pathway analysis, we validated ten additional sterol biosynthesis genes that are 
regulated by mutant p53 in MDA-468 cells (Figure 2.S6C), a subset of which are also regulated 
in MDA-231 cells (Figure 2.S6D).  Of note, DHCR24, also known as Seladin1, was previously 
reported to be a transactivation target of another tumor-derived mutant, p53-R175H (Bossi et al., 
2008).  We also validated additional SREBP target genes that are not part of the mevalonate 
pathway as being regulated by mutant p53 in MDA-468 cells (Figure 2.S6E).  Three of these 
genes (FASN, ELOVL6 and SCD) encode key enzymes within the fatty acid biosynthesis 
pathway, suggesting that this pathway may also be upregulated by mutant p53.  In addition, 
INSIG1, while not an enzyme in the sterol or fatty acid biosynthesis pathways, has been reported 
to be an obligate SREBP target gene (Goldstein et al., 2006), supporting the hypothesis that 
mutant p53 is cooperating with one of the SREBP proteins. Further, a comprehensive list of 
SREBP target genes (Reed et al., 2008) was queried to determine whether there was significant 
overlap with those identified by microarray analysis to be regulated by mutant p53 and there was 
a marked enrichment of SREBP target genes in the set of genes which were affected after mutant 
p53 depletion from breast cancer cells (Figure 2.S6B).  Third, mutant p53 is recruited to the 
promoter regions of genes encoding sterol biosynthesis enzymes.  Using quantitative chromatin 
immunoprecipitation (ChIP) analysis of MDA-468 cells with or without full levels of mutant 
p53, we identified significant binding by mutant p53 in the vicinity of sterol regulatory elements 
(SRE-1), the cognate binding sites for the SREBPs (Boone et al., 2009), in the promoter regions 
of all seven genes tested (Figure 2.6C and 6D).  This ChIP signal varied between 2- to 4-fold 
greater than the signal at a negative region within the CDKN1A gene locus, and was consistently 
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reduced upon shRNA depletion of p53 (Figure 2.6C).  We next used ChIP analysis to scan 
several regions upstream and downstream of the transcriptional start site (TSS) of the gene 
encoding HMG-CoA reductase (HMGCR).  The region of peak binding by mutant p53 was 
located approximately 150 bp upstream of the TSS (Figure 2.6D), which corresponds to the 
known sterol regulatory element (Boone et al., 2009; Vallett et al., 1996).  The peak signal, 
which was on the order of 3-fold greater than that seen with the negative region, was again 
significantly reduced in cells with depleted p53 (Figure 2.6D).    
Fourth, SREBPs are likely necessary for the full recruitment of mutant p53 to these gene 
promoters.  We downregulated by siRNA the SREBPs from MDA-468 cells and found that 
depletion of SREBP-1 slightly, but significantly, reduced the level of binding to the HMG-CoA 
reductase gene promoter (Figure 2.S6), while depletion of SREBP-2 substantially decreased the 
recruitment of mutant p53 to the HMG-CoA reductase gene promoter (Figure 2.6E).  
Additionally, Fatostatin, a recently described inhibitor of SREBP activation (Kamisuki et al., 
2009), significantly reduced the level of mutant p53 binding to the HMG-CoA reductase gene 
promoter (Figure 2.6F).  Finally, to examine whether SREBP activity affects the 3D morphology 
of breast cancer cells in 3D culture, we treated breast cancer cells with Fatostatin and indeed this 
inhibitor had a dramatic effect on the 3D morphology of MDA-231 cells (Figure 2.6G) and 
MDA-468 cells (data not shown).  Taken together, our results strongly implicate a functional 
interaction with SREBPs as being critical for mutant p53-mediated upregulation of the 
mevalonate pathway genes.   
TP53 mutation correlates with elevated expression of sterol biosynthesis genes in human 
breast cancer patients 
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To investigate whether the regulation of the mevalonate pathway by mutant p53 is 
generalizable to human patients, we examined five datasets consisting of a total of 812 human 
breast cancer patient samples (728 of these had known TP53 mutational status).   Each of these 
tumor specimens was previously subjected to both genome-wide expression analysis as well as 
sequencing of TP53 (Enerly et al., 2011; Haakensen et al., 2010; Kyndi et al., 2009; Langerod et 
al., 2007; Miller et al., 2005; Muggerud et al., 2010; Myhre et al., 2010; Nielsen et al., 2006; 
Wiedswang et al., 2003).  After stratifying patients based on the p53 mutational status of their 
tumors, we investigated the expression level of the sterol biosynthesis genes that we had 
previously identified as being regulated by mutant p53 in breast cancer cells grown in 3D 
culture.  Remarkably, eleven of these sterol biosynthesis enzymes exhibited significantly higher 
expression levels in mutant p53 breast tumors compared to those bearing wild-type p53 across 
multiple datasets (Figure 2.7A, S7 and Table 2.S1).   
We also performed the reciprocal analysis on these same breast cancer patient datasets, 
stratifying tumors based on their extent of expression of the mevalonate pathway genes and 
examining the mutation rate of TP53.  Three main groups were observed from the hierarchical 
clustering of the expression matrix from 17 sterol biosynthesis genes on the 812 human breast 
cancer patient samples.  Cluster I has the lowest sterol biosynthesis gene expression pattern and 
the lowest rate of TP53 mutations (46/327 = 14.1%). Cluster III exhibits an intermediate 
expression level in these sterol biosynthesis genes and an intermediate rate of TP53 mutations 
(94/272 = 34.6%).  Cluster II has the highest expression pattern of sterol biosynthesis genes and 
exhibits the highest rate of TP53 mutations (51/129 = 39.5%) (Figure 2.7B).   
To test the biological significance of elevation of the mevalonate pathway in mutant p53 
tumors, we examined whether upregulation of this pathway correlated with patient prognosis.  It 
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is striking that cluster I, which has the lowest expression level of the mevalonate pathway genes, 
is correlated with a favorable prognosis, while cluster III, which has an intermediate expression 
pattern, correlates with an intermediate prognosis and cluster II, which has the highest expression 
of the mevalonate pathway genes, is associated with a significantly poorer survival probability 
(Figure 2.7C).  Therefore, not only was elevation of the mevalonate pathway significantly 
correlated to a higher rate of p53 mutations, but these breast cancer patients also had a 
significantly decreased survival.  We then examined each sterol biosynthesis gene individually to 
investigate which genes contribute most to the prognostic value.  Elevated expression of nine out 
of the seventeen sterol biosynthesis genes correlated with significantly poorer prognosis in these 
breast cancer patients (Figure 2.7D). 
Since breast cancer cells bearing mutant p53 appear to be particularly sensitive to 
inhibition of the mevalonate pathway in the 3D culture system, the fact that multiple members 
this pathway are upregulated in mutant p53 expressing human tumors and correlate with a poor 
prognosis may have important therapeutic implications.   
 
DISCUSSION 
Despite being one of the most well studied tumor suppressors, there is much evidence 
that once mutated, p53 can promote the progression of many cancers.  With respect to breast 
cancer, tumor-derived mutants of p53 have been implicated in survival, chemoresistance, 
invasion, migration and metastasis (Adorno et al., 2009; Lim et al., 2009; Muller et al., 2006; 
Muller et al., 2009; Stambolsky et al., 2010).  Since mammary tissue architecture is invariably 
disrupted during breast carcinogenesis, we sought to delineate the phenotypic effects of mutant 
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p53 in breast cancer.  This study describes a possible oncogenic role for certain missense mutants 
of p53 in disrupting acinar morphogenesis of breast cells, explored using a three-dimensional 
culture system. Depletion of endogenous mutant p53 from breast cancer cells is sufficient to 
induce a phenotypic reversion in 3D culture and functional transactivation domains are necessary 
for mutant p53 to disrupt acinar morphogenesis. 
We also demonstrate that mutant p53 upregulates seventeen genes encoding enzymes in 
the mevalonate pathway.  The phenotypic effects following downregulation of mutant p53 can be 
recapitulated by inhibiting critical enzymes in the mevalonate pathway and can be reversed by 
supplementing breast cancer cells depleted of mutant p53 with two key intermediate metabolites 
produced by this pathway.  Thus, flux through the mevalonate pathway is both necessary and 
sufficient for the phenotypic effects of mutant p53 on breast cancer cell morphogenesis in 3D 
culture. While it has been demonstrated previously that inhibition and/or downregulation of 
oncogenic signaling pathways can phenotypically revert breast cancer cells grown in 3D culture 
(Bissell et al., 2005; Wang et al., 1998; Weaver et al., 1997), we show here that downregulation 
of mutant p53 and/or inhibition of the mevalonate pathway can function in this capacity.   
The mevalonate pathway has recently been implicated in multiple aspects of 
tumorigenesis, including proliferation, survival, invasion and metastasis (Clendening et al., 2010; 
Dimitroulakos et al., 1999; Kidera et al., 2010; Koyuturk et al., 2007; Wejde et al., 1992).  
Competitive inhibitors of the rate-limiting enzyme in the mevalonate pathway, HMG-CoA 
reductase, collectively known as statins, have been reported to be cancer-protective for certain 
malignancies, including breast cancer (Ahern et al., 2011; Blais et al., 2000; Cauley et al., 2003; 
Stein E A, 1993); however, the cancer-protective effects of statins are not without debate 
(Baigent et al., 2005; Browning and Martin, 2007).  The statins have already been employed in 
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multiple preclinical models of breast cancer (Kubatka et al., 2011; Shibata et al., 2004) and it is 
noteworthy that at least two reports have already demonstrated a significant impact of 
Simvastatin treatment on growth of MDA-231 breast cancer xenografts in immunocompromised 
mice (Ghosh-Choudhury et al., 2010; Mori et al., 2009).  In line with this, we were also able to 
demonstrate a significant impact of Simvastatin treatment on MDA-231 breast cancer cells in 
vivo.   
It is interesting to note that at least one clinical study investigating the effect of statins in 
breast cancer noted a subgroup-specific protective effect: specifically, a significantly decreased 
incidence of hormone receptor-negative (ER-/PR-) tumors was documented in patients takings 
statins, while no such effect was observed for hormone receptor-positive tumors (Kumar et al., 
2008).  Preclinical models, employing either breast cancer cell lines or mouse models of breast 
cancer, also support a more dramatic role for statins in ER-/PR- breast cancers (Campbell et al., 
2006; Garwood et al., 2010).  Since the majority of breast tumors that bear p53 mutations most 
commonly are also immunohistochemically classified as ER-/PR- (Han et al., 2011; Sorlie et al., 
2001), it is tempting to speculate that the observed anti-tumorigenic effects of statins are a 
consequence of mutant p53’s upregulation of the mevalonate pathway.   
Gene expression profiling of breast cancers has identified specific subtypes with 
important clinical, biologic and therapeutic implications (Perou et al., 2000).  Using these 
expression signatures, most p53 mutations cluster in the basal-like subgroup of breast cancers, 
which has the poorest prognosis and is notoriously difficult to treat (Sorlie et al., 2001).  
Fascinatingly, using a combination of expression signatures and data from over 40,000 
compounds screened in the NCI-60 cell lines, Mori et al. predicted three FDA-approved drugs to 
be most effective for treating basal-like breast cancers, two of which, Simvastatin and 
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Lovastatin, are inhibitors of HMG-CoA reductase (Mori et al., 2009).  It will be exciting to 
examine whether stratifying breast cancer patients based on their p53 mutational status can 
resolve the apparent discrepancies within the rich body of literature linking statins and cancer.   
Although we have implicated the mevalonate pathway in the phenotypic effects of mutant 
p53, it will be of great interest to further delineate the metabolite(s) as well as the downstream 
signaling pathways that are responsible for these phenotypic effects. While we have 
demonstrated that metabolic flux through the mevalonate pathway is sufficient to disrupt acinar 
morphogenesis, with a specific reliance on geranylgeranylation, we cannot rule out the 
possibility that one or more other metabolites are involved in the phenotypic effects that we 
observe in 3D culture.  For example, metabolites such as mevalonic acid and farnesyl 
pyrophosphate have also been shown to promote cellular proliferation and/or cell survival (Fuchs 
et al., 2008; Graaf et al., 2004; Minutolo et al., 2005; Quesney-Huneeus et al., 1979; Riganti et 
al., 2011).  Alternatively, cholesterol itself may promote survival pathways, by impinging upon 
the PI3K signaling pathway (Zhuang et al., 2002).  If geranylgeranyl pyrophosphate is in fact the 
key metabolite, it will be very interesting to delineate the geranylgeranylated protein target(s) 
that mediate the oncogenic effects of the mevalonate pathway in breast cancer cells in 3D 
culture.   
It is interesting to note that, in addition to the mevalonate pathway, a number of fatty acid 
biosynthesis genes were also significantly affected by mutant p53 depletion from breast cancer 
cells in 3D culture (Figure 2.3B and S6E).  Intriguingly, this is the other major pathway 
controlled by the SREBP family of transcription factors (Horton et al., 2002).  While much of 
our data points to a role for SREBP proteins in the regulation of the mevalonate pathway by 
mutant p53, a direct link is yet to be established.  This regulation is likely to occur through one 
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or more of the SREBP proteins, but we cannot rule out the possibility that another factor or 
factors may also be involved.  Mutant p53 may interact directly with elements in the promoters 
of the sterol biosynthesis genes or alternatively be recruited by a known mutant p53 interacting 
partner such as NF-Y, SP1, Ets-1 or VDR, which have been shown to recruit mutant p53 to their 
cognate binding sites (Chicas et al., 2000; Di Agostino et al., 2006; Sampath et al., 2001; 
Stambolsky et al., 2010). 
A number of scenarios have been proposed to explain why human tumors select for 
mutations in p53 (Brosh and Rotter, 2009).  First, mutant p53 may simply be selected for due to 
loss of wild-type p53 tumor suppressive activity.  Second, mutant p53 may acquire neomorphic, 
or gain-of-function, activities which promote tumor growth, many of which have actually been 
shown to be diametrically opposed to those performed by wild-type p53 (Peart and Prives, 2006; 
Stambolsky et al., 2010).  In line with this hypothesis are the findings that Stearoyl-CoA 
desaturase (encoded by SCD) is a repression target of wild-type p53 (Mirza et al., 2003; Riley et 
al., 2008) as well as that wild-type p53 can suppress a subset of SREBP target genes in a mouse 
model of obesity (Yahagi et al., 2003).    As the pro-survival roles of wild-type p53 are becoming 
more apparent (Bensaad et al., 2006; Kim et al., 2009; Wu et al., 2005), a third scenario could be 
envisaged in which mutant p53 may retain and exaggerate certain wild-type p53 functions, while 
selectively losing certain tumor suppressive mechanisms such as the ability to induce cell cycle 
arrest and apoptosis.  To examine the latter two hypotheses in relation to our findings that mutant 
p53 upregulates sterol biosynthesis genes, it will be interesting for future studies to examine 
whether wild-type p53 and/or its family members (p63 and p73) serve to repress sterol 
biosynthesis genes.  Alternatively, the maintenance of high levels of sterol biosynthesis genes by 
mutant p53 may be a remnant of an unrecognized wild-type p53 function.  
123 
These speculations raise another important consideration, that not all p53 mutations are 
equivalent.  Genetic alterations in p53 are often grouped into two classes based on the type of 
mutant p53 that they produce (Brosh and Rotter, 2009). Contact mutants, exemplified by p53-
R273H, involve mutation of residues that are directly involved in protein-DNA contacts.  
Conformational mutants, typified by p53-R175H, result in conformational distortions in the p53 
protein.  Our findings that a subset of the sterol biosynthesis genes are significantly higher in 
large cohorts of human breast tumors bearing mutant p53 suggests that the ability of mutant p53 
to upregulate the sterol biosynthesis genes is not constrained to a single class of mutations; 
however, it will be very interesting for follow-up studies to examine which tumor-derived 
mutants of p53 can regulate the levels of sterol biosynthesis genes.   
In summary, our results demonstrate that mutant p53 can disrupt mammary acinar 
morphology and that downregulation of mutant p53 from malignant cells is sufficient to 
phenotypically revert these cells. Here we propose one mechanism, the upregulation of the 
mevalonate pathway, although one or more additional pathways may play a role.  Specifically, 
we demonstrate that mutant p53 is recruited to the promoters of many sterol biosynthesis genes 
leading to their upregulation. We hypothesize that tumors bearing p53 mutations evolve to 
become highly reliant on metabolic flux through the mevalonate pathway, making them 
particularly sensitive to inhibition of this pathway.  At a clinical level, inhibition of the 
mevalonate pathway, either alone or in combination with other therapies, may offer a novel, and 





Plasmids, siRNA, Antibodies and Reagents 
pLNCX-Flag-p53-R175H, -G245S, -R248Q, -R248W, -R273H and -L22Q/W23S/W53Q/F54S-
R175H, -G245S, -R248Q, -R248W, -R273H were generated from pLNCX-Flag-p53-WT using 
the Stratagene QuikChange Site-Directed Mutagenesis kit according to the manufacturer’s 
instructions.  Mutagenesis primer sequences are provided in Table 2.S2.  pcDNA3.1-Myc-
mSREBP-1a, -1c and -2 encode the mature forms of the SREBP transcription factors (Datta and 
Osborne, 2005).  All constructs were verified by sequencing.  p53 shRNA (2120) in STGM (tet-
on) (Brekman et al., 2011) were used to establish cells with stable, inducible p53 knockdown.  
For transient knockdown experiments, siRNAs targeting SREBP1 (s129) or SREBP2 (s27) were 
purchased from Invitrogen.  All-Stars (Control) and p53 siRNA were purchased from Qiagen.   
p53 was detected using mAb 1801, DO-1 or 240.  Anti-Actin (A2066), anti-Flag (F3165) and 
control IgG (I5381) antibodies were purchased from Sigma.  Anti-Myc (sc-40) antibody was 
purchased from Santa Cruz.  Anti-SREBP2 (1D2) is a monoclonal antibody raised against human 
SREBP-2 (hybridoma obtained from ATCC catalogue #CRL2545). Anti-SREBP2 (ab30682) 
antibody was purchased from Abcam. Alexa Fluor 594-Phalloidin (A12381) was purchased from 
Invitrogen.   
Simvastatin (#10010344) and YM-53601 (#18113) were purchased from Cayman Chemicals.  
The following drugs were purchased from Sigma Aldrich: ALLN (A6185), Doxycycline 
(D9891), Simvastatin (S6196), Mevastatin (M2537), FTI-277 (F9803), GGTI-2133 (G5294), 
DL-Mevalolactone (M4667), DL-Mevalonic Acid 5-Phosphate (79849) and Geranylgeranyl 
Pyrophosphate (#G6025).  Fatostatin was synthesized by the Medicinal Chemistry Core Facility 
125 
at the Sanford-Burnham Medical Research Institute as previously described (Kamisuki et al., 
2009). 
Cell Lines and Generation of Stable Cell Lines 
MDA-468, MDA-231, HEK 293 and Phoenix cells were maintained in DMEM+10% FBS.  
MCF10A cells were maintained in DMEM/F12 supplemented with 5% horse serum, 10 μg/ml 
Insulin, 0.5 μg/ml Hydrocortisone and 20 ng/ml Epidermal Growth Factor (EGF).  All cells were 
maintained at 37oC in 5% CO2.   
To generate stable cell lines with inducible shRNA, constructs were introduced into MDA-231 or 
MDA-468 cells by the retroviral mediated gene transfer method.  Briefly, Phoenix packaging 
cells were transfected by the calcium phosphate method with either an rtTA plasmid or a vector 
expressing p53 shRNA or no shRNA. The generated viruses were harvested and MDA-231 or 
MDA-468 cells were co-infected with the rtTA and one of the vectors. After selection with 
puromycin (vector with shRNA) and hygromycin (rtTA), clonal cell lines were generated by the 
limited dilution method. Clonal cell lines were selected based on the level of p53 knockdown. 
Experiments shown were carried out on clonal cell lines or stable pools (MDA-468.shp53 pool, 
MDA-468.shp53 clone 1F5 and MDA-231.shp53 clone 1D10). To induce shRNA expression, 
cells were treated with 8 µg/ml doxycycline (DOX) for time periods indicated in the figure 
legends.  
To generate stable, mutant p53 expressing cells, MCF10A cells were infected with pLNCX-Flag-
p53-R175H, -G245S, -R248Q, -R248W, or -R273H, or a transactivation-deficient version of 
each mutant (mTAD): pLNCX-Flag-p53-22/23/53/54-R175H, -G245S, -R248Q, -R248W, -
R273H and selected in G418 to yield stable pools.  
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To generate shRNA-resistant mutant p53 expressing cells, MDA-231.shp53 (Clone 1D10) cells 
were infected with pLNCX or pLNCX-Flag-p53-R273H which lacks the target site for the p53 
shRNA, found in the 3’ UTR of the p53 mRNA.  MDA-468.shp53 (Clone 1F5) cells were 
likewise infected with pLNCX, pLNCX-Flag-p53-R273H or pLNCX-Flag-p53-22/23/53/54-
R273H (p53-R273H-mTAD) to generate shRNA-resistant mutant p53 expressing cells, either 
containing functional or non-functional transactivation domains, respectively. These cell lines 
were selected in G418 to generate stable pools.   
Three Dimensional (3D) Culture 
Three-dimensional culture was carried out as previously described (Debnath et al., 2003).  
Briefly, 8-well chamber slides were lined with 50 μl growth factor reduced Matrigel (BD 
Biosciences).  Cells were then seeded at a density of 5,000 cells/well in Assay Medium 
(DMEM/F12 + 2% Horse Serum + 10 μg/ml Insulin + 0.5 μg/ml Hydrocortisone [+5 ng/ml EGF 
for MCF10A cultures]) containing 2% Matrigel.  Cells were refed with Assay Medium 
containing 2% Matrigel every 4 days.  For RNA/protein analysis from 3D cultures, 35 mm plates 
were lined with 500 μl Matrigel and cells were seeded at a density of 225,000 cells/plate in 
Assay Medium + 2% Matrigel.  Cells were harvested using Cell Recovery Solution (BD 
Biosciences) according to the manufacturer’s instructions.   
Immunostaining and Microscopy 
Cells were fixed using 2% formaldehyde at room temperature for at least 30 min.  Cells were 
permeabilized for 10 min at 4oC with 0.5% Triton X-100 and subsequently blocked for 1 hr at 
room temperature with PBS + 0.1% Tween-20 + 0.1% BSA + 10% goat serum.  Primary 
antibodies were incubated with the cultures for 1-2 hr at room temperature, followed by washing, 
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and addition of fluorescently-conjugated secondary antibodies for 40 min at room temperature.  
Nuclei were counterstained with DRAQ5 (Cell Signaling #4084) or Propidium Iodide (Sigma 
#P4170). Confocal microscopy was conducted using an Olympus IX81 confocal microscope and 
analyzed using Fluoview software. 
Microarray and Data analysis 
RNA was isolated from three independent experiments of MDA-468.shp53 cells cultured under 
3D conditions for 8 days in the presence or absence of DOX, reversed transcribed and hybridized 
to an Affymetrix GeneChip expression array (GEO Accession Number: GSE31812). Data was 
processed using the Robust Multichip Average (RMA) algorithm to give expression signals and 
paired t-test was applied for each probe. Probes with 1% significance were selected for Ingenuity 
Pathway Analysis. 
For Gene Ontology (GO) analysis, probe sets with the Detection Above Background (DABG) p-
value <0.05 in at least one sample were used. Gene expression was calculated based on the mean 
value of all the probesets for a gene. Gene expression changes were estimated by comparing cells 
grown in the presence of DOX versus those grown in the absence of DOX, and the three sample 
sets were analyzed separately. The GO annotation of genes was based on the NCBI Gene 
database. For each GO term, two p-values were calculated using Fisher’s exact test by examining 
whether a significant fraction of genes associated with the GO term were up-regulated or down-
regulated beyond the 1*standard deviation of all genes based on log2(ratio). The smaller p-value 
was used to represent the trend of regulation.   
Quantitative RT-PCR 
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RNA was isolated from cells using the Qiagen RNeasy Mini Kit according to the manufacturer’s 
instructions. Complementary DNA was transcribed using Qiagen Quantitect reverse transcription 
kit. Real-time PCR was carried out on an ABI StepOne Plus using SYBR green dye. Transcript 
levels were assayed in triplicate and normalized to RPL32 mRNA expression. Relative levels 
were calculated using the Comparative-Ct Method (ΔΔCT method). All primers, unless 
otherwise noted, were designed with Primer Express (Applied Biosystems).  qRT-PCR primer 
sequences are provided in Table 2.S2. 
Drug Treatments 
Simvastatin was activated by alkaline hydrolysis to the acidic form prior to usage as previously 
described (Sadeghi et al., 2000). Briefly, 5 mg of the Simvastatin pro-drug was dissolved in 
0.125 ml of 95% ethanol, followed by 0.15 ml of 0.1 N NaOH and the solution was incubated at 
50°C for 2 hr. The final solution was brought to a pH of 7.2.  Working solutions were stored in 
DMSO. 
Cells in 3D culture were treated with Simvastatin or Mevastatin at the following 
concentrations: 100 nM or 1 µM.  This range approximates clinically achievable serum 
concentrations in human patients (Dimitroulakos et al., 1999; Wong et al., 2002).  Cells were 
treated with 6-Fluoromevalonate (200 µM) as previously described (Cuthbert and Lipsky, 1990). 
 Cells were treated with YM-53601, FTI-277 or GGTI-2133 (Lerner et al., 1995; Ugawa et al., 
2000; Vasudevan et al., 1999).  Cells were treated with Fatostatin at either 2 µM or 20 µM as 
previously described (Kamisuki et al., 2009). Cells in 3D culture were treated on Day 1 or Day 4 
of the 3D protocol (as described in the figure legends) and refed every 4 days with fresh drug. 
Add-back experiments  
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MDA-468.shp53 or MDA-231.shp53 cells were cultured under 3D conditions in the presence 
(+DOX) or absence (-DOX) of doxycycline to deplete mutant p53. On Day 1 of 3D culture, cells 
cultured in the presence of doxycycline were supplemented with DL-Mevalolactone (1 mM)/DL-
Mevalonic Acid 5-Phosphate (1 mM) or Geranygeranyl pyrophosphate (25 µM) and re-fed every 
4 days. 
MDA-468  or MDA-231 cells were pretreated with DL-Mevalolactone (1 mM)/DL-Mevalonic 
Acid 5-Phosphate (1 mM) or Geranylgeranyl pyrophosphate (25 µM) and then treated with 
Simvastatin (1 μM). 
Soft-Agar Assay 
35mm petri dishes were coated with base agar (0.6% in DME) and 2x104 MDA-468 or 1x104 
MDA-231 cells were plated in top agar (0.3% in DME).  Cultures were overlaid with 1.5 mL 
DME + 10% FBS with indicated drug concentrations.  Drugs were changed every 3-4 days and 
culture media was changed every 7 days.  Colonies were stained with 0.005% Crystal Violet and 
counted using a 4x objective on a phase contrast microscope.     
Flow cytometry analysis 
MDA-468 or MDA-231 cells were treated with indicated concentrations of Simvastatin for 24 hr 
and processed for FACS.  Cell pellets were washed with phosphate buffered saline and 
fixed/permeabilized with 50% ice-cold ethanol. Pellets were washed and resuspended in 
50 μg/ml ribonuclease A and 62.5 μg/ml propidium iodide. Samples were analyzed on the Becton 
Dickinson FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA). The percentages of cells 
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in various phases of the cell cycle were quantified using the ModFit LT Version 3.0 program 
(Verity Software House, Topsham, ME, USA).  
Mouse study 
MDA-231 cells (2x106), resuspended in 50 µl media + 50 µl Matrigel were injected 
subcutaneously into 8 week-old female NOD-SCID mice. 14 days after implantation, tumors 
were measured by calipers and mice were paired by equal tumor volume and randomized to a 
Simvastatin or Control group (N=5 in both cases).  Simvastatin group received Simvastatin (200 
mg/kg/day) dissolved in H2O + 1% carboxymethyl cellulose (w/v) and administered daily by 
oral gavage, Control group received the vehicle daily by oral gavage.  Mice were weighed 
weekly and tumor measurements were performed weekly using a caliper.  The volume of the 
tumor was calculated as v = a2*b (being a the small diameter and b the long diameter).  After 21 
days of treatment, mice were sacrificed and tumors were extracted and weighed. 
Co-Immunoprecipitation of p53 and SREBP proteins 
To detect exogenously expressed proteins, sub-confluent HEK 293 cells were transiently 
transfected with mutant p53 (Flag-p53-R273H) and an SREBP (Myc-mSREBP-1a, -1c or -2) 
expression constructs using Lipofectamine 2000 (Invitrogen).  Twenty-four hours post-
transfection, cells were subjected to formaldehyde crosslinking (1% formaldehyde for 15 min), 
lysed in RIPA Buffer (150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP-40, 5mM EDTA, 
50 mM Tris pH 8.0, 0.5 mM PMSF, protease inhibitors [1 μM benzamidine, 3 μg/ml leupeptin, 
0.1 μg/ml bacitracin, and 1 μg/ml macroglobulin]) and sonicated.  Anti-Flag antibody (4 µg) 
with protein A/G Sepharose beads (70 µl 1:1 slurry) was used to immunoprecipitate p53 from 2 
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mg whole cell lysate.  Samples were then subjected to SDS-Page and immunoblotted with anti-
Myc or anti-Flag antibodies.  
To detect endogenously expressed proteins, MDA-468.shp53 cells were serum starved (2.5% 
serum) for 24 hours.  Cells were harvested, re-suspended in hypotonic buffer (20 mM HEPES-
KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM PMSF, protease inhibitors [1 μM 
benzamidine, 3 μg/ml leupeptin, 0.1 μg/ml bacitracin, and 1 μg/ml macroglobulin]) for 10 min 
on ice, disrupted by passage through a 25-gauge needle and centrifuged at 1900 rpm for 10 min.  
The resultant nuclear pellet was suspended in lysis buffer (50 mM Tris-HCl pH 7.4, 1% Triton 
X-100, 150 mM NaCl, 2 mM EDTA, 5 mM NaF, 0.5 mM PMSF, protease inhibitors [1 μM 
benzamidine, 3 μg/ml leupeptin, 0.1 μg/ml bacitracin, and 1 μg/ml macroglobulin]) and 
centrifuged at 13000 rpm for 20 min at 4°C. For co-immunoprecipitation of endogenous proteins 
the lysate was incubated at 4°C with either control IgG (Sigma, I5381) or anti-SREBP-2 
antibody (1D2) for 6 hr and subsequently with protein A/G beads for 1 hr.  The bead pellet was 
extensively washed in lysis buffer four times and then electrophoresed on 8% SDS-PAGE gels 
followed by immunoblotting using anti-SREBP-2 (1D2) and anti-p53 (DO-1) antibodies.  
Quantitative Chromatin Immunoprecipitation 
Chromatin Immunoprecipitation (ChIP) experiments were carried out as previously described 
(Beckerman et al., 2009).  Briefly, MDA-468 cells were treated with 1% formaldehyde prior to 
lysis in RIPA Buffer and sonication to yield 500 bp fragments.  Protein A/G Sepharose beads 
were conjugated to anti-p53 antibodies (1801/DO-1) which were subsequently used to 
immunoprecipitate p53 from 1 mg whole cell lysate.  Quantitative ChIP was carried out on an 
ABI StepOne Plus using SYBR green dye.  Genomic Locations of SRE-1 sites within the 
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promoters of sterol biosynthesis genes were located using a literature search: HMGCS1 (Inoue et 
al., 1998), HMGCR (Boone et al., 2009), MVK (Bishop et al., 1998), FDPS (Ishimoto et al., 
2010), FDFT1 (Inoue et al., 1998), SQLE (Nagai et al., 2002) and CYP51A1 (Halder et al., 
2002), respectively. ChIP primer sequences are provided in Table 2.S2. 
Patient Data 
Hierarchical clustering 
Expression data for the sterol biosynthesis genes were extracted from individual cohorts (FW-
MDG, MicMa, Ull, DBCG and Miller). Expression values per gene per dataset were 
standardized to have mean 0 and standard deviation 1 and further merged across the five 
datasets. 
Unsupervised hierarchical clustering was used to discover groups based on the expression pattern 
of the sterol biosynthesis genes. In total, 17 sterol biosynthesis genes were used in the 
unsupervised hierarchical clustering.  
Expression values of the 17 sterol biosynthesis genes on 812 samples (where rows indicate the 
identity of the genes, columns indicate the identity of the patients) were clustered using 
hierarchical clustering with Euclidean distance and ward linkage. Note that gene MVD was not 
present in the DBCG dataset; expression values of MVD on 615 samples were used for the 
distance calculation. The Kaplan-Meier survival curves were plotted for the resulting groups and 
the differences in clinical indications among the clusters were tested by a logrank test. 
Univariate survival analysis for Sterol Biosynthesis Genes 
Breast cancer specific death was used as survival endpoint for the analysis (n = 533 for MVD and 
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n = 723 for others). To remove batch effect across different cohorts, individual gene from each 
expression dataset was standardized to have mean 0 and standard deviation 1. Expression values 
per gene per cohort were pooled across the datasets. A univariate Cox proportional hazards 
model per sterol biosynthesis gene was then fitted:  
 h(t | )  h0(t ) exp(1)  
where X is the expression vector from the specific gene (variable), 1 is the coefficient 
associated with a specific gene, and h0(t) is the (common) baseline hazard function.  
The Hazard Ratio (HR) was used as an accuracy measure for the risk group prediction for 
categorical predictors. The larger the HR, the better is the discrimination between the groups of 
the patients, such as low- and high-risk. In our study, continuous covariates entering the Cox 
models were scaled into mean 0 with standard deviation 1. Thus the estimated HR on the 
standardized data characterized the relative risk for 1-standard-deviation increase in risk 
estimation by a specific sterol biosynthesis gene. 
Benjamini Hochberg procedure (Benjamini and Hochberg, 1995) was used to adjust multiple 
comparisons across the tested genes (n = 17). 
Expression of Sterol Biosynthesis Gene versus TP53 mutation status 
One-tailed t test was performed to assess the significance of the increases in expression level for 
TP53 mutated samples to those with wild type. The alternative hypothesis Ha was expression 
level of TP53 mutated samples is higher than that of wild type samples.  
For individual gene, the test was carried out on five breast cancer datasets: FW-MDG 
(Haakensen et al., 2010; Muggerud et al., 2010), MicMa (Enerly et al., 2011; Wiedswang et al., 
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2003), ULL (Langerød et al., 2007), DBCG (Kyndi et al., 2009; Myhre et al., 2010; Nielsen et 
al., 2006) and Miller (Miller et al., 2005) respectively.  
Combine p values  
Since the datasets do not contain the same patients, we considered the conducted tests in each of 
the datasets for one gene were independent. An overall significance per gene across datasets was 
obtained using the Fisher's Omnibus (Fisher, 1932). Benjamini Hochberg procedure (Benjamini 
and Hochberg, 1995) was used to adjust multiple comparisons across the tested genes. 
Fisher's method (Fisher, 1932) is used to combine the p values from several independent tests 
bearing upon the same overall hypothesis (H0) into one test statistic F: 
 
Fi  2 log( pij )j  
where pi is the p-value from the hypothesis testing for gene i in the jth dataset (j = 1, … k; k is 
the total number of tests being combined; k was five in the study). When all the null hypotheses 
are true, test statistic F has a chi-square distribution with 2k degrees of freedom, Therefore, the 
corresponding overall p-value p0i for one gene across all dataset was computed by:  
p0i  1  2 (Fi ,2k)  
Gene annotation mapping  
The expression sets were annotated using Entrez gene identities. Genes of interest were mapped 
to each of the individual sets through Entrez gene IDs. For FW-MDG and MicMa set, the 
original Agilent probes were mapped to Entrez IDs using BioMart through R library biomaRt 
(Ensembl release 54/NCBI36 (hg18) human assembly). For Miller set, Affymetrix HG u133a 
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probes were mapped to Entrez IDs by BioMart under the same release. For ULL set, annotations 
for Stanford 43k cDNA array were retrieved from SMD SOURCE (http://smd.stanford.edu/cgi-
bin/source/sourceSearch) under UniGene Build Number 222. Gene identity conversion on 
DBCG expression set was done using the provided chip annotation file for Applied Biosystems 
Human Genome Survey Microarray. For the probes shared the same Entrez gene identity, we 
selected probe(s) with the largest interquartile range (IQR: difference between the third and first 
quartiles) among the multiple hits. If this still left with more than one hit per Entrez ID, we 
further averaged the expression values of those probes for each sample.  
Datasets 
FW-MDG 
Two expression sets FW (n = 109) (Muggerud et al., 2010) and MDG (n = 143)  (Haakensen et 
al., 2010) were both from Agilent Whole Human Genome Oligo Microarrays 44k two color 
system. In addition, they both are early stage breast cancer cohorts and clinically similar. In this 
study, we merged the two datasets by gene-median centering on the original probe level. We also 
excluded normal samples in the MDG set in the study. In total, 139 breast tumors expression 
profiles with available information on TP53 status entered the analysis. Among these, 28 
samples with mutated TP53 status and 111 samples with wild-type status.  
MicMa 
This cohort (Wiedswang et al., 2003) consists of mainly stage I and II breast cancers. mRNA 
expression profiling was performed on Agilent catalogue design whole human genome 4x44K 
one color oligo array. Among the 112 tumor samples with available TP53 status in this sets, 39 
samples with mutated TP53 status and 73 samples with wild-type status.  
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ULL 
This cohort consists of mainly stage I and II breast cancers. Eighty tumors, along with one 
normal breast tissue sample, were analyzed using Stanford cDNA 43k two color microarrays. 
We excluded the normal sample in the study, which left 80 tumor samples for the analysis. 
Among these, 20 samples with mutated TP53 status and 60 samples with wild-type status.  
DBCG 
The DBCG series comprise a collection of tumor tissues from 3,083 high-risk Danish breast 
cancer patients diagnosed in the period 1982–1990 (Kyndi et al., 2009; Myhre et al., 2010; 
Nielsen et al., 2006). The profiling was carried out on the Applied Biosystems Human Genome 
Survey one color Microarray. For this study, there were 46 samples with mutated TP53 status 
and 104 samples with wild-type status.  
Miller 
The Miller dataset (Miller et al., 2005) was downloaded from NCBI's Gene Expression Omnibus 
(GEO, http://www.ncbi.nlm.nih.gov/geo/) with identifier GSE3494. Data were preprocessed and 
normalized as described previously (van Vliet et al., 2008). Among the 247 samples, there were 
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Figure 2.1 Depletion of mutant p53 from breast cancer cells induces a phenotypic reversion 
in 3D culture 
(A) Depletion of mutant p53 dramatically affects 3D morphology of MDA-231 cells. MDA-
231.shp53 cells were grown under 3D conditions for 8 days in the absence of DOX, thus 
retaining full levels of mutant p53, or grown in the presence of DOX to knockdown endogenous 
mutant p53. Representative differential interference contrast (DIC) images are shown. Scale Bar, 
200 µm. 
 
(B)  shRNA mediated reduction of mutant p53 in MDA-231 cells.  MDA-231.shp53 cells were 
grown in 3D culture for 8 days in the presence or absence of DOX as indicated prior to lysis and 
immunoblotting analysis as in Methods.  p53 was detected using anti-p53 antibody (PAb1801).  
Actin serves as a loading control. 
 
(C) Morphologic categories in MDA-468 cells.  MDA-468.shp53 cells were grown in 3D 
cultures for 8 days and structures were grouped into three morphological categories: Malignant, 
Intermediate and Hollow Lumen.   Actin cytoskeleton was stained with Phalloidin (Green) and 
nuclei were stained with DRAQ5 (Red). Structures were analyzed by confocal microscopy. Scale 
bar, 50 µm. 
 
(D) Depletion of mutant p53 induces a phenotypic reversion in MDA-468 cells.  MDA-
468.shp53 cells were grown in 3D cultures for 8 days in the presence of DOX, leading to 
induction of an shRNA targeting p53, and thus to depleted levels of mutant p53.  Left panel: 
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GFP (Green) serves as a marker for shRNA induction. Right panel: Nuclei were stained with 
DRAQ5 (Red) and analyzed by confocal microscopy. The larger structure is representative of 
intermediate colony morphologies, while the smaller structure is representative of acinus-like 
structures with hollow lumen morphology.  White arrow indicates cell debris from apoptosis 
within the luminal space.  Scale bar, 50 µm. 
 
(E) Knockdown of mutant p53 in MDA-468 cells.  MDA-468.shp53 cells were grown in 3D 
culture for 8 days in the presence or absence of DOX as indicated and processed as in (B).  p53 
was detected using an anti-p53 antibody (PAb1801).  Actin serves as a loading control. 
  
(F) Morphometry of MDA-468.shp53 pooled population.  A stable pool of MDA-468.shp53 cells 
were grown in 3D cultures for 8 days in the presence or absence of DOX as indicated and 
structures were analyzed by confocal microscopy and categorized as in (C).  Left panel illustrates 
population distribution.  Right panel shows the percent of acinus-like structures with hollow 
lumens without (-) or with (+) mutant p53 depletion by treatment with DOX.  Structures (50-
100) were counted for each condition.  *denotes p<0.01.   
 
(G) Morphometry of MDA-468.shp53 clonal population.  A stable clone of MDA-468.shp53 
cells were grown in 3D cultures for 8 days in the presence or absence of DOX as indicated and 
structures were analyzed by confocal microscopy as in (F).   Structures (50-100) were counted 




Figure 2.2 Mutant p53 requires functional transactivation sub-domains to disrupt 
morphology of mammary cells in 3D culture 
(A) MDA-468.shp53 cells expressing a control vector (pLNCX) were grown in 3D cultures for 5 
days in the absence of DOX thus retaining full levels of mutant p53 (left panel), or grown in the 
presence of DOX inducing an shRNA that targets p53 (right panel), leading to depleted levels of 
mutant p53 as in Figure 2.1 or in (D) below. Representative DIC images are shown.  Scale bar, 
200 µm. 
 
(B) MDA-468.shp53 cells expressing an shRNA-resistant Flag-tagged p53-R273H were grown 
in 3D cultures for 5 days in the absence or presence of DOX as in (A).  Representative DIC 
images are shown.  Scale bar, 200 µm. 
 
(C) MDA-468.shp53 cells expressing an shRNA-resistant Flag-tagged p53-R273H-mTAD 
(mutant p53 with non-functional transactivation region, p53-R273H- L22Q/W23S/W53Q/F54S) 
were grown in 3D cultures for 5 days in the absence or presence of DOX as in (A).  
Representative DIC images are shown.  Scale bar, 200 µm. 
 
(D) Immunoblot of mutant p53 in MDA-468 cells.  Cells either with control vector or expressing 
shRNA resistant versions of Flag-tagged p53-R273H mutant p53 or transactivation defective 
Flag-tagged p53-R273-mTAD were grown in 3D culture for 5 days in the absence or presence of 
DOX as indicated followed by lysis and processing for immunoblotting as in Figure 2.1B.  p53 
was detected using an anti-p53 antibody (PAb240).  Note that exogenously expressed Flag-
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tagged mutant p53 variants migrate more slowly than endogenously expressed mutant p53. Actin 
serves as a loading control. 
 
Figure 2.3 Knockdown of mutant p53 from breast cancer cells in 3D culture significantly 
downregulates the mevalonate pathway 
(A) Pathway analysis of breast cancer cells following mutant p53 depletion.  Data were analyzed 
through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com). 
Significant (p<0.01) expression changes from genome-wide expression analysis were queried.  
Blue bars that cross the threshold line (p<0.05) represent pathways that are significantly changed 
following mutant p53 depletion from MDA-468 cells. 
 
(B) Biological processes significantly altered by mutant p53 in 3D culture.  Significant 
expression changes from genome-wide expression analysis were analyzed by Gene Ontology 
(GO) analysis.  1, 2, 3 represent three independent experiments. GO terms were sorted based 
their significance and redundant terms were discarded. 
 
(C) Validation of sterol biosynthesis genes regulated by mutant p53.  MDA-468.shp53 cells were 
grown in 3D cultures for 8 days in the presence or absence of DOX as indicated to deplete cells 
of mutant p53.  Isolated RNA was reverse transcribed and qRT-PCR was performed for the 
seven sterol biosynthesis genes identified by Ingenuity Pathway Analysis: HMGCR, HMG-CoA 
reductase; MVK, Mevalonate Kinase; MVD, Mevalonate Decarboxylase; FDPS, Farnesyl 
Diphosphate Synthase; SQLE, Squalene Epoxidase; LSS, Lanosterol Synthase; DHCR7, 7-
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Dehydrocholesterol reductase. Data is presented as mean ± st dev of three independent 
experiments.  **indicates p<0.005 by two-sided t-test.  
 
Figure 2.4 Downregulation of the mevalonate pathway is both necessary and sufficient to 
phenotypically revert breast cancer cells in 3D culture 
(A) Intermediate metabolites rescue the phenotypic effects of depleting breast cancer cells of 
mutant p53.  MDA-468.shp53 cells were grown in 3D cultures for 8 days in the presence or 
absence of DOX to deplete mutant p53.  Parallel wells of cells which were grown in the presence 
of DOX were supplemented with metabolites produced within the mevalonate pathway: 
mevalonic acid/mevalonic acid-phosphate (MVA/MVAP) beginning on Day 1. Morphological 
categories as indicated were determined for 50-100 structures using confocal microscopy which 
were then plotted as a percentage of the population.  A representative experiment is shown here 
and a second representative experiment is shown in Figure 2.S4. 
 
(B) Inhibition of the mevalonate pathway affects MDA-468 cell morphology in 3D cultures.  
MDA-468 cells were grown in 3D culture conditions for 13 days untreated or treated with 
vehicle (DMSO), Simvastatin (100 nM) or Simvastatin (1 µM) as indicated.  Drugs were added 
on Day 4.  Scale Bar, 200 µm. 
 
(C) Inhibition of the mevalonate pathway affects MDA-231 cell morphology in 3D cultures.  
MDA-231 cells were grown in 3D culture conditions for 13 days untreated or treated with 
vehicle (DMSO), Simvastatin (100 nM) or Simvastatin (1 µM) as indicated.  Drugs were added 
on Day 4.  Scale Bar, 200 µm. 
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(D) The effects of Simvastatin are due to inhibition of HMG-CoA reductase.  MDA-468 cells 
(top panel) or MDA-231 cells (bottom panel) were grown in 3D cultures for 13 days with 
Simvastatin (1 µM) as in (B) and (C), respectively, but were supplemented with mevalonic 
acid/mevalonic acid-phosphate, the early enzymatic products after HMG-CoA reductase.  Scale 
Bar, 200 µm. 
 
(E) Supplementation with mevalonic acid is sufficient to block luminal clearance in MCF10A 
cells.  MCF10A cells were grown in 3D culture for 8 days in the absence (Control) or presence 
(MVA) of 1 mM mevalonic acid.  Nuclei were stained with DRAQ5 (Red) and structures were 
analyzed by confocal microscopy for the presence of a hollow or filled lumen (right panel).  
Structures (50-100) were counted for each condition. An average of two experiments is 
presented.  Scale Bar, 50 µm.  
 
Figure 2.5 Modulation of geranylgeranylation mediates many of the phenotypic effects of 
mutant p53 depletion and HMG-CoA reductase inhibition in MDA-231 cells 
(A) Inhibition of downstream enzymes in the mevalonate pathway affects MDA-231 cell 
morphology in 3D cultures.  MDA-231 cells were grown in 3D culture conditions for 8 days 
untreated or treated with vehicle (DMSO), YM-53601 (1 µM), FTI-277 (1 µM) or GGTI-2133 (1 
µM) as indicated.  Drugs were added on Day 1.  Scale Bar, 200 µm. 
 
(B) Geranylgeranyl pyrophosphate can partially rescue the morphological effects of mutant p53 
depletion.  MDA-231.shp53 cells were grown in 3D culture conditions for 9 days in the absence 
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(-DOX) or presence (+DOX) of doxycycline as indicated.  Parallel wells of cells which were 
grown in the presence of DOX were supplemented with geranylgeranyl pyrophosphate (GGPP) 
(25 µM) beginning on Day 1.  Scale Bar, 200 µm. 
 
(C) Geranylgeranyl pyrophosphate can rescue the morphological effects of HMG-CoA reductase 
inhibition.  MDA-231 cells were grown in 3D culture conditions for 13 days either treated with 
vehicle (DMSO) or Simvastatin (1 µM) as indicated.  Parallel wells of cells which were grown in 
the presence of Simvastatin (1 µM) were supplemented with geranylgeranyl pyrophosphate 
(GGPP) (25 µM) beginning on Day 1.  Scale Bar, 200 µm. 
 
Figure 2.6 Mutant p53 is recruited to mevalonate pathway gene promoters and this 
recruitment is dependent on SREBP proteins 
(A) Mutant p53 interacts with sterol regulatory element binding proteins.  HEK 293 cells were 
transiently transfected with Flag-p53-R273H and either Myc-mSREBP-1a, -1c or -2.  Cells were 
subjected to crosslinking with formaldehyde prior to cell lysis and sonication as described in 
Methods.  Mutant p53 was immunoprecipitated from 2 mg whole cell lysates using anti-Flag 
antibody with Protein A/G Sepharose beads followed by SDS-PAGE and immunoblotting with 
anti-Myc (upper panel) and anti-Flag (lower panel).  Input is 2.5% of IP sample.  
 
(B) Endogenous SREBP-2 interacts with endogenous mutant p53. Nuclear lysates from serum-
starved MDA-468.shp53 cells were immunoprecipitated with an anti-SREBP-2 antibody (1D2) 
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or Mouse IgG (Mock IP) and then immunoblotted with anti-SREBP-2 (1D2) and anti-p53 
antibodies (DO-1). Input is 10% of IP sample.   
 
(C) ChIP analysis of mutant p53 in the vicinity of SRE-1 sites.  MDA-468.shp53 cells were 
grown in 2D culture for 8 days in the absence or presence of DOX to deplete mutant p53.  
Mutant p53 was immunoprecipitated from 1 mg of MDA-468.shp53 lysates using anti-p53 
antibodies (1801/DO1).  Parallel samples were processed without antibody (Mock IP, “C”) to 
serve as a negative control.  Data is presented as mean ± st dev of three independent 
experiments.  Values were normalized to the highest immunoprecipitation signal. **indicates 
p<0.01 or *indicates p<0.05 compared to all of the following: negative site, +DOX and Mock IP.   
 
 (D) ChIP analysis of mutant p53 at different regions of the HMGCR promoter.  MDA-468.shp53 
cells were grown in 2D culture for 8 days in the absence or presence of DOX to deplete p53.  
Mutant p53 was immunoprecipitated from 1 mg of MDA-468.shp53 lysates using anti-p53 
antibodies (1801/DO1).  Parallel samples were processed without antibody (Mock IP, “C”) to 
serve as a negative control.  Data is presented as mean ± st dev of three independent 
experiments.  Values were normalized to the highest immunoprecipitation signal.  ** indicates 
p<0.01 compared to all of the following: negative site, +DOX, Mock IP, upstream and 
downstream sites.  Genomic locations of PCR primers are illustrated in a schematic of the 
HMGCR promoter.  SRE-1 denotes sterol regulatory element. 
 
(E) ChIP analysis of mutant p53 on the HMGCR promoter after SREBP2 knockdown.  MDA-
468 cells were treated with siRNA directed against SREBP2 and subjected to ChIP analysis for 
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mutant p53 recruitment to the vicinity of the SRE-1 site in the HMGCR promoter (-150bp). Data 
is presented as mean ± st dev of three independent experiments.  Values were normalized to the 
highest immunoprecipitation signal. *designates p<0.05. See Figure 2.S6 for extent of SREBP2 
knockdown. 
 
(F) ChIP analysis of mutant p53 on the HMGCR promoter after SREBP inhibition by Fatostatin.  
MDA-468.shp53 cells were treated with Fatostatin (20 µM) and subjected to ChIP analysis for 
mutant p53 recruitment to the vicinity of the SRE-1 site in the HMGCR promoter (-150bp). Data 
is presented as mean ± st dev of six independent experiments.  Values were normalized to the 
highest immunoprecipitation signal. **designates p<0.01.  
 
(G) Inhibition of SREBP activation affects MDA-231 cell morphology in 3D cultures.  MDA-
231.shp53 cells were grown in 3D culture conditions for 8 days treated with vehicle (DMSO), 
Fatostatin (2 µM) or Fatostatin (20 µM) as indicated.  Drugs were added on Day 1.  Scale Bar, 
200 µm. 
 
Figure 2.7 Mutant p53 is correlated with higher expression of a subset of mevalonate 
pathway genes in human breast cancer patient datasets 
(A) Five human breast cancer patient datasets were analyzed to determine whether tumors 
bearing mutant p53 correlate with higher expression of sterol biosynthesis genes. Patients were 
stratified based on TP53 status (wild-type vs. mutant) and expression levels for sterol 
biosynthesis genes were analyzed.  One of the significantly associated genes, Isopentenyl 
Pyrophosphate Isomerase (IDI1), exhibited higher expression levels in mutant p53 tumors 
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compared to wild-type p53 tumors (p<0.05) across all five datasets. p-value represents the result 
of a one-sided t-test.  See Table 2.S1 for all genes. 
 
(B) Unsupervised hierarchical clustering with Euclidean distance and ward linkage of expression 
matrix from the 17 sterol biosynthesis genes on 812 samples (728 of which have TP53 
mutational status). MVD was not present in the DBCG dataset and its missing expression values 
were grayed out on the heatmap.  Rows indicate the identity of the genes and columns indicate 
the identity of the patients.  The TP53 mutational status for each tumor is depicted directly above 
each column.  Cluster I exhibits the lowest expression of the mevalonate pathway genes, cluster 
III exhibits an intermediate expression level and cluster II exhibits the highest expression level of 
the mevalonate pathway genes.   
 
(C) The Kaplan-Meier curves for the resulting clusters from the unsupervised hierarchical 
clustering in (B). 
 
(D) Estimated hazard ratios (HRs; the relative risk for 1 unit increasing in the gene expression) 
with 95% confidence interval for risk of breast cancer specific death. Expression levels of 
following genes were positively associated with the risk of breast cancer specific death at FDR 
(q) 5%: ACAT2 (HR = 1.23, q = 0.0069), HMGCS1 (HR = 1.21, q = 0.007), HMGCR (HR = 
1.17, q = 0.032), IDI1 (HR = 1.26, q < 0.001), FDPS (HR = 1.17, q = 0.012), SQLE (HR = 1.35, 
q < 0.001), LSS (HR = 1.16, q = 0.032), NSDHL (HR = 1.17, q = 0.032), DHCR7 (HR = 1.26, q 
< 0.001). Blue indicates q<0.05, grey indicates q>0.05.   
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Figure 2.S1 Depletion of mutant p53 from breast cancer cells induces a phenotypic 
reversion in 3D culture, (Related to Figure 2.1) 
(A) Doxycycline curve in MDA-231.shp53 cells.  MDA-231.shp53 cells were grown in 2D 
culture in the presence of the indicated concentrations of DOX for 8 days.  p53 was detected 
using an anti-p53 antibody (PAb1801).  Actin serves as a loading control. 
 
(B) Doxycycline curve in MDA-231.shp53 cells in 3D culture.  MDA-231.shp53 cells were 
grown in 3D culture for 8 days in the presence of the indicated concentrations of DOX and 
imaged using differential interference microscopy.  Scale Bar, 200 µm. 
 
(C) Doxycycline curve in MDA-468.shp53 cells.  MDA-468.shp53 cells were grown in 2D 
culture in the presence of the indicated concentrations of DOX for 8 days.  p53 was detected 
using an anti-p53 antibody (PAb1801).  Actin serves as a loading control. 
 
(D) Doxycycline curve in MDA-468.shp53 cells in 3D culture.  MDA-468.shp53 cells were 
grown in 3D culture for 8 days in the presence of the indicated concentrations of DOX and 
imaged using differential interference microscopy.  Scale Bar, 200 µm. 
 
(E) Reverted MDA-468.shp53 cells regain proper localization of α6 integrin.  MDA-468.shp53 
cells well grown in 3D culture for 8 days in the presence (top panels) or absence (bottom panels) 
of DOX to deplete levels of endogenous mutant p53.  Alpha 6 integrin (red) was immunostained 
using a monoclonal antibody directed against α6 integrin and nuclei were stained with DRAQ5 
(Blue). Structures were analyzed by confocal microscopy. Scale bar, 50 µm. 
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(F) Expression of shRNA-resistant p53-R273H can compensate for depletion of p53-R280K 
from MDA-231 cells. MDA-231.shp53 cells expressing a control vector were grown in 3D 
culture for 8 days in the absence of DOX (top left panel), thus retaining full levels of mutant p53, 
or grown in the presence of DOX (top right panel) to ablate endogenous mutant p53.  MDA-
231.shp53 cells expressing a shRNA-resistant Flag-tagged version of mutant p53 (p53-R273H) 
were grown in 3D culture for 8 days in the absence of DOX (bottom left panel), thus retaining 
full levels of both exogenous and endogenous mutant p53, or grown in the presence of DOX 
(bottom right panel) to ablate endogenous mutant p53, but retain exogenous p53-R273H. Scale 
Bar, 200 µm. 
 
(G)  Levels of endogenous mutant p53 and retention of exogenous mutant p53.  Cells were 
grown for 8 days in the presence or absence of DOX as indicated.  p53 was detected using an 
anti-p53 antibody (PAb1801).  Actin serves as a loading control. 
 
Figure 2.S2 Tumor-derived mutants of p53 disrupt acinar morphogenesis in non-malignant 
mammary epithelial cells, (Related to Figure 2.2) 
(A) Schematic of normal mammary acinar development. 
 
(B-G) Mutant p53 disrupts normal mammary morphogenesis.  MCF10A cells expressing an 
empty vector (B) or Flag-tagged versions of p53-R175H (C), p53-R248W (D), p53-R273H(E), 
p53-R248Q (F) or p53-G245S (G) were grown in 3D culture for 8 days.  Structures were 
analyzed by confocal microscopy.  Nuclei were stained with DRAQ5 (Red).  Scale Bar, 50 µm. 
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(H) Immunoblot for p53 expression demonstrating endogenous wild-type p53 and exogenous 
Flag-tagged mutants.  MCF10A cells expressing Flag-tagged versions of mutant p53 were grown 
in 3D culture for 8 days.  p53 was detected using an anti-p53 antibody (PAb1801).  Actin serves 
as a loading control.   
 
(I) Morphometry of structures.  MCF10A cells expressing tumor-derived mutants of p53, or their 
transactivation-deficient (mTAD) equivalents, were grown in 3D culture for 8 days and analyzed 
by confocal microscopy for the presence of a hollow or filled lumen.  Structures (50-100) were 
counted for each condition.  A representative experiment is shown. 
 
(J) Immunoblot for p53 expression demonstrating exogenous Flag-tagged mutants.  MCF10A 
cells expressing Flag-tagged versions of mutant p53 with wild-type of mutant (mTAD) 
transactivation domains were grown in 2D culture, lysed and whole cell extracts were subjected 
to SDS-PAGE and then immunoblotted.  Exogenous p53 was detected using an anti-Flag 
antibody.  Actin serves as a loading control.   
 
Figure 2.S3. Schematic of the mevalonate pathway, (Related to Figure 2.3) 
(A) Schematic of the mevalonate pathway.  Key intermediate metabolites are shown in bold.  
Gene names are shown in parentheses.  Inhibitors are indicated using gray boxes.   
 
Figure 2.S4 Downregulation of the mevalonate pathway is both necessary and sufficient to 
phenotypically revert breast cancer cells in 3D culture, (Related to Figure 2.4) 
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(A) Intermediate metabolites rescue the phenotypic effects of depleting breast cancer cells of 
mutant p53.  MDA-468.shp53 cells were grown in 3D culture for 8 days in the presence or 
absence of DOX to knockdown mutant p53.  Cells which were grown in the presence of DOX 
were then supplemented with two metabolites produced within the mevalonate pathway: 
mevalonic acid/mevalonic acid-phosphate (MVA/MVAP). Morphological categories were 
determined for 50-100 structures using confocal microscopy which were then plotted as a 
percentage of the population.  A representative experiment is shown. 
 
(B) Add-back of mevalonic acid/mevalonic acid-phosphate (MVA/MVAP) does not affect 
mutant p53 depletion by doxycycline.  MDA-468.shp53 cells were cultured in the presence of 
doxycycline to knockdown mutant p53 with or without supplementation of 1mM MVA/MVAP.  
Whole cell extracts were then subjected to SDS-PAGE and then immunoblotted.  p53 was 
detected using an anti-p53 antibody (PAb1801).  Actin serves as a loading control.   
  
 (C) Simvastatin treatment does not affect the morphology of MCF10A cells.  MCF10A cells 
were grown in 3D culture for 13 days untreated or treated with vehicle (DMSO), Simvastatin 
(100 nM) or Simvastatin (1 µM) as indicated.  Drugs were added on Day 4.  Scale Bar, 200 µm. 
 
 (D) Mevastatin profoundly affects the 3D morphology of MDA-231 cells.  MDA-231 cells were 
grown in 3D culture for 13 days.  On Day 4, vehicle (DMSO) or Mevastatin (1 µM) were added 
as indicated for the remainder of the experiment.  Scale Bar, 200 µm. 
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(E) Mevastatin profoundly affects the 3D morphology of MDA-468 cells.  MDA-468 cells were 
grown in 3D culture for 13 days.  On Day 4, vehicle (DMSO) or Mevastatin (1 µM) were added 
as indicated for the remainder of the experiment.  Scale Bar, 200 µm. 
 
(F) Inhibition of Mevalonate Decarboxylase affects the 3D morphology of MDA-468 cells.  
MDA-468 cells were grown in 3D cultures for 8 days.  On Day 1, vehicle (DMSO) or 6-
Fluoromevalonate (200 µM) was added for the remainder of the experiment.  Scale Bar, 200 µm. 
 
(G) Inhibition of Mevalonate Decarboxylase affects the 3D morphology of MDA-231 cells.  
MDA-231 cells were grown in 3D cultures for 8 days.  On Day 1, vehicle (DMSO) or 6-
Fluoromevalonate (200 µM) was added for the remainder of the experiment.  Scale Bar, 200 µm. 
 
Figure 2.S5 Simvastatin prevents growth in breast cancer cells in vivo and induces a cell 
cycle arrest in cells grown in 2D culture, (Related to Figure 2.5) 
(A) Simvastatin prevents anchorage-independent growth in breast cancer cells.  MDA-231 or 
MDA-468 cells were grown in soft-agar for 21 days in the presence of DMSO vehicle control or 
presence of Simvastatin (0.1, 1, 10 µM).  Plates were subsequently stained with crystal violet and 
colonies were counted for each condition.  Quantitation of three independent experiments 
illustrating relative colony number for MDA-231 (left) and MDA-468 (right) cells.  Data 
presented as mean ± st dev. *denotes p<0.05, **denotes p<0.01 using a two-tailed students t-test. 
 
(B-C) Simvastatin induces a G1 arrest in breast cancer cells grown in 2D culture.  Flow 
cytometric analysis of cell cycle distribution for three independent experiments in MDA-468 
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cells (B) or MDA-231 cells (C).  Data presented as mean ± st dev. *denotes p<0.05, **denotes 
p<0.01 using a two-tailed students t-test. 
 
(D) Simvastatin significantly impacts tumor growth in vivo.  MDA-231 cells (2x106) were 
injected subcutaneously into 8 week-old NOD-SCID mice.  Fourteen days after implantation 
mice were paired by equal tumor volumes and randomized to either a Simvastatin (200 
mg/kg/day) or Control (placebo) group (N=5 for each group).  Tumor measurements were 
performed weekly using calipers.  After 21 days of treatment, mice were sacrificed and tumors 
were extracted and weighed.  Tumor volumes as a function of time (left) and tumor weights at 
day 21 (right) are presented.  *denotes p<0.01, **denotes p<0.001 using a two-tailed students t-
test. 
  
Figure 2.S6 Mutant p53 regulates SREBP target genes in breast cancer cells, (Related to 
Figure 2.6) 
(A) Endogenous SREBP-2 interacts with endogenous mutant p53. Nuclear lysates from serum-
starved MDA-231.shp53 cells were immunoprecipitated with an anti-SREBP-2 antibody (1D2) 
or Mouse IgG and then immunoblotted with anti-SREBP-2 (1D2) and anti-p53 antibodies (DO-
1). Input is 10% of IP sample.   
 
(B) Venn diagram illustrating overlap between SREBP target genes and genes changed after 
mutant p53 knockdown.  Significant gene expression changes (p<0.05) from genome-wide 
expression analysis of MDA-468 cells depleted of mutant p53 were queried against a 
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comprehensive list of SREBP1 target genes (Reed et al., 2008).  P-value was determined by the 
Chi-squared method.   
 
(C) Sterol biosynthesis genes regulated by mutant p53.  MDA-468.shp53 cells were grown in 3D 
culture for 8 days in the presence or absence of DOX to knockdown mutant p53.  qRT-PCR of 
three independent experiments of sterol biosynthesis genes not initially identified using IPA.  
Data presented as mean ± st dev. *indicates p<0.05, ** indicates p<0.01 using a two-tailed t-test. 
 
(D) Sterol biosynthesis genes regulated by mutant p53 in MDA-231 cells.  MDA-231.shp53 cells 
were grown in 3D culture for 8 days in the presence or absence of DOX to knockdown mutant 
p53.  qRT-PCR of three independent experiments of sterol biosynthesis genes.  Data presented as 
mean ± st dev. *indicates p<0.05 using a two-tailed t-test. 
 
(E) SREBP target genes, including fatty acid biosynthesis genes, regulated by mutant p53.  
MDA-468.shp53 cells were grown in 3D culture for 8 days in the presence or absence of DOX to 
knockdown mutant p53.  qRT-PCR of three independent experiments of SREBP target genes.  
Data presented as mean ± stdev.    **indicates p<0.01 using a two-tailed t-test. 
 
(F) Immunoblot demonstrating knockdown of SREBP2.  MDA-468 cells were treated with a 
control siRNA or siRNA directed against SREBP1, SREBP2 or p53 as in Figure 2.6.  Whole cell 
lysates were then subjected to SDS-PAGE. Full-length SREBP2 was detected using an anti-
SREBP2 antibody (1D2) and p53 was detected using an anti-p53 antibody (PAb1801).  Actin 
serves as a loading control. 
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 (G) ChIP analysis of mutant p53 on the HMGCR promoter after SREBP1 knockdown.  MDA-
468 cells were treated with siRNA directed against SREBP1 and subjected to ChIP analysis for 
mutant p53 recruitment to the vicinity of the SRE-1 site in the HMGCR promoter (-150bp). Data 
is presented as mean ± st dev of three independent experiments.  Values were normalized to the 
highest immunoprecipitation signal. *designates p<0.05. 
 
(H) ChIP analysis of mutant p53 on the HMGCR promoter after p53 knockdown.  MDA-468 
cells were treated with siRNA directed against p53 and subjected to ChIP analysis for mutant 
p53 recruitment to the vicinity of the SRE-1 site in the HMGCR promoter (-150bp). Data is 
presented as mean ± st dev of three independent experiments.  Values were normalized to the 
highest immunoprecipitation signal. **designates p<0.01. See Figure 2.S5C for extent of p53 
knockdown. 
 
Figure 2.S7 Mutant p53 is correlated with higher expression of a subset of mevalonate 
pathway genes in human breast cancer patient datasets, (Related to Figure 2.7) 
Five human breast cancer patient datasets were analyzed to determine whether tumors bearing 
mutant p53 correlate with higher expression of sterol biosynthesis genes. Patients were stratified 
based on TP53 status (wild-type vs. mutant) and expression levels for sterol biosynthesis genes 
were analyzed.  p-value represents the result of a one-sided t-test.  See Table 2.S1 for all genes. 
 
(A) Farnesyl Diphosphate Synthase (FDPS) exhibited higher expression levels in mutant p53 
tumors compared to wild-type p53 tumors (p<0.05) in three out of five datasets. 
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(B) Squalene Epoxidase (SQLE) exhibited higher expression levels in mutant p53 tumors 
compared to wild-type p53 tumors (p<0.05) in four out of five datasets. 
 
(C) 7-Dehydrocholesterol reductase (DHCR7) exhibited higher expression levels in mutant p53 
tumors compared to wild-type p53 tumors (p<0.05) across all five datasets. 
 
 
Table 2.S1 Mutant p53 is correlated with higher expression of a subset of mevalonate 
pathway genes in human breast cancer patient datasets, (Related to Figure 2.7) 
(A) Five human breast cancer patient datasets, FW-MDG, MicMa, ULL, DBCG and Miller were 
analyzed to determine whether tumors bearing mutant p53 correlated with higher expression of 
sterol biosynthesis genes. Patients were stratified based on TP53 status (wild-type vs. mutant) 
and expression levels for sterol biosynthesis genes were analyzed.  p-value represents the result 
of a one-sided t-test for seventeen sterol biosynthesis genes.  The right-hand column provides the 
False Discovery Rate (FDR) for each gene across the five datasets.    
 





















 Freed-Pastor et al., Figure 2.7 
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Cluster III = 34.6% 
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The p53 protein plays a pivotal role in myriad aspects of tumorigenesis and is frequently mutated 
in a majority of human cancers.  We identified a role for mutant forms of p53 in maintaining the 
malignant, disorganized and invasive, state of breast cancer cells using a three-dimensional (3D) 
culture model of breast cancer.  In this study, we queried a number of pathways/proteins that had 
previously been shown to be sufficient to effect a phenotypic reversion in 3D culture to search 
for additional mechanisms by which mutant p53 might contribute to mammary carcinogenesis. 
Using this approach, we identified β4 integrin as a novel target of mutant p53 in breast cancer 
cells and demonstrated that stable knockdown of β4 integrin is sufficient to severely blunt the 
invasive phenotype of breast cancer cells grown in 3D culture.  We also demonstrate that 
inhibition of NF-κB signaling, a downstream mediator of β4 integrin, is sufficient to elicit a 
phenotypic reversion to acinar-like structures in 3D culture.  Furthermore, we show that mutant 
p53 associates with the promoter of ITGB4, the gene encoding β4 integrin, providing a plausible 
mechanism for its upregulation of ITGB4 expression.  These findings suggest that integrin β4 






p53 is one of the most widely studied proteins in tumor biology and is the most 
frequently mutated gene in all of human cancer (Petitjean et al., 2007b; Vogelstein et al., 2000).  
Wild-type p53 is activated in response to a number of cellular stressors including DNA damage, 
hypoxia and oncogene activation, which leads to cell cycle arrest, apoptosis or senescence, 
thereby functioning to suppress tumor development (Riley et al., 2008; Vousden and Prives, 
2009).  TP53, the gene encoding p53 protein, is most commonly mutated by single amino acid 
substitutions (missense mutations) that lead to elevated expression of a mutant form of p53 
(Brosh and Rotter, 2009; Levine et al., 1995).   While wild-type p53 functions as a tumor 
suppressor, certain mutant forms of p53 have been shown to exert oncogenic (also termed gain-
of-function) effects independent of wild-type p53 (Brosh and Rotter, 2009; Goh et al., 2011; 
Oren and Rotter, 2010).    
Gain-of-function effects of mutant p53 have been shown to impact multiple stages of 
tumorigenesis including proliferation, inhibition of apoptosis, chemoresistance, invasion, 
migration and metastasis (Bossi et al., 2006; Dhar et al., 2008; Di Agostino et al., 2006; Lang et 
al., 2004; Lim et al., 2009; Muller et al., 2009; Olive et al., 2004; Stambolsky et al., 2010).  Just 
as wild-type p53 functions primarily as a transcription factor, many mutant p53 gain-of-function 
effects are mediated through transcriptional regulation of target genes (Di Agostino et al., 2006; 
Kim and Deppert, 2007; Matas et al., 2001; Strano et al., 2007; Weisz et al., 2007; Weisz et al., 




targets of mutant p53 are often repression targets of wild-type p53 (Brosh and Rotter, 2009; Di 
Agostino et al., 2006; Peart and Prives, 2006; Stambolsky et al., 2010).   
Integrins are transmembrane receptors, each of which consists of one α and one β 
subunit, that transmit both chemical and mechanical signals between cells and between the cell 
and the extracellular matrix (Guo and Giancotti, 2004).  Integrin β4, encoded by ITGB4, almost 
exclusively associates with α6 integrin and functions as a receptor for laminins 1, 2, 4 and 5 (Lee 
et al., 1992). The α6β4 integrin is located on the basal surface of most epithelial tissues where it 
mediates hemidesmosome formation (Guo and Giancotti, 2004).  The importance of this integrin 
is highlighted by the fact that β4-knock-out mice die a few hours after birth due to respiratory 
failure, gastrointestinal problems and severe skin blistering (Dowling et al., 1996).  The observed 
phenotype in knock-out mice is remarkably similar to those observed in the inherited human 
condition, junctional epidermolysis bullosa with pyloric atresia, many cases of which have been 
shown to be due to mutation of integrin β4 (Dowling et al., 1996; Niessen et al., 1996; Takaoka 
et al., 1998; van der Neut et al., 1996).   
In contrast to other integrins, which have extremely short C-terminal, intracellular 
domains, the C-terminus of integrin β4 contains a very long cytoplasmic tail that has been shown 
to impact multiple intracellular signaling pathways (PI3K, Rac1 and RhoA, with NF-κB serving 
as a common downstream mediator) (Guo and Giancotti, 2004; Guo et al., 2006; Mercurio et al., 
2001; Takaoka et al., 1998; Tennenbaum et al., 1996; Weaver et al., 2002).  While the regulation 
of integrin β4 expression is not well understood, it is known to be regulated at both the 




The role that integrins play in tumorigenesis is becoming increasingly recognized.  
Paradoxically, tumors often secrete abundant levels of basement membrane proteins and 
overexpress β4 integrin, in spite of the fact that they concomitantly express high levels of matrix 
degrading enzymes (Weaver et al., 2002).  In addition, high levels of integrin β4 have been 
linked to the basal-like subtype of breast cancer and have been shown to have prognostic 
significance (Lu et al., 2008).  A large body of literature has linked the α6β4 integrin to multiple 
aspects of tumorigenesis including increased survival, angiogenesis and invasion (Lipscomb et 
al., 2005; Nikolopoulos et al., 2004; Shaw et al., 1997).  In fact, integrin β4 was first discovered 
as a tumor antigen (originally called TSP180 for “Tumor Specific Protein of 180 kDa”) 
expressed at high levels in invasive carcinomas (Giancotti et al., 1992).  However, as mentioned 
in Chapter 1, the role that α6β4 integrin plays in tumorigenesis is still debated.     
 We had previously found that depletion of endogenous mutant p53 from breast cancer 
cell lines can dramatically alter their behavior in a three-dimensional culture system by co-opting 
the SREBP transcription factors and driving flux through the mevalonate pathway.  We found 
that depletion of mutant p53 from MDA-231 cells results in a profound reduction in invasive 
characteristics, while depletion of mutant p53 from MDA-468 cells is sufficient to elicit a 
phenotypic reversion to acinar-like structures in 3D culture (Chapter 2).  In this study, we have 
sought additional transcriptional targets of mutant p53 which might contribute to the disrupted 
morphology of breast cancer cells in 3D culture.   
RESULTS 




 As reviewed in Chapter 1, a number of pathways and/or proteins have previously been 
demonstrated to be necessary to maintain the malignant state of breast cancer cells (Table 3.1).  
We performed a genome-wide expression analysis of MDA-468 breast cancer cells grown in 3D 
cultures with full or depleted levels of endogenous mutant p53 (Figure 2.3) and queried the genes 
significantly affected by mutant p53 depletion for those previously shown to produce a 
phenotypic reversion in tumorigenic breast cells grown in a laminin-rich extracellular matrix. 
 We examined the mRNA expression of seventeen genes corresponding to fifteen known 
pathways/proteins demonstrated to be necessary to maintain the disrupted morphology of breast 
cancer cells in 3D culture, seven of which were significantly affected (p<0.05) by mutant p53 
depletion.  However, only two such genes (ITGB1 and ITGB4), encoding two integrins, were 
significantly altered in the expected direction to contribute to the phenotypic reversion we 
observed upon mutant p53 depletion (Table 3.1).  Integrin β1 is one of the most well studied 
integrins in respect to mammary acinar morphogenesis and inhibition of integrin β1 has been 
shown in multiple reports to revert disrupted tumorigenic breast cells to a more acinar-like 
morphology (Wang et al., 2002; Wang et al., 1998; Weaver et al., 1997).  Integrin β4 is much 
less studied in relation to mammary tissue architecture disruption, but a number of studies have 
demonstrated that inhibition of integrin β4 can dramatically alter the morphology of breast 
cancer cells grown in 3D culture (Dutta and Shaw, 2008; Gabarra et al., 2010; Lipscomb et al., 
2005). 
We first validated these expression changes using reverse transcription followed by 
quantitative polymerase chain reaction (qRT-PCR) in three independent experiments of MDA-
468.shp53 cells cultured in 3D conditions.  While ITGB1 was significantly downregulated in 




effect was not observed with mutant p53 knockdown in MDA-231.shp53 cells (Figure 3.1C and 
1E).  Additionally, we examined integrin β1 levels, the protein encoded by ITGB1, upon mutant 
p53 depletion from MDA-468 cells, but observed only a mild decrease in protein levels (Figure 
3.S1B).  ITGB4 mRNA expression was significantly affected by mutant p53 depletion in both a 
stable pool and stable clone of MDA-468.shp53 cells, as well as in MDA-231.shp53 cells grown 
in 3D culture (Figure 3.1A, 1C and 1E).  Additionally, we examined whether mutant p53 
depletion affected nascent transcripts of ITGB4 by using primers that anneal to a region within 
intron 3.  As mutant p53 depletion also downregulated primary transcripts of ITGB4, this 
regulation occurs as a result of transcription (as opposed to mRNA stability or some later point 
of regulation) (Figure 3.1C and 1E).  Finally, we confirmed that the levels of integrin β4, the 
protein encoded by ITGB4, were also downregulated upon mutant p53 depletion from MDA-
468.shp53 and MDA-231.shp53 cells and that this regulation is present in cells grown in both 2D 
and 3D culture (Figure 3.1B, 1D and 1F).  Interestingly, we consistently noted higher protein 
expression of integrin β4 when cells were grown in 3D compared to 2D culture (Figure 3.1). 
Endogenous mutant p53 associates with DNA in the vicinity of transcriptional start sites in 
the ITGB4 promoter and within the first intron 
Wild-type p53 functions primarily as a transcription factor and we and others have 
previously demonstrated that mutant p53 can associate with promoter regions to transactivate 
target genes (Chapter 2) (Stambolsky et al., 2010; Yan and Chen, 2009).  The ITGB4 gene has 
two alternate transcriptional start sites, which both produce the same protein, but differ in their 5’ 
untranslated region (UTR) (Takaoka et al., 1998).  To examine the mechanism by which mutant 




quantitative PCR for a number of regions upstream and downstream of both transcriptional start 
sites (Figure 3.2A).   
We identified two peaks of significant binding by mutant p53 in the vicinity of the ITGB4 
gene, just upstream of each transcriptional start site (TSS1 and TSS2).  More specifically these 
were located approximately 300 bp upstream of TSS1 and approximately 1.8 kb into the first 
intron and just upstream of TSS2, with an intervening “valley” (Figure 3.2B and 2C).  We 
observed similar mutant p53 binding in both 2D and 3D culture conditions (Figure 3.2B and 2C, 
respectively) and this binding was approximately 2-5 fold above binding at a negative site 
(downstream of the CDKN1A gene) and upstream and downstream regions surrounding the 
ITGB4 gene and was consistently reduced upon mutant p53 depletion.   
Depletion of integrin β4 reduces invasive morphology of MDA-231 breast cancer cells 
grown in 3D culture 
 We next examined whether downregulation of integrin β4 following mutant p53 
depletion might contribute to the phenotypic effects we observed in 3D culture (Figure 2.1).  
Using lentiviral transduction, we engineered MDA-231 cells to stably express either a control 
shRNA or an shRNA targeting integrin β4 in exon 3 using two different hairpin loop structures 
(shβ4-#1a and shβ4-#1b).  When these cells were grown under 3D culture conditions, the 
parental cells and those infected with a scrambled shRNA lentivirus (Control) exhibited an 
invasive (“stellate”) morphology as previously described (Kenny et al., 2007) and (Chapter 2).  
However, MDA-231 cells depleted of integrin β4 formed much smaller clusters of cells with 
almost a complete loss of invasive processes (Figure 3.3A).  Nicely, the morphologies of these 




agreement with previous reports that integrin β4 can promote migration and invasion in a variety 
of cell lines through either the phosphatidylinositol 3-kinase (PI3K) pathway or the small 
GTPases (RhoA or Rac1) (Mercurio et al., 2001).   
Importantly, this profound reduction in invasive processes closely resembles the 
phenotypic changes upon mutant p53 depletion from MDA-231 cells (Figure 2.1), but it should 
be pointed out that these cells do not undergo a complete phenotypic reversion to form acinar-
like structures with a hollow lumen upon either mutant p53 or integrin β4 depletion.   
NF-κB inhibition is sufficient to induce a phenotypic reversion in MDA-468 breast cancer 
cells grown in 3D culture 
Since we were unable to obtain MDA-468 cells with stable knockdown of integrin β4, we 
examined whether modulation of downstream signaling pathways might be sufficient to 
substitute for integrin β4 depletion.  While integrin β4 has been shown to influence a number of 
intracellular signaling pathways, one of the key downstream mediators of many pro-survival 
effects of integrin β4 is NF-κB (Friedland et al., 2007; Nikolopoulos et al., 2004).  As a readout 
for NF-κB activity downstream of integrin β4, we examined whether canonical NF-κB target 
genes such as CXCL1 and IL8 (Anisowicz et al., 1991; Kang et al., 2007; Kunsch and Rosen, 
1993) were affected by mutant p53 depletion.  Indeed, CXCL1 was significantly downregulated 
upon mutant p53 depletion from both MDA-468.shp53 and MDA-231.shp53 cells grown in 3D 
culture (Figure 3.4A and 4B) and IL8 was significantly downregulated in MDA-468.shp53 
grown in 3D culture upon mutant p53 depletion (Figure 3.4A).   
To examine whether activation of NF-κB was necessary to maintain the malignant, 




inhibitor of NF-κB (CAY10512) (Heynekamp et al., 2006; Lukiw et al., 2008).  MDA-468 breast 
cancer cells cultured in a laminin-rich ECM in the absence (Control) developed highly 
disordered, malignant appearing structures as described in Chapter 2.   Strikingly however, 
inhibition of NF-κB activity was sufficient to induce a phenotypic reversion, leading to an 
increase in the hollow lumen acinar-like population in MDA-468 cells, similar to mutant p53 
depletion from these cells (Figure 3.4C and 4D).    
TP53 mutational status and integrin β4 expression may predict patient prognosis 
As presented in Chapter 1, the role of α6β4 integrin in tumorigenesis remains 
controversial.  While most studies report elevated expression and oncogenic activities of integrin 
β4 (nearly all of which have utilized mutant p53 bearing cell lines), there are now multiple 
publications detailing tumor suppressive functions of integrin β4.  Integrin β4 has been shown to 
induce apoptosis in a wild-type p53 dependent manner, as well as mediate cell cycle arrest 
through the p53-target gene, p21 (Bachelder et al., 1999; Clarke et al., 1995; Davis et al., 2001; 
He et al., 2008). With this in mind, we hypothesized that p53 mutation might function as a 
molecular switch between the tumor suppressive and oncogenic functions of α6β4 integrin. 
While both mutant p53 and integrin β4 have been used as prognostic tools in breast 
cancer (Lu et al., 2008; Petitjean et al., 2007a), our hypothesis suggested that the combination of 
p53 status and integrin β4 expression level might serve as a better prognostic indicator in breast 
cancer than either factor alone.  We first examined five human breast cancer patient datasets 
(totaling 812 patients) to determine whether mutant p53 status correlated with elevated 
expression of ITGB4.  Elevated expression in mutant p53 tumors compared to wild-type p53 




3.5A).  Since expression data from this dataset fit with our findings using human breast cancer 
cell lines in 3D culture, we reasoned that this patient population would be the best cohort in 
which to examine the hypothesis that p53 mutation serves a molecular switch for integrin β4 
function.    
To do this, we stratified the ULL dataset (80 patients) for TP53 status (wild-type vs. 
mutant) and ITGB4 expression (high vs. low) and found that breast cancer patients with wild-
type p53 expressing tumors had a significantly improved disease-free survival time if their 
tumors concomitantly expressed high levels of β4 integrin (p<0.01) (Figure 3.5B, left panel).  
Interestingly, this trend was reversed in the presence of mutant p53 (Figure 3.5B, right panel), 
fitting with the notion that p53 mutation might function as molecular switch for integrin β4.  It is 
important to note however that this trend was no longer observed when we examined all five 
breast cancer datasets pooled together, even when stratified for estrogen receptor (ER) status 
(Figure 3.5C).  This discrepancy may be due to the different patient characteristics, different 
expression arrays, etc. that were used to generate the different patient datasets, which may also 
account for the lack of correlation between p53 mutant status and elevated ITGB4 expression in 
these patient populations.  While we cannot yet conclude that p53 mutation does in fact serve to 
switch integrin β4 from a tumor suppressor (in the setting of wild-type p53) to an oncogene (in 
the setting of mutant p53), these data are suggestive that such an effect may occur in at least a 






In this study, we queried a set of genes, the protein products of which have previously 
been shown to be necessary to maintain the disordered, malignant state of tumorigenic breast 
cells in a 3D ECM model for mammary tumorigenesis. We identified two genes, ITGB1 and 
ITGB4, as being significantly downregulated upon mutant p53 depletion from MDA-468 breast 
cancer cells grown in 3D culture.  We show that at least in the case of ITGB4, this regulation 
occurs at the level of transcription as primary transcripts are also regulated by mutant p53 and 
endogenous mutant p53 associates with DNA surrounding the ITGB4 promoter region.  This 
regulation may have important biological consequences as both mutant p53 and integrin β4 have 
previously been linked to invasion (Adorno et al., 2009; Mercurio et al., 2001; Muller et al., 
2009) and we have demonstrated that downregulation of either mutant p53 or integrin β4 is 
sufficient to impair invasion in a laminin-rich ECM.  Additionally, as NF-κB is a key 
downstream target of integrin β4, we demonstrate that inhibition of this pro-survival factor is 
sufficient to elicit a phenotypic reversion in 3D culture to structures with acinar-like 
morphology.    
As mentioned earlier, one of the emerging themes in p53 gain-of-function seems to be 
that many transactivation targets of mutant p53 are repression targets of wild-type p53 and in 
fact the focus of this investigation, integrin β4, has previously been shown to be a wild-type p53 
repression target (Bon et al., 2009).  In fact, integrin β4 has also been reported to be a 
transcriptional target of both p63 and p73 (Bon et al., 2009; Carroll et al., 2006).  Whereas wild-
type p53 does not physically interact with its family members, mutant p53 has been shown to 
bind to both p63 and p73 (Gaiddon et al., 2001).  However, this interaction usually results in 
inhibition of p63/p73 activity (Di Agostino et al., 2008; Di Como et al., 1999; Gaiddon et al., 




mutant p53 and p63/p73 usually results in inhibition of p63/p73 function, but in certain 
circumstances might actually exaggerate other functions of p63 or p73. 
As mentioned previously, integrin β4 is quite unique within the integrin family due to its 
very large C-terminal cytoplasmic domain.  A truncated, dominant negative, version of integrin 
β4 (β4-1355T) which can still form hemidesmosomes, but in which has the C-terminal signaling 
domain is deleted has been previously described (Nikolopoulos et al., 2005).  This mutant 
integrin β4 has been used to separate the adhesive functions from the signaling functions of 
integrin β4 and expression of this mutant form is sufficient to delay mammary tumorigenesis 
induced after ErbB2 overexpression in a mouse model of breast cancer, suggesting that integrin 
β4 is necessary for oncogenic activity of ErbB2 (Guo et al., 2006).  It will be very interesting to 
examine the role of the C-terminal cytoplasmic domain of integrin β4 in the context of mammary 
tissue architecture.   
As noted above, integrin β4 has been shown to impinge upon multiple intracellular 
signaling pathways, a number of which have been implicated in tumorigenesis (PI3K, Rac1, 
RhoA and NF-κB) (Guo and Giancotti, 2004; Mercurio et al., 2001; Weaver et al., 2002).  While 
we have demonstrated a particular reliance on NF-κB for disruption of acinar morphogenesis, it 
will be very interesting to examine additional mediators of integrin β4 signaling in the 3D culture 
system. Of note, both Rac1 and RhoA must be geranylgeranylated in order to function (Zhang 
and Casey, 1996).   As we have previously demonstrated that geranylgeranylation is critical for 
the pro-invasive phenotypic effects of mutant p53 in 3D culture, this may provide a link between 
the findings presented in Chapters 2 and 3.  In other words, both integrin β4 and the mevalonate 




RhoA signaling.  With that in mind, it will very interesting to examine the effect of Rac1 or 
RhoA inhibition on breast cancer cells in 3D culture.    
Our findings, in at least one cohort of human breast cancer patients, that TP53 mutation 
can switch the prognostic impact of ITGB4 expression from high expression predicting good 
outcome in wild-type p53 tumors to high expression correlating with a worse prognosis in 
mutant p53 tumors suggest that p53 mutation may indeed serve as a molecular switch for 
integrin β4 function.  Although our results suggest that prediction models for breast cancer 
disease recurrence may be enhanced if p53 status is combined with β4 integrin expression, this 
may only be true for a subset of patients.  In addition, while it is not yet possible to firmly 
conclude that p53 mutation can switch integrin β4 from a tumor suppressing protein to a tumor 
promoting factor, with many groups pushing for the development of integrin β4 inhibitors as 
cancer therapeutics (Giancotti, 2007), our findings issue a cautionary note for use of such 
inhibitors in wild-type p53 expressing tumors, while also suggesting that integrin β4 may be a 






Plasmids, siRNA, Antibodies and Reagents 
Lentiviruses carrying shRNA directed against integrin β4 were cloned using the Gateway cloning 
system (Invitrogen).  p53 was detected using mAb 1801 or DO-1.  Anti-integrin β4 (7) and anti-
integrin β1 (M-106) antibodies were purchased from Santa Cruz.  Anti-phospho-Akt (Thr308) 
and anti-phospho-p44/42 MAPK (Thr202/Tyr204) (E10) antibodies (Cell Signaling) were kindly 
provided by Ron Prywes.  Anti-Actin (A2066) antibodies and doxycycline (D9891) were 
purchased from Sigma-Aldrich.  CAY10512 (#10009536) was purchased from Cayman 
Chemicals.   
Cell Lines and Generation of Stable Cell Lines 
MDA-468 and MDA-231 cells were maintained in DMEM+10% FBS.  All cells were 
maintained at 37oC in 5% CO2.   
Generation of MDA-468.shp53 and MDA-231.shp53 has been described previously (Chapter 2).  
To induce shRNA expression, cells were treated with 8 µg/ml doxycycline (DOX) for time 
periods indicated in the figure legends.  
MDA-231.shβ4-#1 and MDA-231.shβ4-#2 were generated by producing lentiviruses carrying 
shRNAs targeting integrin β4, produced in 293T cells and infecting MDA-231 cells.  Cells were 
selected with puromycin to yield stable pools. 




Three-dimensional culture was carried out as previously described (Debnath et al., 2003).  
Briefly, 8-well chamber slides were lined with 50 μl growth factor reduced Matrigel (BD 
Biosciences).  Cells were then seeded at a density of 5,000 cells/well in Assay Medium 
(DMEM/F12 + 2% Horse Serum + 10 μg/ml Insulin + 0.5 μg/ml Hydrocortisone) containing 2% 
Matrigel.  Cells were refed with Assay Medium containing 2% Matrigel every 4 days.  For 
RNA/protein analysis from 3D cultures, 35 mm plates were lined with 500 μl Matrigel and cells 
were seeded at a density of 225,000 cells/plate in Assay Medium + 2% Matrigel.  Cells were 
harvested using Cell Recovery Solution (BD Biosciences) according to the manufacturer’s 
instructions.   
Immunostaining and Microscopy 
Cells were fixed using 2% formaldehyde at room temperature for at least 30 min.  Cells were 
permeabilized for 10 min at 4oC with 0.5% Triton X-100 and subsequently blocked for 1 hr at 
room temperature with PBS + 0.1% Tween-20 + 0.1% BSA + 10% goat serum.  Primary 
antibodies were incubated with the cultures for 1-2 hr at room temperature, followed by washing, 
and addition of fluorescently-conjugated secondary antibodies for 40 min at room temperature.  
Nuclei were counterstained with DRAQ5 (Cell Signaling #4084). Confocal microscopy was 
conducted using an Olympus IX81 confocal microscope and analyzed using Fluoview software. 
Quantitative RT-PCR 
RNA was isolated from cells using the Qiagen RNeasy Mini Kit according to the manufacturer’s 
instructions. Complementary DNA was transcribed using Qiagen Quantitect reverse transcription 
kit. Real-time PCR was carried out on an ABI StepOne Plus using SYBR green dye. Transcript 




were calculated using the Comparative-Ct Method (ΔΔCT method). All primers, unless 
otherwise noted, were designed with Primer Express (Applied Biosystems). 
Immunoblotting 
Cells were lysed in TEGN Buffer (420 mM NaCl, 10% glycerol, 0.5% NP-40, 1 mM EDTA, 10 
mM Tris pH 8.0, 0.5 mM PMSF, protease inhibitors [1 μM benzamidine, 3 μg/ml leupeptin, 0.1 
μg/ml bacitracin, and 1 μg/ml macroglobulin]) and subjected to SDS-PAGE.  Gels were 
transferred to nitrocellulose membrane and then blocked in 5% milk in PBS. Membranes were 
incubated with primary antibody for 1 hour at room temperature, followed by three wash steps 
and a 20 min incubation with IR-conjugated secondary antibodies.  Bands were visualized using 
the Licor Odyssey system.    
Quantitative Chromatin Immunoprecipitation 
Chromatin Immunoprecipitation (ChIP) experiments were carried out as previously described 
(Beckerman et al., 2009).  Briefly, MDA-468 cells were treated with 1% formaldehyde prior to 
lysis in RIPA Buffer and sonication to yield 500 bp fragments.  Protein A/G Sepharose beads 
were conjugated to anti-p53 antibodies (1801/DO-1) which were subsequently used to 
immunoprecipitate p53 from 1 mg whole cell lysate.  Quantitative ChIP was carried out on an 
ABI StepOne Plus using SYBR green dye.  Genomic locations of putative mutant p53 binding 
sites were determined using UCSC Human Gene Sorter (hg18). 
Patient Analysis 
One-tailed t-test was performed to assess the significance of the increase in expression level for 




level of TP53 mutated samples is higher than that of wild type samples.  
For individual gene, the test was carried out on five breast cancer datasets: FW-MDG 
(Haakensen et al., 2010; Muggerud et al., 2010), MicMa (Enerly et al., 2011; Wiedswang et al., 
2003), ULL (Langerød et al., 2007), DBCG (Kyndi et al., 2009; Myhre et al., 2010; Nielsen et 
al., 2006) and Miller (Miller et al., 2005) respectively.  
Gene annotation mapping  
The expression sets were annotated using Entrez gene identities. Genes of interest were mapped 
to each of the individual sets through Entrez gene IDs. For FW-MDG and MicMa set, the 
original Agilent probes were mapped to Entrez IDs using BioMart through R library biomaRt 
(Ensembl release 54/NCBI36 (hg18) human assembly). For Miller set, Affymetrix HG u133a 
probes were mapped to Entrez IDs by BioMart under the same release. For ULL set, annotations 
for Stanford 43k cDNA array were retrieved from SMD SOURCE (http://smd.stanford.edu/cgi-
bin/source/sourceSearch) under UniGene Build Number 222. Gene identity conversion on 
DBCG expression set was done using the provided chip annotation file for Applied Biosystems 
Human Genome Survey Microarray. For the probes shared the same Entrez gene identity, we 
selected probe(s) with the largest interquartile range (IQR: difference between the third and first 
quartiles) among the multiple hits. If this still left with more than one hit per Entrez ID, we 
further averaged the expression values of those probes for each sample.  
Datasets 
FW-MDG 
Two expression sets FW (n = 109) (Muggerud et al., 2010) and MDG (n = 143)  (Haakensen et 




system. In addition, they both are early stage breast cancer cohorts and clinically similar. In this 
study, we merged the two datasets by gene-median centering on the original probe level. We also 
excluded normal samples in the MDG set in the study. In total, 139 breast tumors expression 
profiles with available information on TP53 status entered the analysis. Among these, 28 
samples with mutated TP53 status and 111 samples with wild-type status.  
MicMa 
This cohort (Wiedswang et al., 2003) consists of mainly stage I and II breast cancers. mRNA 
expression profiling was performed on Agilent catalogue design whole human genome 4x44K 
one color oligo array. Among the 112 tumor samples with available TP53 status in this sets, 39 
samples with mutated TP53 status and 73 samples with wild-type status.  
ULL 
This cohort consists of mainly stage I and II breast cancers. Eighty tumors, along with one 
normal breast tissue sample, were analyzed using Stanford cDNA 43k two color microarrays. 
We excluded the normal sample in the study, which left 80 tumor samples for the analysis. 
Among these, 20 samples with mutated TP53 status and 60 samples with wild-type status.  
DBCG 
The DBCG series comprise a collection of tumor tissues from 3,083 high-risk Danish breast 
cancer patients diagnosed in the period 1982–1990 (Kyndi et al., 2009; Myhre et al., 2010; 
Nielsen et al., 2006). The profiling was carried out on the Applied Biosystems Human Genome 
Survey one color Microarray. For this study, there were 46 samples with mutated TP53 status 





The Miller dataset (Miller et al., 2005) was downloaded from NCBI's Gene Expression Omnibus 
(GEO, http://www.ncbi.nlm.nih.gov/geo/) with identifier GSE3494. Data were preprocessed and 
normalized as described previously (van Vliet et al., 2008). Among the 247 samples, there were 
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Figure 3.1 Depletion of mutant p53 from breast cancer cells reduces expression of integrin 
β4 
(A)  Integrin β4 mRNA is reduced in a stable pool of MDA-468.shp53 cells.  A stable pool of 
MDA-468.shp53 cells was grown in 3D culture for 8 days in the presence or absence of DOX as 
indicated to deplete cells of mutant p53.  Isolated RNA was reverse transcribed and quantitative 
PCR was performed for ITGB4 as described in methods.  Data presented as mean ± SD for two 
independent experiments.  *indicates p<0.05 from a two-tailed t-test. 
 
(B)  Integrin β4 protein is reduced in a stable pool of MDA-468.shp53 cells.  A stable pool of 
MDA-468.shp53 cells was grown in 3D culture as in (A) prior to lysis and immunoblotting.  p53 
was detected using an anti-p53 antibody (PAb1801).  Integrin β4 was detected using an anti-
integrin β4 antibody (7).  Actin serves as a loading control. 
 
(C)  Integrin β4 mRNA is reduced in a stable clone of MDA-468.shp53 cells.  A stable clone of 
MDA-468.shp53 cells was grown in 3D cultures as in (A).  Samples were processed and 
analyzed as in (A) for ITGB4, nascent ITGB4 (primers within intron 3) and ITGB1. Data 
presented as mean ± SD for three independent experiments.  **indicates p<0.005 from a two-
tailed t-test. 
 
(D)  Integrin β4 protein is reduced in a stable clone of MDA-468.shp53 cells.  A stable clone of 
MDA-468.shp53 cells was grown in 2D or 3D cultures for 8 days in the presence or absence of 




antibody (PAb1801).  Integrin β4 was detected using an anti-integrin β4 antibody (7).  Actin 
serves as a loading control. 
 
(E)  Integrin β4 mRNA is reduced in MDA-231.shp53 cells.  A stable clone of MDA-231.shp53 
cells was grown in 3D cultures as in (A).  Samples were processed and analyzed as in (A) for 
ITGB4, nascent ITGB4 (primers within intron 3) and ITGB1.  Data presented as mean ± SD for 
three independent experiments.  *indicates p<0.05, **indicates p<0.005 from a two-tailed t-test. 
 
(F)  Integrin β4 protein is reduced in MDA-231.shp53 cells.  A stable clone of MDA-231.shp53 
cells was grown in 2D or 3D cultures for 8 days in the presence or absence of DOX as indicated 
prior to lysis and immunoblotting. p53 was detected using an anti-p53 antibody (PAb1801).  
Integrin β4 was detected using an anti-integrin β4 antibody (7).  Actin serves as a loading 
control. 
 
Figure 3.2 Endogenous mutant p53 associates with the ITGB4 promoter 
(A) Genomic locations of PCR primers are indicated beneath schematic of the ITGB4 promoter.  
5’ UTR illustrated as white rectangles, CDS exons illustrated as black rectangles.  TSS1 denotes 
first transcriptional start site; TSS2 denotes second transcriptional start site.  Genomic locations 
are numbered in relation to TSS1 and were located using hg18.   
 
 (B) ChIP analysis of mutant p53 on the ITGB4 promoter.  MDA-468.shp53 cells were grown in 
2D culture for 8 days in the absence or presence of DOX to deplete p53.  Mutant p53 was 




(1801/DO1).  Parallel samples were processed without antibody (Mock IP, “C”) to serve as a 
negative control.  Data is presented as mean ± SD of three independent experiments.  Values 
were normalized to the highest immunoprecipitation signal.  **indicates p<0.01 compared to all 
of the following: negative site, +DOX, Mock IP, upstream and downstream sites.   
 
(C) ChIP analysis of mutant p53 on the ITGB4 promoter.  MDA-468.shp53 cells were grown in 
3D culture for 8 days in the absence or presence of DOX to deplete p53.  Mutant p53 was 
immunoprecipitated from 1 mg of MDA-468.shp53 lysates using anti-p53 antibodies 
(1801/DO1).  Parallel samples were processed without antibody (Mock IP, “C”) to serve as a 
negative control.  Data is presented as mean ± SD of three independent experiments.  Values 
were normalized to the highest immunoprecipitation signal.  *indicates p<0.05 compared to all 
of the following: negative site, +DOX, Mock IP, upstream and downstream sites.   
 
Figure 3.3 Depletion of integrin β4 from breast cancer cells reduces invasive phenotype in 
3D culture 
 (A)  Depletion of integrin β4 affects MDA-231 cell morphology in 3D cultures.  MDA-231 
parental (top left panel), expressing a control shRNA (top right panel) or expressing an shRNA 
targeting integrin β4 (bottom panels) were grown in 3D cultures for 8 days.  Representative 
differential interference contrast (DIC) microscopy images are shown.  Scale bar, 200 µm. 
 
(B)  Efficient depletion of integrin β4 protein in MDA-231 stable cell lines.  MDA-231.shScr 




lysis and immunoblotting. Integrin β4 was detected using an anti-integrin β4 antibody (7).  Actin 
serves as a loading control. 
 
Figure 3.4 NF-κB inhibition reverts MDA-468 breast cancer cells in 3D culture 
(A)  NF-κB target genes are significantly downregulated by mutant p53 depletion in MDA-
468.shp53 cells.  MDA-468.shp53 cells were grown in 3D cultures as in Figure 3.1C.  Samples 
were processed and analyzed for IL8 and CXCL1.  Data presented as mean ± SD for three 
independent experiments.  **indicates p<0.005 from a two-tailed t-test. 
 
(B)  NF-κB target genes are significantly downregulated by mutant p53 depletion in MDA-
231.shp53 cells.  MDA-231.shp53 cells were grown in 3D cultures as in Figure 3.1E.  Samples 
were processed and analyzed for IL8 and CXCL1.  Data presented as mean ± SD for three 
independent experiments.  *indicates p<0.05 from a two-tailed t-test. 
 
(C)  Inhibition of NF-κB leads to a phenotypic reversion in MDA-468 cells grown in 3D 
cultures.  MDA-468 cells were grown in 3D cultures for 8 days in the presence of DMSO (left 
panel) or CAY10512 (1 µM) (right panel).  Nuclei were stained using DRAQ5 (blue) and 
analyzed by confocal microscopy.  Representative images are shown.  Scale bar, 50 µm. 
 
(D) Morphometry of MDA-468 cells treated with NF-κB inhibitor.  MDA-468.shp53 cells were 
grown in 3D cultures as in (C) and structures were analyzed by confocal microscopy for 




(25-50) were counted for each condition and plotted as a percentage of the population.  An 
average of two experiments is shown. 
 
Figure 3.5 Prognostic Impact of TP53 Status and ITGB4 Expression in Breast Cancer 
(A) Five human breast cancer patient datasets, FW-MDG, MicMa, ULL, DBCG and Miller were 
analyzed to determine whether tumors bearing mutant p53 correlated with higher expression of 
ITGB4. Patients were stratified based on TP53 status (wild-type vs. mutant) and expression 
levels of ITGB4 were analyzed.  p-value represents the result of a one-sided t-test.   
 
(B) Kaplan-Meier plots measuring Disease-Free Survival using the ULL breast cancer dataset 
(Langerod et al., 2007) for wild-type p53 tumors (left panel) and mutant p53 tumors (right 
panel).  Red = High ITGB4 expression; Blue = Low ITGB4 expression.  Period shown in months. 
 
(C) Expression data from five human breast cancer patient datasets, FW-MDG, MicMa, ULL, 
DBCG and Miller were pooled together to give 664 patients.  Patients were stratified based on 
TP53 status (wild-type vs. mutant) and expression levels of ITGB4 (high vs. low) and by 
estrogen receptor (ER) status (ER+ vs. ER-) and disease-free survival was plotted using a 
Kaplan-Meier plot.  p-value represents the difference between wild-type p53 and mutant p53 
tumors from a log-rank test.     
 
Table 3.1 Overlap between expression changes after mutant p53 knockdown and known 




A literature search was performed to identify proteins and/or pathways modulation of which has 
been shown to be sufficient to elicit a phenotypic reversion in 3D cultures.  Each identified gene 
was queried against genome-wide expression changes in MDA-468 cells grown in 3D culture 





SUPPLEMENTAL FIGURE LEGENDS 
Figure 3.S1 ERK-1/2 and PI3K pathways are not affected by mutant p53 depletion from 
MDA-468 breast cancer cells in 3D culture 
(A)  A stable pool of MDA-468.shp53 cells were grown in 3D culture as in Figure 3.1A prior to 
lysis and immunoblotting. p53 was detected using an anti-p53 antibody (PAb1801).  P-Akt was 
detected using an anti-Phosho-Akt (Thr308) antibody.  P-ERK-1/2 was detected using an anti-
Phosho-p44/p42 (Thr202/Tyr204) antibody. Actin serves as a loading control. 
 
(B)  A stable pool of MDA-468.shp53 cells were grown in 3D culture as in (A) prior to lysis and 
immunoblotting. p53 was detected using an anti-p53 antibody (PAb1801).  Integrin β1 was 
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Perspectives and Future Directions 
 In this dissertation, we have reviewed the importance of the p53 tumor suppressor gene in 
human cancer and highlighted growing evidence that missense mutations in p53 not only 
abrogate tumor suppressor function, but can actually endow p53 with oncogenic (gain-of-
function) properties.  While the gain-of-function hypothesis has existed almost as long as the p53 
field, recent years have seen a renewed interest in pro-oncogenic properties of mutant p53 
following the seminal finding that mutant p53 knock-in mice exhibit an altered tumor spectrum 
compared to p53 knock-out mice and mutant p53 confers a metastatic phenotype not observed in 
p53 null mice (Donehower and Lozano, 2009; Lang et al., 2004; Liu et al., 2000; Olive et al., 
2004; Terzian et al., 2008).  Over the last five years alone, p53 mutants have been found to 
actively contribute to tumor proliferation, survival, limitless replication, somatic cell 
reprogramming, genomic instability, inflammation, migration, invasion, angiogenesis and 
metastasis (Adorno et al., 2009; Bossi et al., 2006; Brosh and Rotter, 2009; Di Agostino et al., 
2006; Girardini et al., 2011; Mizuno et al., 2010; Muller et al., 2009; Oren and Rotter, 2010; 
Sarig et al., 2010; Song et al., 2007; Stambolsky et al., 2010; Weisz et al., 2007).  Amazingly, 
this places mutant p53 in a central role in tumorigenesis, impacting nine out of the ten (updated) 
“hallmarks of cancer” proposed by Weinberg and Hanahan (Hanahan and Weinberg, 2011).  
Interestingly the “hallmark” in which mutant p53 has been least explored to date is “deregulating 
cellular energetics,” which happens to be the focus of Chapter 2. 
 In Chapter 2, we sought to delineate the phenotypic effects of mutant p53 in breast 




carcinogenesis (Debnath et al., 2003).  We describe a novel role for mutant p53 in disrupting 
acinar morphogenesis and implicate this oncoprotein as a necessary component to maintain the 
disordered, malignant state of breast cancer cells using a three-dimensional culture model of 
breast cancer.  Specifically, we found that depletion of endogenous mutant p53 from breast 
cancer cells dramatically reduces invasion or induces a phenotypic reversion in the 3D ECM 
system, depending on the cellular context.  Furthermore, expression of a number of tumor-
derived p53 mutants in non-malignant mammary epithelial cells is sufficient to disrupt normal 
acinar morphogenesis.  Intriguingly, both of these functions require an intact transactivation 
domain suggesting that mutant p53-mediated transcription is responsible for the phenotypic 
effects on mammary tissue architecture.  This is in line with the idea that mutant p53 exerts this 
activity largely through transcriptional upregulation of seventeen genes in the mevalonate 
pathway by co-opting the endogenous regulators of this pathway, the sterol regulatory element 
binding proteins (SREBPs).  Mutant p53 is recruited to the promoter regions of a number of 
SREBP-target genes, which encode enzymes within the mevalonate pathway.  Importantly, we 
also found that supplementation with intermediate metabolites within the mevalonate pathway 
can substitute for mutant p53 and that inhibition of a number of key enzymes in the mevalonate 
pathway can profoundly impact the malignant behavior of breast cancer cells grown in a laminin-
rich ECM, suggesting that flux through the mevalonate pathway is necessary and sufficient to 
maintain the malignant state.  While it has been demonstrated previously that inhibition and/or 
downregulation of oncogenic signaling pathways can phenotypically revert breast cancer cells 
grown in 3D culture (Beliveau et al., 2010; Bissell et al., 2005; Wang et al., 1998; Weaver et al., 
1997), we show here that downregulation of mutant p53 and/or inhibition of the mevalonate 




evolve to become highly reliant on metabolic flux through the mevalonate pathway.  As a 
number of well-tolerated inhibitors targeting the mevalonate pathway are commonly used in the 
clinic, this work may offer a novel, and much needed, therapeutic option for tumors bearing 
mutant p53.  In addition to the potential implications of this work, one can envision many 
avenues in which to follow up on these findings, some of which will be outlined below. 
Further Exploration of Mutant p53 in 3D Culture 
One interesting avenue might be to examine which mutants of p53 can affect mammary 
tissue architecture and what aspects of p53 are responsible for these phenotypic effects.  We have 
already demonstrated that an shRNA-resistant version of mutant p53 (R273H) can prevent the 
phenotypic reversion observed in 3D culture, while a mutant p53 protein that lacks functional 
transactivation subdomains (L22Q/W23S/W53Q/F54S “mTAD”) (Lin et al., 1994; Zhu et al., 
1998) cannot rescue this phenotypic reversion (Figure 2.2).  To examine whether other tumor-
derived mutants of p53 can substitute for endogenous p53-R273H in maintaining the malignant, 
disordered state of MDA-468 breast cancer cells in 3D culture, we engineered MDA-468.shp53 
cells to express a number of other shRNA-resistant p53 mutants, along with their respective 
transactivation-deficient versions.  Interestingly, while p53-R273H, -G245S and -R248W can 
partially rescue the effect of depleting MDA-468 cells of endogenous mutant p53, p53-R175H 
and all mTAD versions do not have a similar effect on MDA-468 morphology in 3D culture 
(Figure 4.1) although this must be interpreted with caution, as expression of p53-R175H is lower 
than other mutants (data not shown).    
Similar to the approach taken with mutation of the transactivation domains of mutant 




aspects of p53 biology.  For example, mutation of leucine at position 344 has previously been 
shown to modulate oligomerization status, L344A prevents tetramerization, but allows dimer 
formation, while L344P abolishes all oligomerization (Davison et al., 1998).  If placed in the 
context of a tumor-derived mutation, this would provide insight into whether mutants of p53 
need to oligomerize in order to exert their gain-of-function effects.  One can also probe whether 
the subcellular localization can impact mutant p53 gain-of-function by introducing a second 
point mutation (K305N) into a tumor-derived mutant p53, which would prevent nuclear 
translocation by blocking p53 binding to the nuclear localization signal (NLS) receptor (Liang 
and Clarke, 1999).  A subset of tumor-derived mutant p53 proteins have recently been 
demonstrated to aggregate, a property which can be suppressed by mutation (I254R) within the 
“aggregation signal” (Xu et al., 2011).  It will be interesting to introduce this mutation into the 
context of tumor-derived p53 mutants to examine whether aggregation is involved in the gain-of-
function effects of mutant p53 on mammary tissue architecture.  Finally, as the C-terminus of 
mutant p53 has been shown in some circumstances to be necessary for gain-of-function effects 
and in other circumstances to play an inhibitory role (Muller et al., 2009; Yan and Chen, 2010), 
it will be interesting to examine what effect, if any, deletion of this region has in terms of the 
behavior of breast cancer cells in a laminin-rich ECM.   
Additionally, to explore how pervasive the phenomenon that breast cancer cells become 
reliant on expression of mutant forms of p53 and the mevalonate pathway, it will be interesting 
to engineer a larger panel of breast cancer cells to express shRNA targeting endogenous mutant 
p53 and examine their morphology in 3D culture as well as the response of the mevalonate 
pathway genes to mutant p53 depletion.  One of the large unanswered questions from this work 




genes.  We have demonstrated that an endogenous mutant p53 (R273H) can upregulate 
seventeen genes in the mevalonate pathway, as well as a number of other SREBP-target genes.  
Additionally, we show that a separate endogenous mutant p53 (R280K) can upregulate at least a 
subset of these SREBP target genes.  However, it will be interesting to examine if we can find 
appropriate cellular conditions under which exogenous mutant p53 can upregulate these genes as 
this will allow one to investigate a large panel of tumor-derived p53 mutants for their ability to 
regulate the expression of these genes.  Additionally, if these conditions can be readily identified, 
this will allow one to further explore the mechanism by which tumor-derived p53 mutants 
upregulate these genes by utilizing many of the altered versions of p53 described above.   
Global Analysis of Mutant p53 DNA Binding 
 During the course of dissecting the effect of mutant p53 in 3D culture, we also performed 
chromatin immunoprecipitation for mutant p53 followed by massively parallel sequencing 
(ChIP-Seq) to identify potential mutant p53 binding sites in the genome following mutant p53 
depletion from MDA-468.shp53 breast cancer cells grown in 3D culture.   After mapping reads 
to the human genome using Bowtie, we employed model-based analysis of ChIP-Seq (MACS) 
(Zhang et al., 2008) to identify peaks (potential mutant p53 binding sites).  We identified 11,072 
peaks with p-value ≤ 10-6 and fold enrichment ≥ 5 compared to “Mock IP (IgG)” control samples 
or samples from MDA-468.shp53 cells cultured in the presence of DOX (“+DOX”) to deplete 
endogenous mutant p53 and subjected to ChIP-Seq.   
We next identified 2,386 genes with at least one putative mutant p53 binding sites.  To 
assign peaks to genes, we focused on significant peaks that were located in the -3,000 bp to 




previously found that mutant p53 is responsible for controlling the expression of a number of 
sterol biosynthesis genes in human breast cancer cells (Chapter 2), we examined our ChIP-Seq 
results to see if any mevalonate pathway genes were identified using this method.  Indeed, sterol 
biosynthesis genes were significantly (p<0.01) overrepresented in our ChIP-Seq results (Figure 
4.2) supporting our original finding that mutant p53 associates with the promoters of a number of 
mevalonate pathway genes (Figure 2.6).  In fact, one of our collaborators recently performed 
ChIP-Seq for SREBP-1 and SREBP-2 in the human hepatocellular carcinoma cell line HepG2.  
We plan to compare our ChIP-Seq data with these results to expand upon our findings that link 
SREBP and mutant p53 in breast cancer.  Likewise, as we have demonstrated that Fatostatin, a 
small molecule that prevents SREBP activation, has profound phenotypic effects on a number of 
mutant p53 bearing breast cancer cell lines in 3D culture, it will very interesting to perform 
genome-wide expression analyses on breast cancer cells grown in 3D culture untreated or treated 
with Fatostatin and compare these with expression changes identified after mutant p53 depletion 
from these same cells.  In addition, it could be interesting to perform a second mutant p53 ChIP-
Seq following Fatostatin treatment of MDA-468 breast cancer cells grown in 3D culture to 
determine what portion of mutant p53 binding events require the SREBP transcription factors.  
These should provide further insight into the connection between SREBP and mutant p53.   
In terms of additional analyses on the existing ChIP-Seq, we first plan to investigate the 
question: where exactly does mutant p53 tend to bind (i.e. promoters, intragenic regions, 
intergenic regions, etc.)?  Our quantitative ChIP results presented in Chapters 2 and 3 suggest 
that mutant p53 may have a low level of promiscuous binding with DNA, as even “negative” 
regions showed a decrease in binding upon mutant p53 depletion.  While our initial assignment 




transcriptional start sites, it will be of interest to take an unbiased approach for all peaks 
identified by MACS and examine where mutant p53 tends to bind.  We also plan to compare 
ChIP-Seq results with expression microarray data to examine which binding events actually lead 
to changes in gene expression.  This will be particularly informative since these analyses were 
performed on MDA-468.shp53 cells grown in parallel in 3D culture and thus may offer valuable 
information about the role of mutant p53 in 3D culture.  As a part of this analysis, it will be 
interesting to examine how many of these genes are upregulated versus downregulated upon 
mutant p53 depletion from breast cancer cells to determine whether mutant p53 functions as a 
transcriptional activator or repressor for given genes.  In addition, we plan to perform Gene 
Ontology (GO) analysis on targets identified by ChIP-Seq, similar to the analysis performed in 
Figure 2.3, to examine the pathways/processes that mutant p53 is directly regulating.   
It may also be interesting to compare putative mutant p53 binding sites identified by 
ChIP-Seq with previously described genome-wide analyses of wild-type p53 binding (Botcheva 
et al., 2011; Smeenk et al., 2011; Wei et al., 2006).  As wild-type p53 has been demonstrated to 
have a preference for regions enriched in CpG islands in non-tumorigenic cells, it will be 
interesting to examine whether mutant p53 global binding displays a similar pattern in breast 
cancer cells (Botcheva et al., 2011; Freed-Pastor, 2011).  Additionally, it may be of interest to 
perform ChIP-Seq analyses for different histone modifications using MDA-468 breast cancer 
cells in 3D culture and then compare these patterns to the global pattern of mutant p53 binding. 
To date there is no “mutant p53 response element,” so perhaps, in addition to recruitment 
through other transcription factors, mutant forms of p53 are recruited to certain promoters based 




As introduced above, one of the more common mechanisms for mutant p53-mediated 
transcriptional regulation appears to be that mutant forms of p53 can interact with other 
sequence-specific transcription factors.  This allows mutant p53 to be recruited to the cognate 
binding site of the other cellular transcription factor and either strengthen or dampen the target 
response.  We plan to identify transcription factor response elements that are over-represented in 
our mutant p53 ChIP-Seq.  This method has been previously utilized using a mutant p53 ChIP-
on-chip from SK-BR-3 cells, which identified the ability of p53-R175H to interact with and 
regulate vitamin D receptor (VDR) genes (Stambolsky et al., 2010). 
Nearly all studies report that tumor-derived mutants of p53 have lost sequence-
specificity, but in general this is meant that they can no longer recognize canonical wild-type p53 
response elements.  We plan to perform a motif analysis to search for sequences that are over-
represented in our mutant p53 ChIP-Seq to examine if p53-R273H may have a preference for 
certain sequence motifs.  These may be similar to or distinct from the wild-type p53 response 
element.  We recognize that interpretation of this analysis may be difficult as it will not be 
possible to discriminate which motifs mutant p53 is binding to directly, as opposed to those that 
it is binding to through a separate transcription factor. However, as will be described below, we 
plan to pursue this question in a combined approach with in vitro studies guiding the 
identification of putative sequence-specific binding sites.  This second approach will be 
described below. 
Statins: A new therapy for mutant p53 tumors? 
Our findings that tumor-derived p53 mutants upregulate multiple enzymes in the 




on breast cancer cell morphology in 3D culture, with no effect on wild-type p53 expressing 
MCF10A cells, suggest that tumors bearing mutant p53 may be more sensitive to inhibition of 
the mevalonate pathway compared to wild-type p53 expressing cells.  However, while we have 
very strong evidence that inhibition of the mevalonate profoundly affects mutant p53 breast 
cancer cells, further studies are warranted to examine the relative sensitivity to inhibition of the 
mevalonate pathway between wild-type and mutant p53 tumors.  In fact, one of the more 
exciting avenues for future research will be to expand upon this finding.  It will be interesting to 
examine a large panel of breast cancer cell lines (or perhaps primary breast tumor samples) for 
their sensitivity to inhibition of the mevalonate pathway.  Of particular interest will be to 
evaluate inhibition of HMG-CoA reductase using statins, as these drugs are FDA-approved and 
well-tolerated, and then correlate the relative sensitivities to p53 mutational status.  Ideally, this 
type of study would include cell lines (or primary tumor samples) grown in 3D culture in the 
presence or absence of a statin, as well as parallel samples xenografted into 
immunocompromised mice and then untreated or treated with a statin.  A study of this kind that 
included sufficient numbers of both wild-type and mutant p53 samples would add greatly to our 
understanding of the connection between mutant p53 tumors and statins.   
In addition to xenograft experiments using human cancer cells implanted into 
immunocompromised mice, it will also be interesting to investigate the effect of statins in mouse 
models of cancer.  One such study might evaluate the effect of statins using knock-in mutant p53 
mice compared to p53 knock-out mice (Donehower et al., 1992; Lang et al., 2004; Olive et al., 
2004).  Alternatively, carcinogen-induced tumor models may offer another potential avenue 
through which to investigate this relationship (Russo and Russo, 1996; Sukumar et al., 1995).  




receiving a placebo or a statin could be treated with 7,12-Dimethylbenz(a)anthracene (DMBA) 
as a mutagen and resulting tumors could subsequently be analyzed for p53 mutations.  If our 
hypothesis is correct, that mutant p53 tumors are more sensitive to inhibition of the mevalonate 
pathway, one would expect fewer mutant p53 tumors to arise in statin-treated rats than in the 
placebo group.  
Additionally, it will be very exciting to evaluate mutation of p53 as a potential modifier 
of statin treatment in clinical studies on breast cancer as well as potentially other tumor types.  
There are a large number of epidemiologic studies which have investigated the effect of statins in 
breast cancer and a portion of these report that they included tissue samples for each patient’s 
tumor (Ahern et al., 2011; Fagherazzi et al., 2010). Similar to the pre-clinical studies, we would 
expect fewer mutant p53 tumors to arise in statin-treated patients than in non-statin-treated 
patients if our hypothesis is correct.  Perhaps the quickest and easiest assay would be to perform 
p53 immunohistochemical (IHC) staining on tumor sections as a surrogate for p53 mutation; 
however, this method introduces an unacceptable loss of specificity and sensitivity (Alsner et al., 
2008; Bartek et al., 1990), thus we strongly advocate for full sequencing of the TP53 locus for 
these analyses.  Importantly, it is relatively straightforward to sequence TP53 from fresh frozen 
or formalin-fixed, paraffin-embedded (FFPE) tumor sections (Chrisanthar et al., 2011; Lumachi 
et al., 2009).   
Wild-type p53, SREBPs and the Mevalonate Pathway 
As mentioned in previous chapters, one of the emerging paradigms in the mutant p53 
field is that mutant p53 gain-of-function effects tend to be diametrically opposed to the effects 




Ets-1 and VDR, while mutant p53 enhances the functions of these same proteins (Bargonetti et 
al., 1997; Brosh and Rotter, 2009; Chicas et al., 2000; Di Agostino et al., 2006; Peart and Prives, 
2006; Sampath et al., 2001; Stambolsky et al., 2010).  In Chapter 2, we described a novel role for 
tumor-derived p53 mutants in promoting aberrant activation of the mevalonate pathway through 
the SREBP transcription factors.  An interesting question arises as to what might be the effect (if 
any) of wild-type p53 on this pathway.   
To begin to address this question, we first employed hepatocellular carcinoma cell lines 
treated with different stimuli to activate wild-type p53.  We chose cells derived from liver tissue 
to investigate potential repression of this pathway since liver cells express high levels of the 
mevalonate pathway genes (Seo et al., 2009; Seo et al., 2011).  The first compound utilized, 5-
Fluorouracil (5-FU), is a commonly used chemotherapeutic in breast and colorectal carcinomas 
(Sun et al., 2007).  Once inside cells 5-FU, a pyrimidine analog, is quickly converted to 5-fluoro-
deoxyuridine triphosphate (5-fluro-dUTP) and 5-fluoro-deoxyuridine monophosphate (5-fluro-
dUMP), which binds to and inhibits the activity of thymidylate synthase, the enzyme responsible 
for de novo synthesis of deoxythymidine monophosphate (dTMP).  This results in a change in 
the deoxynucleotide pool, effectively shutting down new DNA synthesis and resulting in DNA 
damage.  In addition, 5-FU (after being converted to 5-fluoro-dUTP) can be incorporated into 
ribosomal RNA (rRNA) leading to a halt in ribosome biosynthesis and releasing ribosomal 
proteins such as L5 and L11 from the nucleolus, which can bind to and inhibit Mdm2 (Sun et al., 
2007).   Both of these mechanisms have been credited for the activation of wild-type p53 in 
response to 5-FU treatment, although the mechanism is still not firmly established.  The second 
compound used in this study was Nutlin-3a, a small molecule that disrupts the p53-Mdm2 




To examine if wild-type p53 has any effect on the mevalonate pathway, SK-Hep1 and 
HepG2 cells, both of which harbor wild-type p53, were treated with 5-FU and Nutlin-3a to 
activate p53 and the mRNA expression of mevalonate pathway genes was assessed.  We 
observed a downregulation upon treatment with both compounds in SK-Hep1 (Figure 4.3A) and 
HepG2 cells (data not shown), although in general the effects of 5-FU were more pronounced.  
However, it is important to note that 5-FU can exert many p53-independent effects.  To address 
this, we used RNAi to deplete cells of wild-type p53 concomitantly treated with 5-FU.  While the 
downregulation of mevalonate pathway genes was blunted in the setting of depleted p53, there is 
most likely an additional p53-independent component to the downregulation (data not shown). 
 To circumvent the p53-independent effects of 5-FU treatment, we exploited another 
hepatocellular carcinoma cell line (Hep3B-4Bv), which had been engineered to stably express a 
temperature-sensitive mutant p53.  This cell line expresses a mutant of p53 (p53-A135V) that is 
structurally unfolded at 37oC, but which re-folds to a wild-type conformation when the 
temperature is lowered to 32oC (Friedman et al., 1997).  We cultured Hep3B-4Bv cells at 37oC 
or 32oC for 48 hours and assessed mRNA expression of the mevalonate pathway genes.  
Remarkably, this shift in temperature was sufficient to significantly downregulate all seventeen 
mevalonate pathway genes tested (Figure 4.3B).  Importantly, while these results suggest that 
wild-type p53 may suppress the mevalonate pathway genes, we cannot yet rule out the 
possibilities that temperature alone might have an effect or that the mutant p53 (A135V) in these 
cells might be activating the mevalonate pathway genes and thus we are observing a loss of 
activation, as opposed to active repression by wild-type p53.    
While this is a fascinating area of research, there is still much work to confirm that wild-




initial finding, that mevalonate pathway genes are downregulated upon 5-FU and Nutlin-3a 
treatment, by examining a larger panel of cell lines with a larger panel of chemotherapeutic 
drugs.  In addition to testing the p53-dependence of this effect, it will also be interesting to 
examine what role p21 might play as this p53-target gene has been linked to many p53 
repression targets (Barsotti and Prives, 2010).  In the context of the temperature-sensitive mutant 
p53, we plan to investigate whether wild-type p53 is actively repressing the mevalonate pathway 
genes or whether this is simply an alleviation of transactivation.  We will use RNAi to deplete 
p53 at either 37oC or 32oC and examine the expression of the mevalonate pathway genes.  If in 
fact we are observing active repression by wild-type p53, we should only see an effect at 32oC, 
while the opposite will be true if p53-A135V is actively upregulating these genes. 
In addition, it will be potentially very interesting to examine the effect of p53 family 
members, p63 and p73, on SREBP-target genes, with a specific focus on the mevalonate 
pathway.  There is some evidence to suggest that these proteins may impact upon SREBP-
mediated transcription as both p63 and p73 have been shown to upregulate the expression of 
FASN, which encodes fatty acid synthase (Sabbisetti et al., 2009).  Furthermore, similar to p53, 
p73 is induced following DNA damage (Urist et al., 2004) and thus may account for a portion of 
the p53-independent effects noted after 5-FU treatment of HepG2 and SK-Hep1 cell lines.  We 
also plan to examine whether wild-type p53 or its family members can physically interact with 
the SREBP family of transcription factors and whether wild-type p53 or its family members can 
interact with the promoter regions of the mevalonate pathway genes as assessed by chromatin 
immunoprecipitation.   
 Although we cannot yet conclude that wild-type p53 is repressing the sterol biosynthesis 




out to exist.  For example, a connection between p53, the mevalonate pathway and the mammary 
gland may be re-visited.  Wild-type p53 has been found to be excluded from the nucleus during 
normal lactation (Moll et al., 1992).  Milk is rich in both cholesterol and fatty acids and SREBPs 
have been documented to play a role in normal lactation (Rodriguez-Cruz et al., 2006; Rudolph 
et al., 2007).  If wild-type p53 does in fact repress mevalonate pathway genes, it is tempting to 
speculate that p53 is excluded from the nucleus during lactation in order for efficient milk 
production to occur.  As described in Chapter 1, Eph4 cells, a non-malignant murine mammary 
epithelial cell line that harbors wild-type p53, can be stimulated to induce lactation-specific 
genes (β-casein, etc.) by growth in a laminin-rich ECM and treatment with lactogenic hormones.  
In fact, we have grown Eph4 cells in 3D culture treated with Prolactin (PRL) a lactogenic 
hormone and verified that β-casein mRNA expression is dramatically induced as a read-out for 
milk synthesis (data not shown).  It might be interesting to examine this hypothesis by culturing 
Eph4 cells in a 3D laminin-rich ECM treated with Prolactin and immunostain these structures for 
p53 to confirm that it is excluded from the nucleus during lactation.  In addition to β-casein 
expression, one would want to confirm that the mevalonate pathway genes are upregulated in 
response to lactogenic hormones.  If both of these held true for Eph4 murine mammary epithelial 
cells stimulated to lactate in 3D culture, one could explore the hypothesis that exclusion of wild-
type p53 is necessary for lactation to occur by culturing these cells in the presence of leptomycin 
B (LMB), which has been shown to prevent nuclear export of p53.  However, LMB is not 
specific to p53, therefore one could also engineer these cells to express a version of p53 in which 





In Chapter 3, we examined alternate mechanisms by which mutant p53 might contribute 
to maintenance of the malignant state.  By querying a set of genes, the protein products of which 
had previously been shown to be necessary to maintain the disordered, malignant state of 
tumorigenic breast cells in the 3D ECM model system, we identified two genes, ITGB1 and 
ITGB4, that were significantly downregulated upon mutant p53 depletion from breast cancer 
cells grown in 3D culture in the expected direction.  We demonstrate that endogenous mutant 
p53 directly regulates integrin β4, as it associates with DNA surrounding the ITGB4 promoter 
region.  We also show that downregulation of either mutant p53 or integrin β4 is sufficient to 
severely attenuate breast cancer invasion in a laminin-rich ECM.  Furthermore, as NF-κB is a 
key mediator of integrin β4 intracellular signaling, we demonstrate that inhibition of this pro-
survival factor is sufficient to elicit a phenotypic reversion in 3D culture to structures with 
acinar-like morphology. 
While we have implicated mutant p53, integrin β4 and NF-κB in maintenance of the 
malignant state, there are a number of ways in which to expand upon these findings.  One the key 
ways to confirm that these findings are in fact necessary for the phenotypic effects would be to 
overexpress integrin β4 to prevent the phenotypic reversion normally observed after mutant p53 
depletion.  Likewise, one could express a constitutively active version of NF-κB (or a dominant 
negative version of the NF-κB inhibitor, IκB) to examine whether this can rescue the phenotypic 
effects of mutant p53 or integrin β4 knockdown.  Interestingly, tumor-derived mutants of p53 
have already been demonstrated to promote nuclear translocation and activation of NF-κB, 
although the mechanisms by which mutant p53 elicits this effect have not yet been determined 
(Weisz et al., 2007).  It is tempting to speculate that this earlier observation is due to mutant p53-




one could examine if inhibition of integrin β4, by RNAi or perhaps by function-blocking 
antibodies (Gabarra et al., 2010), could prevent the ability of mutant p53 to activate NF-κB.   
While we have demonstrated that mutant p53 can interact with two regions of DNA 
surrounding the ITGB4 gene using chromatin immunoprecipitation, we cannot yet say by what 
mechanism mutant p53 is recruited to these sites.  It will be very interesting to look for putative 
transcription factor response elements in the regions with peak mutant p53 binding.  Perhaps 
mutant p53 is recruited to these regions by one of its known interacting partners (NF-Y, Sp1, 
Ets-1, SREBP or VDR), a novel mutant p53 interacting protein or perhaps it is recruited directly 
by specific DNA sequences, DNA structures or perhaps histone modifications. 
Additionally, since integrin β4 is reported to impinge upon a number of intracellular 
signaling pathways, it will be very interesting to examine the genome-wide expression changes 
following depletion of integrin β4 from breast cancer cells grown in 3D culture.  Ideally, this will 
be performed on cell lines engineered with inducible shRNA targeting integrin β4 to exclude cell 
line differences.  Similarly, as we have already implicated NF-κB in this 3D phenotype, it will be 
very interesting to examine the mRNA expression changes following NF-κB inhibition in breast 
cancer cells grown in 3D culture.  If one were to compare expression changes from these two 
approaches with expression changes following mutant p53 depletion, one might gain better 
insight into the target genes necessary for the observed effects on mammary tissue architecture. 
Similar to the experiments proposed in relation to mutant p53’s ability to upregulate the 
mevalonate pathway, it will be very interesting to examine which p53 mutants are able to 
upregulate ITGB4.  As discussed in Chapter 1, mutant p53 proteins are often classified as “DNA-




shown to have differential affinity toward certain interacting partners, such as p63/p73, perhaps 
one class may interact preferentially with the SREBP or other transcription factors.  While we do 
not yet known whether mutant p53 is directly recruited to the ITGB4 promoter or if it is brought 
there by another other DNA binding protein, it will be interesting to examine whether different 
mutants have an altered recruitment to this region of DNA. 
Improving 3D models of mammary morphogenesis 
 Much has already been discovered by utilizing three-dimensional culture of mammary 
epithelial cells in a laminin-rich ECM and this system has been shown to closely model many 
processes with in vivo relevance.  While the role of the microenvironment in tumorigenesis is 
becoming increasing recognized, it is crucial to remember that mammary epithelial cells 
normally develop in the context of a diverse array of stromal components that may play critical 
roles in development and carcinogenesis.  
 One avenue to more faithfully recapitulate the in vivo microenvironment is the 
development of heterotypic 3D culture systems, in which mammary epithelial cells are cultured 
in combination with other cell types (myoepithelial cells, fibroblasts, endothelial cells, etc.).  
While carcinogenesis is often simplified to sequential genetic alterations in epithelial cells, 
tumors do not arise in a vacuum.  In the mammary gland, luminal epithelial cells are normally 
surrounded by myoepithelial cells.  As previously described, luminal epithelial cells can develop 
into acinar-like structures with correct apicobasal polarity and a hollow lumen when cultured in a 
laminin-rich ECM; however, when these same cells are placed in a collagen-I matrix, they 
develop into spherical structures that exhibit inverted apicobasal polarity and with no apparent 




myoepithelial cells in a collagen-I environment, the resulting bi-layered structures regained 
proper apicobasal polarity, a function which was shown to be dependent on laminin-111 
expression by myoepithelial cells.  Intriguingly, many tumor-associated myoepithelial cells have 
lost the ability to synthesize laminin-111 and are thus unable to direct polarity in luminal 
epithelial cells (Gudjonsson et al., 2002).  Myoepithelial cells are retained during ductal 
carcinoma in situ, but are often lost at the transition to invasive breast cancer (Holliday et al., 
2009).  While loss of myoepithelial cells was long thought to be an effect of tumor progression, 
there is now substantial data suggesting that myoepithelial cells may exert tumor suppressive 
functions which must be overcome in order to progress to invasive breast cancer.  Some of these 
effects are thought to be paracrine mechanisms as conditioned media from myoepithelial cells 
has been shown to exert anti-proliferative and anti-invasive effects on a number of breast cancer 
cells through the secretion of maspin or other factors (Shao et al., 1998).  While heterotypic 3D 
culture models offer much promise to more closely mimic the cellular microenvironment found 
in vivo, many technical limitations limit the use and interpretation of these systems as it is often 
difficult to determine which cell type is exerting an effect on another.  One particularly 
auspicious avenue might be to develop inter-species heterotypic 3D culture systems, which 
would allow reliable testing for paracrine effects using species-specific primers/antibodies.  
Additionally, each cell type can be engineered to express unique fluorescence markers for rapid 
discrimination and sorting. 
Another important aspect of improving 3D culture models of breast cancer is a larger 
collection of non-malignant mammary epithelial cell lines.  As noted above, commonly used cell 
lines include MCF10A and S1 human mammary epithelial cells, as well as Eph4 and SCp2 




in xenograft models (Soule et al., 1990), the term “non-malignant” is often preferred over 
“normal” (although many reports use these cells as “normal” cells).  MCF10A cells were derived 
from a reduction mammoplasty of a patient with fibrocystic changes, and then spontaneously 
immortalized in culture (Soule et al., 1990).  They have been shown to be near-diploid with a 
stable karyotype; however, they also have amplified MYC as well as a deletion of the locus 
encoding p16 and p14ARF.  Additionally, they express multiple markers of both luminal and 
myoepithelial cells, suggesting that this cell line may not perfectly mimic pure mammary 
epithelial cells in vivo (Debnath et al., 2003).  That being said, these cells continue to provide 
valuable insights into mammary development and the effects of cancer-associated genes on 
tissue architecture.  However, a wider array of non-tumorigenic, immortalized mammary 
epithelial cells will greatly advance our understanding of mammary development and 
carcinogenesis.  
Saudade: The Hunt for a Mutant p53 Response Element(s) 
 Finally, one of the most fascinating questions in the p53 field may have specific 
relevance to this project.  As mentioned previously, it is often assumed that tumor-derived 
mutants of p53 completely lack sequence-specificity.  It is well documented that at least the hot-
spot p53 mutants can no longer recognize canonical wild-type p53 response elements (Bargonetti 
et al., 1991; Bargonetti et al., 1993; Kern et al., 1992; Thukral et al., 1995).  However, as many 
of these mutations affect residues which bind to DNA, they may in fact acquire novel cognate 
binding sites, which may be similar or dissimilar to the canonical wild-type p53 response 
element.  This is especially possible for DNA-contact mutants which retain near wild-type 
conformation of the DNA-binding domain, with one altered amino acid that contacts the DNA 




To our knowledge, a thorough analysis on individual p53 mutants has not been performed 
to determine whether there is such a thing as a “mutant p53 response element(s).”  One of our 
future plans is to investigate this hypothesis using a combined approach.  We first plan to utilize 
a novel method for Systematic Evolution of Ligands by Exponential Enrichment with 
concomitant massively parallel sequencing (“SELEX-Seq”).  SELEX is a common technique 
used to identify specific sequences that bind with high-affinity to a target protein and has been 
successfully applied to wild-type p53 and p63 in the past (Conrad et al., 1996; Fitzwater and 
Polisky, 1996; Perez et al., 2007; Tuerk and Gold, 1990).  However, from traditional SELEX, 
one only identifies the sequences that bind with highest affinity.  With the addition of massively 
parallel sequencing between each round of SELEX, one can use a novel algorithm developed in 
the Bussemaker laboratory (Harmen Bussemaker and Todd Riley, personal communication) to 
more accurately infer nucleotide preferences at a given position.  This allows one to see relative 
preferences at each site, which may be much more important when investigating DNA binding 
by neomorphic p53 proteins.  We plan to search for sequences which bind to a number of 
frequently occurring p53 mutants (p53-R175H, -G245S, -R248Q, -R248W, -R273H, -R280K), 
and we plan to include wild-type p53 as a control for the technique.  This may provide novel 
information regarding specific sequence motifs that might serve as “mutant p53 response 
elements,” in addition to deepening our understanding about the mechanisms by which wild-type 
p53 recognizes DNA elements.  The second part of the approach will be to confirm any sequence 
elements identified as potential mutant p53 binding sequences.  We plan to search for this site(s) 
in our mutant p53 ChIP-Seq to examine whether these are enriched over the control samples as 
well as perform electrophoretic mobility shift assays (EMSA), mutating key nucleotides, to 





 Overall in this dissertation, we describe a novel role for tumor-derived p53 mutants in the 
disruption of mammary tissue architecture.   Using the three-dimensional (3D) ECM culture 
model, in which non-malignant mammary epithelial cells form structures highly reminiscent for 
many features of acini in vivo, while breast cancer cells for disorganized, malignant-appearing 
structures, we were able to uncover novel functions of mutant forms of p53.  These include 
upregulation of multiple genes associated with the mevalonate pathway, as well as a key integrin 
responsible for cell-ECM communication.  Interestingly, both of these have been implicated in 
tumorigenesis, although not previously connected to mutant p53.  This work not only contributes 
to our understanding of breast carcinogenesis, but may also provide potentially valuable 
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Figure 4.1 shRNA-resistant mutant p53 can rescue the phenotypic reversion observed after 
depletion of endogenous mutant p53 
MDA-468.shp53 were engineered to express shRNA-resistant versions of tumor-derived p53 
mutants and assessed for their morphology in 3D culture.  Cells were grown in 3D cultures for 5 
days in the presence or absence of DOX as indicated.  Representative differential interference 
contrast (DIC) microscopy is shown for (A) MDA-468.shp53, (B) MDA-468.shp53/pLNCX-
Empty, (C) MDA-468.shp53/Flag-p53-R175H, (D) MDA-468.shp53/Flag-p53-R175H-mTAD, 
(E) MDA-468.shp53/Flag-p53-R273H, (F) MDA-468.shp53/Flag-p53-R273H-mTAD, (G) 
MDA-468.shp53/Flag-p53-R248W, (H) MDA-468.shp53/Flag-p53-R248W-mTAD, (I) MDA-
468.shp53/Flag-p53-G245S, (J) MDA-468.shp53/Flag-p53-G245S-mTAD. 
Figure 4.2 Sterol biosynthesis genes are significantly enriched in a mutant p53 ChIP-Seq 
from MDA-468.shp53 cells grown in 3D culture 
MDA-468.shp53 cells were grown in 3D culture for 8 days in the presence or absence of DOX to 
deplete cells of p53.  Samples were crosslinked with 1% formaldehyde, sonicated and mutant 
p53 was immunoprecipitated with anti-p53 antibodies (DO-1 or 421) or control mouse IgG.  
DNA was then subjected to Illumina sequencing.  Reads were mapped to the human genome 
using Bowtie and peaks were identified using MACS (Zhang et al., 2008).  After assigning peaks 
to annotated genes based on the criteria: p-value ≤ 10-6 and fold enrichment ≥ 5 compared to IgG 




SREBP1 ChIP-on-chip target genes (Reed et al., 2008) was assessed.  P-values are based on 
Fisher’s exact test. 
Figure 4.3 Wild-type p53 can repress the mevalonate pathway genes 
(A) SK-Hep1 cells were treated for 24 hours with DMSO control, Nutlin-3a (10 µM) or 5-
fluorouracil (5-FU) (0.5 µM).  Cells were harvested and the mRNA expression of the specified 
sterol biosynthesis genes was assessed by qRT-PCR.  A representative experiment is shown. 
(B) Hep3B-4Bv cells, expressing a temperature-sensitive version of p53, were cultured at either 
37oC (mutant p53 conformation) or 32oC (wild-type p53 conformation) for 48 hours.  Cells were 
harvested and the mRNA expression of the specified sterol biosynthesis genes was assessed by 
qRT-PCR.  Data presented as mean ± st dev of three independent experiments.  *indicates 
p<0.05, **indicates p<0.01 from a two-sided t-test. 
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